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SUMMARY 
The single-cell intestinal epithelial layer is composed of cells specialized for the uptake and exchange of 
nutrients, and cells of the immune system. Together, these form a tightly controlled barrier, regulating the 
passage of components from the intestinal lumen to the rest of the body. Pathogens such as specific 
bacteria, viruses and parasites may breach this barrier. Homeostasis may also be challenged by stress-, 
inflammation- or substance-induced cell transformation. As such, there is a need for intestinal 
intraepithelial immune cells to respond to barrier invasion and transformation with a rapid and robust 
response. 
Intestinal intraepithelial T lymphocytes (IEL) are resident immune cells of the gut epithelium, 
characterised by an ‘activated yet resting’ phenotype. Intrinsically this implies that IEL are quiescent upon 
exposure to a large number of antigens, promoting tolerance and homeostasis. However, specific antigen-
mediated triggering of these cells results in rapid and efficient immune response. Type 1 innate lymphoid 
cells (ILC1s) are the putative innate counterpart of adaptive immune IEL cells. These cells lack re-
arranged antigen receptors, but similarly have the capacity to respond rapidly to breaching of the 
intestinal epithelium. Together, IEL and ILCs provide crucial front-line defense at the intestinal mucosal 
surface. 
The Ly49E receptor is a member of the Ly49 NK receptor family, exhibiting a unique expression profile 
and ligand binding. As such, previous work showed that Ly49E is expressed by a number of innate-like 
immune populations, including natural killer (NK) cells and CD8αα+ IEL in the small intestine. Moreover, 
Ly49E expressed on the cell surface can be triggered by urokinase plasminogen activator (uPA), where 
uPA has been implicated in numerous pathologies, including inflammatory bowel disease (IBD) and 
colorectal cancer. 
Here we show that Ly49E is not only expressed by small intestinal IEL, but also shows relatively high 
expression on colonic IEL. Expression of Ly49E by small intestinal and colonic IEL does not influence the 
development or progression of IBD, nor that of intestinal cancer. Surprisingly, however, we identified a 
novel NKp46-negative ILC population that could be characterised by Ly49E expression and ILC1-like 
properties. This population was also resident to the intestinal epithelium, and preliminary data suggests 
that this population may be important in Th1-mediated immune responses. 
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SAMENVATTING 
Het darmepitheel is een eencellige laag opgebouwd uit cellen gespecialiseerd voor de opname en het 
uitwisselen van nutriënten, en cellen van het immuun systeem. Tezamen vormen ze een sterk 
gereguleerde barrière die instaat voor de gecontroleerde passage van stoffen van de luminale zijde van de 
darm naar het inwendige lichaam. Pathogenen, waaronder bepaalde bacteriën, virussen en parasieten, 
zijn in staat om door de darmbarrière te dringen en intestinale homeostase te verstoren. Daarnaast leidt 
stress- of inflammatie-gemedieerde cel transformatie vaak ook tot het ontwrichten van de intestinale 
balans. Om darm homeostase te bewaren en het lichaam te beschermen tegen pathogenen, is er nood aan 
immuuncellen die op snelle en efficiënte wijze reageren op invasie en cel transformatie. 
Intestinale intraepitheliale T lymfocyten (IEL) zijn residente immuuncellen van het darmepitheel, 
gekarakteriseerd door een ‘geactiveerd maar rustend’ fenotype. Dit impliceert dat IEL een interne 
rusttoestand behouden bij blootstelling aan een grote waaier van intestinale antigenen. Deze cellen 
worden echter snel geactiveerd door triggering van antigeen-specifieke receptoren. Omwille van deze 
eigenschap kunnen IEL zowel bijdragen tot het behoud van darm homeostase als darm bescherming. Type 
1 innate/aangeboren lymfoïde cellen (ILC1) kan men beschouwen als de aangeboren equivalenten van 
adaptieve IEL immuuncellen. ILC1 cellen brengen geen herschikte antigeen receptoren tot expressie, doch 
zijn zij, net als IEL, in staat om snel en efficiënt te reageren op verstoring van de darmbarrière. Samen 
staan IEL en ILC1 cellen aan de frontlinie in bescherming van de darm mucosa.  
De Ly49E receptor behoort tot de familie van Ly49 NK receptoren, en heeft een uniek expressie patroon 
en ligand. Zo hebben voorgaande studies aangetoond dat Ly49E uitgedrukt wordt op de celmembraan van 
verschillende aangeboren celpopulaties in de dunne darm, zoals natural killer (NK) cellen en CD8αα+ IEL. 
Bovendien werd aangetoond dat urokinase plasminogeen activator (uPA) de Ly49E receptor triggert. uPA 
is een protease dat betrokken is bij de ziektes van Crohn en colitis (tesamen IBD genoemd), alsook bij 
tumor ontwikkeling.  
In deze thesis wordt aangetoond dat Ly49E niet enkel uitgedrukt wordt door IEL in de dunne darm, maar 
ook door IEL afkomstig van het colon. Ly49E expressie door IEL heeft geen invloed op de ontwikkeling en 
progressie van IBD, of darmtumour vorming.  Daarnaast beschrijven we een nieuwe NKp46-negatieve ILC 
populatie in het darmepitheel, welke gekarakteriseerd wordt door Ly49E expressie en ILC1-like 
eigenschappen. Preliminaire data suggereren dat deze populatie een belangrijke rol zou kunnen hebben in 
het Th1-gemedieerd immuun antwoord. 
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Chapter 1: 
General introduction and research 
objectives 
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I. General introduction 
As we live our daily lives, our bodies are under constant attack from a wide array of pathogens, including 
bacteria, viruses and parasites. To defend ourselves from this onslaught, we have evolved and developed a 
sophisticated immune system. In general terms, the mammalian immune system can be divided into two 
branches – the innate and the adaptive immune system. The innate immune system is comprised of innate 
lymphoid cells (ILCs), which include natural killer (NK), innate lymphoid (IL)C1, ILC2 and ILC3 cells, and 
myeloid cells, such as dendritic cells (DCs), macrophages and neutrophils/eosinophils/basophils. Innate 
immune cells are programmed to provide a rapid and robust response to pathogen invasion. In this 
context, DCs and macrophages are programmed to recognize and engulf pathogens. Synergistically, ILCs 
are programmed to evoke a rapid cytotoxic and/or cytokine-mediated response. As a result, the innate 
immune system is capable of eliminating many threats. However, more often than not, eradicating a 
pathogen requires collaboration between cells of the innate and adaptive immune system. DCs and 
macrophages from the innate immune system, and B cells from the adaptive immune system, are capable 
of presenting pathogen peptides in the groove of major histocompatibility complex (MHC) molecules to T 
cells of the adaptive immune system.  T cells expressing rearranged antigen receptors specific for a 
pathogen peptide may then mount an antigen-specific immune response. B cells, in parallel, may be 
activated to produce antigen-specific antibodies. Although the adaptive immune response is slower than 
the innate immune response, it is often of vital importance for the total clearance of pathogens from the 
body, and will also contribute to the formation of memory cells. These are important in subsequent 
encounters of the immune system with re-occurring pathogens. 
Alongside the many immune cells that can be found circulating our bodies, we have also evolved specific 
tissue-resident immune cells. These can be found in many organs, but are particularly present at mucosal 
surfaces, such as the skin and gut. 
The work in this thesis has focused on elucidating new functions for tissue-resident intestinal 
intraepithelial T lymphocytes (IEL) and intestinal ILCs. 
II. Structure of the small intestine and colon
Structurally, the intestine is a complex organ composed of multiple layers (Fig. 1). Going inwards towards 
the lumen of the gut are the muscularis externa, submucosa and mucosa. The mucosa is composed of the 
lamina propria and epithelium, and folds onto itself into villi and microvilli. The purpose of this folding is 
to create the maximal possible mucosal surface area for absorption of e.g. nutrients and minerals from the 
lumen. For the purpose of this work, the emphasis is placed on the lamina propria and epithelium, which 
contain the immune cells of interest.  
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The lamina propria is a loose connective tissue layer and contains immune cells of both the myeloid and 
lymphoid lineage, as well as fibroblasts. The epithelium, in turn, is a single cell layer composed of 
enterocytes, and contains specialized cells such as enteroendocrine cells, Paneth cells, goblet cells and 
microfold cells, but also cells of the lymphoid immune system. Together, immune cells from the lamina 
propria and epithelium mount an effective immune response at the intestinal barrier surface.  
Fig. 1 Structure of the small intestine. Illustration showing the structural layers that make up the 
intestinal wall. Going inward toward the lumen are the serosa, muscularis externa, submucosa and mucosa. 
The mucosa is comprised of the lamina propria and the mucous epithelium. Pearson Education, Inc. 2004. 
III. Immune subsets at the intestinal mucosal barrier
1. Intestinal intraepithelial T lymphocytes
i. Classification of intestinal intraepithelial T lymphocytes
T cells may be classified according to the composition of the T cell receptor (TCR) and the expression of 
co-receptors on the cell surface membrane. Conventional T cells are characterised by a TCR that is 
composed of an alpha(α)-chain and a beta(β)-chain. Together with a TCRαβ receptor, these cells often 
express the co-receptors CD4 or CD8αβ. Non-conventional T cells, on the other hand, often express a TCR 
that is composed of a gamma(γ)-chain and delta(δ)-chain, in combination with the co-receptors CD4, 
CD8αβ or CD8αα. Whereas conventional T cells are found circulating the periphery and are present in the 
majority of peripheral organs, non-conventional T cells are tissue resident and adapted to carry out tissue-
specific functions. 
16
Intestinal intraepithelial T cells (IELs) are evolutionary conserved cells and comprise a large number of 
the body’s T cells, where >90% and 80-90% of intraepithelial lymphocytes in the small intestine and 
colon, respectively, are T cells [1-3]. On average, one in ten cells in the epithelium is thought to be an IEL 
[4]. IEL T cells are TCRαβ+ and TCRγδ+ cells, with further subset classification on the basis of CD4, CD8αβ 
and CD8αα co-receptor expression. This yields TCRαβ cells that express either CD4, CD8αβ or CD8αα (or 
double-positives that express both CD4 and CD8αα or CD8αβ), and TCRγδ cells that are either CD4 and 
CD8 double-negative (DN) or that express the CD8αα homodimer [1-3,5]. CD4 and CD8αβ TCRαβ cells are 
conventional T cells and are often termed ‘type a/induced’ IELs, whereas CD8αα TCRαβ and TCRγδ cells 
are non-conventional T cells and are often termed ‘type b/natural’ IELs. Classification is based on the 
mechanism by which ‘type a’ and ‘type b’ IELs become activated, and on the type of antigen recognized by 
each. Natural IELs become activated during development in the thymus upon exposure to self-antigens. 
Induced IELs are activated post-thymically following an encounter with non-self antigen presented by 
antigen-presenting cells, after which these cells are recruited to the intestinal epithelial surface [1-3,5]. 
Furthermore, type b/natural IELs may also be distinguished from type a/induced IELs by their oligoclonal 
TCR repertoire and lack of the classical T cell markers CD2, CD5, CD28 and CD90 (Thy-1) [3,6-10].  
ii. Development of intestinal intraepithelial T lymphocytes
Intestinal IEL development has been a heavily debated topic for many years. Whereas there is a general 
consensus that conventional CD4 and CD8αβ TCRαβ cells develop in the thymus along the classically 
accepted paths of positive and negative selection, there is uncertainty as to the location and pathways by 
which non-conventional TCRαβ CD8αα and TCRγδ IELs develop. What follows is a short synopsis of 
different theories and evidence that has been put forward to elucidate non-conventional IEL development.  
Early studies on TCRαβ CD8αα and TCRγδ IEL development found evidence to support an extrathymic 
origin for non-conventional IELs. In this respect, Guy-Grand et al. [11] showed that CD8αα-positive IELs 
are present in nude and thymectomised mice. Alongside, Saito et al. [12] demonstrated that intestinal 
cryptopatches contain Lineage (Lin)- CD117hi CD127+ CD90+/- cells, where cryptopatches are small 
organized structures located in the basal lamina propria containing predominantly Lin (CD3, CD4, CD8, 
B220)- cells [13]. These cells, when adoptively transferred into severe combined immune deficiency 
(SCID) mice, give rise to mature TCRαβ- and TCRγδ-positive IELs [12]. To provide additional evidence for 
the existence of an IEL T cell progenitor residing in cryptopatches, athymic CRγ-/Y mice were generated. 
These mice have a mutation in the common cytokine receptor gamma-chain (γc), and are devoid not only 
of a thymus, but also of Peyer’s patches (PPs), cryptopatches and TCR+ cells [14]. Suzuki et al. [15] 
demonstrated that transplantation of wild-type (WT) T-cell depleted bone marrow (BM) cells into 
athymic CRγ-/Y mice results in restoration of cryptopatch structures, but not PPs, and subsequent 
repopulation of the gut with TCR+ IELs, which are mainly TCRαβ CD8αα and TCRγδ cells. Taken together, 
this provides evidence for the existence of an extrathymic IEL progenitor that gives rise to TCRαβ CD8αα 
and TCRγδ IELs in the intestine. 
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However, a large array of studies have questioned athymic development of non-conventional IELs, and 
instead provide evidence for a thymic origin of TCRαβ CD8αα and TCRγδ IELs. A strong argument against 
the athymic development of IELs from a cryptopatch progenitor population is the appearance of TCRαβ 
CD8αα and TCRγδ IELs in the gut before the appearance of cryptopatches [16,17]. As well as this, 
cryptopatches have yet to be identified in humans, arguing against a cryptopatch origin for non-
conventional IELs in humans [13,18]. 
Arguments to support a partial or complete thymic origin for non-conventional TCRαβ CD8αα and TCRγδ 
IELs are strong. Guy-Grande et al. [11] demonstrated that although CD8αα+ IELs are present in the gut of 
athymic mice, numbers are strongly decreased as compared with WT mice, arguing against a solely 
extrathymic origin for development of these cells. A follow-up study by this group subsequently used 
reporter mice that express green fluorescent protein (GFP) under control of the promotor of recombinase 
activating gene (RAG)2, to demonstrate that RAG2 expression, and thus extrathymic T cell development, 
may occur in the mesenteric lymph nodes (MLN) and to some extent in the PPs, in nude mice. However, 
extrathymic development is blocked in healthy euthymic mice, and only observed in mice under 
conditions of severe lymphocytic depletion. Taken together, these data suggest that the thymus functions 
as the main lymphoid organ for IEL differentiation, but that extrathymic differentiation may occur under 
conditions of defective thymopoeiesis [19]. A thymic origin for non-conventional IEL development was 
further corroborated by a fate-mapping study performed by Eberl et al. [20]. Here, mice expressing 
enhanced GFP (eGFP) under control of the RAR-related orphan receptor gamma t (RORγt) promoter were 
analysed. The results showed that cryptopatch cells, double-positive (DP)-thymocytes and TCRαβ CD8αα 
IELs express RORγt, suggesting that TCRαβ CD8αα IELs go through a cryptopatch or DP progenitor stage. 
Survival of DP thymocytes and TCRαβ CD8αα IEL numbers are sharply decreased in Rorc(γt)-/- mice, but 
can be rescued by expression of a B-cell lymphoma extra large (Bcl-XL) transgene. Importantly, whilst 
cryptopatches are also absent in Rorc(γt)-/- mice, these structures cannot be rescued by Bcl-XL expression. 
Thus, this study elegantly demonstrated the ability of non-conventional IELs to develop in the absence of 
cryptopatches, and provided evidence for the existence of a DP thymic IEL progenitor. Further evidence to 
support TCRαβ CD8αα IEL differentiation from a  thymocyte progenitor was provided by Gangadharan et 
al. [21] (Fig. 2). Studying heterogeneity of the DP thymocyte population, Gangadharan et al. showed that 6- 
9% of all CD4+ CD8αβ+ DP thymocytes express the CD8αα-homodimer, generating a CD4+  CD8αβ+ CD8αα+ 
triple-positive (TP) thymocyte population. Interestingly, many TP cells survive and differentiate in vitro in 
response to agonist antigen and IL-15, with a majority of cells becoming mature TCRαβ CD8αα IELs. To 
confirm the differentiation of TP thymocytes into TCRαβ CD8αα IELs in vivo, TP (CD45.1+) cells were 
sorted and adoptively transferred into (CD45.2+) recipient B6 mice, where they were shown to 
differentiate into non-conventional TCRαβ CD8αα IELs with a CD5- Thy1- phenotype. Additional evidence 
to support agonist-based thymic selection for TCRαβ CD8αα IELs was also provided by Yamagata et al. 
[22] , who illustrated that some DP cells survive exposure to their cognate antigen and differentiate to 
single-positive (SP) TCRαβ CD8αα cells that express many transcripts in common with TCRαβ CD8αα 
IELs. 
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Fig. 2 A model for IEL development. In the thymus, immature CD4+ CD8αβ+ CD8αα+ (triple-positive) 
thymocytes undergo agonist (‘alternative’) selection and differentiate into double-negative TCRαβ+ cells that 
are the precursors of natural TCRαβ+ CD8αα+ intestinal intraepithelial lymphocytes (IELs). CD4+ CD8αβ+ 
(double-positive) thymocytes undergo ‘conventional’ thymic selection and differentiate into CD4+ and CD8αβ+ 
TCRαβ+(single-positive) T cells that migrate to the periphery. These naive T cells may differentiate into 
effector T cells in response to peripheral antigens and subsequently migrate to the gut and become 
incorporated into the induced IEL compartment. APC: antigen-presenting cell; MLNs: mesenteric lymph 
nodes. Cheroutre et al. [1]. 
Lambolez et al. [23] also suggest a thymic origin for non-conventional IELs, showing that thymic 
precursors at the DN2-DN3 developmental stage (prior to the DP stage) are capable of leaving the thymus 
and migrating to the gut. This was shown through transplantation of CD45.1+ neonatal thymi, or adoptive 
transfer of specific CD45.1+ thymic populations, into CD45.2+ Rag2-/- Il2rg-/- mice. Whereas a full neonatal 
thymus transplant, or transfer of T-cell committed DN2-DN3 precursors, resulted in reconstitution of 
CD8αα+ IELs in the gut, injection of more mature DP or SP thymocyte populations did not. Peaudecerf et al. 
[24] later showed the existence of a DN1-DN2 intermediate thymocyte population, characterised as Lin 
(CD3, CD4, CD8)- CD45+ CD117+ CD127int/- CD25int Sca-1int CD90int, which could egress from the thymus, 
colonize the gut, and differentiate into CD8αα IEL. Here, neonatal thymi from WT mice were transplanted 
into Rag2-/- γc-/- or Rag2-/- mice. In the first mouse strain, the cryptopatch niche is empty and immature 
local precursors are almost entirely absent. Thus, DN precursor cells from the transplanted neonatal 
thymus should be able to colonize the gut. In the latter mouse strain, the cryptopatch niche is full and this 
should hinder entry of new DN precursor cells from the neonatal transplanted thymus. Results showed 
that CD8αα+ IEL generation occurred in Rag2-/- γc-/- mice, but was virtually absent in Rag2-/- mice, 
suggesting that almost all CD8αα+ IELs derive from a DN progenitor. A breakthrough in elucidating the 
mechanism of TCRαβ CD8αα IEL development was achieved in 2012 by Podezinsky et al. [25], who 
showed that clonal deletion during negative selection in the thymus requires CD28-mediated co-
stimulation of autoreactive thymocytes. Autoreactive thymocytes that did not express CD28 or that had 
sufficiently high in vitro-induced overexpression of the anti-apoptotic factors B-cell lymphoma 2 (Bcl-2) 
and myeloid cell leukemia 1 (Mcl-1) survived clonal deletion. Interestingly, these surviving thymocytes 
had a TCRαβ+ CD4- CD8- phenotype and were shown to preferentially home to the gut, where they 
subsequently re-expressed CD8α to become mature unconventional TCRαβ CD8αα IELs. Thus, TCRαβ 
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CD8αα IEL can develop from autoreactive thymocytes that escape clonal deletion and survive negative 
selection in the thymus. Finally, two recent papers by McDonald et al. [26] and Mayans et al. [27] illustrate 
that TCR specificity plays an important role in directing development of non-conventional TCRαβ CD8αα 
IELs. By cloning and expression of several endogenous TCRαβ CD8αα IEL TCRs in WT thymocytes, 
McDonald et al. [26] showed that unconventional IEL TCRs induced the generation of a DP (CD4, CD8)lo 
population in the thymus. These cells developed into CD4- CD8-/lo cells that had high expression of CD122, 
expressed markers such as 2B4, Ly49 and CD160, and had downregulated expression of CD90. Thus, these 
cells exhibited all characteristics of unconventional IELs and accordingly could be recovered from the 
intestinal epithelium. In contrast, TCRs cloned and expressed from conventional IELs were unable to 
generate DPlo cells, but instead generated a population of DPhi cells that could develop into conventional 
TCRαβ CD8αβ cells. Interestingly, DPlo thymocytes also expressed high levels of CD69, early growth 
response 2 (Egr2), nerve growth factor IB (Nur77) and Bcl-2-interacting mediator of cell death (Bim), 
which have previously been associated with elevated TCR signalling and negative selection [28-30]. 
Indeed, a large proportion of these cells had increased caspase-3 activity and stained positive for annexin-
V, suggestive of large-scale apoptosis following signalling through the TCR receptor. Investigating the 
underlying mechanism, the authors showed that thymocytes took on a DPlo phenotype following exposure 
to their cognate antigen. However, some cells were able to survive thymic deletion (i.e. were agonistically 
selected) and migrated to the intestine where they developed into unconventional TCRαβ+ IEL. Hence, this 
paper showed conclusively that TCRαβ CD8αα IEL can develop from a DPlo precursor population, and that 
the TCR specificity dictates thymocyte phenotype and development. In parallel, Mayans et al. [27]  cloned 
TCRs from unconventional TCRαβ+ IEL and transfected these into BM cells, creating BM chimeras on an 
MHC-sufficient or MHC-restricted background. Results showed that all BM precursor cells developed into 
unconventional TCRαβ+ IELs, which were predominantly CD8αα+ CD69+ CD122+ and CD90lo. Furthermore, 
the authors identified TCRαβ+ DN thymic precursors for these cells and demonstrated that the specificity 
of TCRs from unconventional TCRαβ+ IEL was not restricted to classical MHC-class I or II ligands, but also 
included specificity for β2-microglobulin (β2m)-dependent nonclassical MHC molecules and antigens 
presented in a transporter associated with antigen processing (TAP)-independent context. Once more, 
this study corroborates the importance of the TCR in lineage development of non-conventional TCRαβ+ 
cells, and provides evidence for the existence of an agonist-selected thymic precursor for these cells. 
Very little is known with respect to the development of unconventional TCRαβ CD4+ CD8αα+ IELs [5,31]. 
However, a recent study by Van Kaer et al. [32] showed that CD4+ IEL can be differentiated in vitro to CD4+ 
CD8α+ IELs  T cells in the presence of  interleukin (IL)-7 and transforming growth factor (TGF)-β.  
Several factors are known to influence development of IELs, including IL-7, T-bet, T-helper inducing POZ-
Kruppel like factor (ThPOK), runt-related transcription factor 3 (Runx3) and G-protein coupled receptor 
(GPR)18.  Il7-/- and Il7rα-/- mice lack γδ IEL, suggesting that IL-7 is crucial to γδ T cell development [33-
35]. Indeed, Laky et al. [36,37] showed that IL-7 is required for both intrathymic and extrathymic TCRγδ 
IEL development. When Il7-/- thymi were grafted into TCRβ-/- host mice, no graft-derived TCRγδ cells 
developed, indicating that intrathymic IL-7 is required for thymic IEL development. Alongside, it was 
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shown that TCRγδ cells can develop extrathymically in adult, thymectomized and irradiated mice 
reconstituted with Il7-/- BM, suggesting that peripheral IL-7 is sufficient to sustain extrathymic TCRγδ 
development [37]. Moreover, an elegant study performed by this same group illustrated that TCRγδ cells 
can develop in Il7-/- mice that overexpress IL-7 specifically in the intestinal epithelium [36]. More recently, 
Shitara et al. [38] have corroborated these results, showing the necessity of thymic IL-7 for TCRγδ IEL 
development by demonstrating that IL-7flox/flox FoxN1-Cre mice, in which thymic epithelial cells lack IL-7 
expression, have significantly decreased numbers of TCRγδ cells in the gut epithelium. As well, Ye et al. 
[39] have demonstrated that IL-7 is required for initiating TCRγ gene rearrangements. Thus, IL-7 plays a 
crucial role in the development of TCRγδ–positive IELs. An interplay of transcription factors, most notably 
T-bet, Runx3 and ThPOK, has also been shown to influence IEL development and plasticity. All IELs 
express high levels of the transcription factor T-bet, with T-bet expression in these cells exceeding that of 
peripheral T cells. Consequently, Tbx21-/- mice, that are T-bet deficient, have severely reduced numbers of 
all CD8αα-expressing and TCRγδ IELs [40]. Included in this are induced CD4+ CD8αα+ IELs, which 
constitute a population of peripheral CD4+ T cells that have acquired CD8αα expression and an IEL 
phenotype in the gut [5,40]. Mucida et al. [5] demonstrated that CD4+ CD8αα+ IEL may evolve from CD4+ 
effector T cells that downregulate ThPOK expression and upregulate Runx3 expression. Functionally, this 
results in reactivation of the cytotoxic T cell program and endows these cells with cytotoxic properties. 
Differentiation of CD4+ CD8αα+ cytotoxic T lymphocytes (CTLs) was shown to be driven by antigen and 
excessive cytokine stimulation in vivo. Interestingly, Reis et al. [40] show the ability of T-bet to bind 
transcriptional elements of Runx3, and in conjunction with Runx3 the ability to bind ThPOK regulatory 
elements, resulting in downmodulation of ThPOK. Indeed, Tbx21-/- ThPOK-GFP reporter mice have 
impaired CD8αα induction and display reduced ThPOK downregulation. Also, overexpression of Tbx21 in 
CD4+ T cells resulted in enhanced CD8αα expression and ThPOK loss, where these effects were abrogated 
in the absence of Runx3 [40]. As such, changes in T-bet levels may regulate downstream Runx3 and ThPOK 
expression, which in turn influence development and differentiation of specific IEL subpopulations. 
Factors mediating T-bet expression levels are diverse, and include IL-15, TGF-β, retinoic acid, interferon 
(IFN)-γ and IL-27 [21,25,40-43]. Lastly, a recent paper by Wang et al. [44] has identified GPR18 as 
important to the development of CD8αα-expressing IELs. Gpr18-/- mice have a significant reduction in the 
total numbers of IELs, with a marked deficiency in TCRγδ CD8αα and TCRαβ CD8αα IELs.  Remaining 
Gpr18-/- TCRγδ cells are Thy1hi , depleted for Vγ7, and show only low granzyme B expression, consistent 
with a less mature effector state [44]. The mechanism through which GPR18 regulates IEL differentiation 
is unknown. 
iii. Survival of IELs
IELs readily undergo spontaneous apoptosis ex vivo, making it a challenge to study these cells [45,46]. 
Nonetheless, several factors have been shown to influence the survival of gut IELs, most notably IL-7 and 
IL-15 [45,47-49]. Yada et al. [45] showed that addition of IL-7 or IL-15 to IEL cultures decreased 
spontaneous apoptosis of IEL by 50-60%. Adding both IL-7 and IL-15 did not synergistically enhance the 
observed effect. Further study into the mechanisms underlying IL-7-mediated IEL survival showed that 
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addition of IL-7 reduced IEL caspase-3 activity. Additionally, IL-7 could prevent spontaneous apoptosis of 
IELs through inhibition of a Bcl-2 decrease, where Bcl-2 is an anti-apoptotic cell factor [45]. Similarly, IL-
15 was shown to sustain IEL survival through maintenance of Bcl-2 and Bcl-XL [45,50,51]. More recently, 
Lai et al. [52] have shown that, in addition to maintaining Bcl-2 levels, IL-15 activation of the Jak3-Jak1-
PI3K-Akt pathway also results in phosphorylation of Bim. In adoptive transfer studies, they subsequently 
showed that overexpression of Bcl-2 or Bim deficiency in CD8αα-positive IELs promoted their survival in 
Il15-/- mice. Moreover, a study by Jiang et al. [53] demonstrated that upstream signalling through the 
intracellular sensor nucleotide-binding oligomerisation domain-containing protein (NOD)2 is implicated 
in IL-15-mediated IEL survival. In this study, it was shown that Nod2-/- mice have severely reduced 
numbers of unconventional IELs. Loss of IELs in these mice is correlated to impaired expression of IL-15 
by antigen presenting cells. Thus, under normal circumstances, microbial stimulation of antigen 
presenting cells, resulting in IL-15 expression, is important for IEL homeostasis and survival. 
iv. Function of intestinal intraepithelial T lymphocytes
IELs in the small intestine are primarily ‘natural’ TCRγδ and TCRαβ CD8αα cells (~60%). In contrast, IELs 
of the large intestine are primarily ‘induced’ TCRαβ CD4 and TCRαβ CD8αβ T cells (~70%)[1,2]. The ratio 
of ‘natural’ to ‘induced’ IELs in the gut changes gradually with age, with accumulation of ‘induced’ IELs 
following exposure to exogenous antigen. As a result, the mucosal immune system develops an almost 
‘personal’ immune repertoire, allowing for adaptation and an optimal response to challenges of the 
immune system [1]. 
An interesting property of IELs is their activation state, which has been described as ‘activated but resting’ 
[3]. This is due to high expression of effector molecules, such as granzymes A and B and FasL, as well as 
expression of the activation marker CD69, by IELs even when these cells are unchallenged. On the other 
hand, low expression levels of cytokine receptor chains CD25 (IL-2Rα) and CD215 (IL-15Rα), which are 
strongly induced upon activation, are reminiscent of a resting state. These results were confirmed by 
serial analysis of gene expression (SAGE), which showed that all IELs constitutively express genes 
associated with immediate response, whereas conventional cytokines and growth factors are 
underrepresented. Moreover, SAGE identified a high number of tags for the transcription factor JunB, 
where JunB is known to aid in maintaining highly differentiated cells in a resting state [3]. An ‘activated 
yet resting’ phenotype allows IELs to remain quiescent when exposed to numerous luminal antigens, yet 
simultaneously allows for a rapid response when challenged with an immunological attack [4]. 
IELs have been implicated in numerous immunological processes, both beneficial and pathological to the 
host. With respect to conventional TCRαβ CD8αβ IELs, these cells are known to have both protective and 
pathogenic effector functions [3]. Previous studies indicate that TCRαβ CD8αβ IELs have an antigen-
specific cytotoxic potential that exceeds cytotoxicity of spleen CD8 T cells. Thus, these cells are very potent 
at fighting infection, and have been reported an important role in a number of infectious systems, 
including rotavirus [54-56], vaccinia virus [57], lymphocytic choriomeningitis virus (LCMV) [58,59] and 
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Toxoplasma gondii infections [60]. Alongside, numerous studies have shown that TCRαβ CD8αβ T cells are 
required for an effective anti-tumour response. In this setting, conventional TCRαβ CD8αβ IEL recognize 
tumour antigens expressed in an MHC class-I restricted manner. Upon recognition, activated TCRαβ 
CD8αβ  IEL expand clonally and kill tumour cells through the release of lytic granules [61]. Cytotoxic 
CD8αβ IEL are crucial in the colorectal cancer anti-tumour response. Naito et al. [62] reported that 
infiltration of tumours by CD8 T cells expressing granzyme B is associated with better patient survival. 
Chiba et al. [63] confirmed the importance of intraepithelial CD8 T cells in immune response to colorectal 
cancer, showing that increased numbers of these cells are positively correlated with favourable tumour 
staging and patient survival. Moreover, Watson et al. [64] illustrated a role for TCRαβ CD8αβ IEL in 
colorectal cancer anti-tumour response, showing that tumours with low MHC class I expression conferred 
a significantly poorer survival prognosis. TCRαβ CD8αβ IEL have also been shown to exacerbate coeliac 
disease, where natural-killer group 2, member D (NKG2D) expressed on the surface of these cells interacts 
with MHC class I polypeptide-related sequence-A (MIC-A) on stressed intestinal epithelial cells (IECs), and 
elicits villous atrophy [65,66]. 
A role for TCRαβ CD4 IELs in mediating immune response to parasitic infection has been demonstrated by 
McDonald et al. [67]. In this study, infection of SCID mice with Cryptosporidium muris oocysts resulted in 
severe chronic infection, where co-transfer of IEL procured protection. Depletion of CD4 IEL abrogated the 
ability to provide immunity upon infection of SCID mice, thus showing the importance of TCRαβ CD4 IEL 
in this model [67]. TCRαβ CD4 IELs have also been attributed important regulatory functions, where a role 
for these cells has been demonstrated in the CD4 T cell transfer model of induced colitis. In this model, 
CD4+ CD45RBhi splenic or lymph node cells are transferred to immune-deficient recipient mice, where 
transfer of these cells elicits severe intestinal inflammation [68,69]. In this model, co-transfer of CD4+ 
CD103+ [70,71] and CD4+ CD8αα+ [72] IELs has been shown to reduce intestinal pathology and 
inflammation. Nonetheless, aberrant CD4+ are known to drive intestinal inflammation in both Crohn’s 
disease and ulcerative colitis [73,74]. Conventional TCRαβ CD4 T cells may also be beneficial in cancer 
immunosurveillance, where through production of Th1-type cytokines, these cells aid in proliferation of 
cytotoxic TCRαβ CD8 T cells [61]. TCRαβ CD4 T cells may also function as a prognostic marker in 
colorectal cancer, where Matsuda et al. [75] described significant infiltration of CD4 T cells into 
moderately differentiated colon adenocarcinoma tissue, whereas infiltration was low in poorly-
differentiated adenocarcinoma. 
Testament to the plasticity of immune cells in the gut is the described presence of tumour-infiltrating 
TCRαβ CD4 CD8αβ CD103+ IEL in the context of colorectal cancer. Numbers of CD4+ CD8αβ+ cells were 
shown to be increased in metastatic colorectal cancer, and cells were shown to secrete high levels of IL-4 
and IL-13, suggesting that these cells may promote immune tolerance and therein tumour growth and 
metastasis [76].  
A role for TCRαβ CD4 CD8αα IEL in intestinal immune response has been demonstrated by Das et al. [72], 
who showed that CD4+ T cells stimulated with Th2 cytokines acquired CD8αα expression when reaching 
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the gut upon adoptive transfer in Rag1-/- mice. Subsequent co-transfer of sorted CD4 CD8αα TCRαβ IEL 
with Th1-polarised cells in syngeneic Rag1-/- mice was shown to reduce inflammation, as compared with 
transfer of Th1-polarised cells alone, in these mice. Protection was shown to be IL-10-mediated, as 
transfer of CD4+ CD8αα+ IEL sorted from Il10-/- mice did not protect mice from development of intestinal 
inflammation in this model [72]. Thus, CD4+ CD8αα+ IEL may exert an important regulatory role in IBD. 
Contrary to these studies, and as previously mentioned, Mucida et al. [5] demonstrated that CD4+ CD8αα+
IEL can differentiate from CD4+ effector T cells that downregulate ThPOK and upregulate Runx3 
expression, respectively. Functionally, this results in reactivation of the cytotoxic T cell program, and 
endows these cells with cytotoxic properties. As such, it was shown that stimulation of diet-induced 
ThPOK− OT-II CD4+ CTLs with IL-15 results in marked upregulation of CD107a expression and a significant 
increase in IFN-γ and TNFα production by these cells [5]. These studies demonstrate and suggest that 
TCRαβ CD4 CD8αα IEL may differ in functionality and exert both protective and pathogenic roles in 
intestinal immunity dependent on the type of cytokine exposure during differentiation from CD4+ T cells. 
Unconventional TCRγδ IELs have been designated an important role in a number of immune-mediated 
processes. TCRγδ cells have been studied extensively with regard to their role in infectious disease 
models, IBD, recognition of stress-induced ligands and repair of the intestinal epithelium. With respect to 
infectious disease models, an early study by Roberts et al. [77] demonstrated that infection of TCRδ-/- mice 
with Eimeria vermiformis, an intracellular protozoan parasite, results in a pro-inflammatory αβ T-cell 
mediated response. Interestingly, adoptive transfer of bulk IEL to these mice is able to significantly reduce 
inflammation, suggesting that TCRγδ cells exert a protective role in this model through regulation of the 
αβ T cell response. Subsequent studies have gone on to show an important role for γδ T cells in other 
infection models. Inagaki-Ohara et al. [78] showed that γδ T cells are important in resistance to infection 
with the nematode Nippostrongylus brasiliensis. In this model, TCRδ-/- mice showed more severe clinical 
disease and microscopic lesions, and succumbed more rapidly to infection as compared with WT controls. 
Moreover, nematode egg production and worm burden were significantly higher in TCRδ-/- as compared 
with WT infected mice. Here, intraepithelial γδ T cells were shown to produce IL-13, and administration of 
recombinant IL-13 to TCRδ-/- mice was able to partially ameliorate disease, reducing N. brasiliensis egg 
production. Furthermore, TCRδ-/- mice expressed higher levels of IFN-γ than WT mice, where αβ T cells 
were shown to be the main IFN-γ producers. This suggests that TCRγδ IEL may indirectly control N. 
brasiliensis infection through regulation of the intestinal αβ T cell compartment. Lastly, TCRδ-/- mice had a 
decreased crypt/villus ratio and fewer Ki67 (a proliferation marker)-positive epithelial cells, suggesting 
that γδ T cells are also involved in epithelial cell turnover, an important mechanism in nematode 
expulsion [78]. Protection against T. gondii infection is mediated in part by conventional TCRαβ CD8αβ 
cells. Interestingly, protection of T. gondii-infected mice by TCRαβ CD8αβ cells was shown to be partly 
dependent on the presence of TCRγδ IELs [79]. Here, primed CD8β+ T cells were isolated from WT mice at 
6 days post-infection and adoptively transferred into naïve TCRδ-/- mice or WT control mice. Indeed, 
transfer of CD8β+ T cells into WT mice protected these mice from mortality upon challenge with T. gondii, 
whereas TCRδ-/- mice survival was reduced by 50%. Furthermore, TCRδ-/- mice had a significantly 
increased cyst burden as compared to infected WT mice [79]. TCRγδ IEL have also been implicated in 
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resistance to Salmonella typhimurium infection, where Zhiyuan et al. [80] showed that numbers of TCRγδ 
CD8αα are strongly increased following infection, and that IEL cytotoxicity towards infected intestinal 
epithelial cells is high. In both T. gondii and S. typhimurium infections, γδ T cells were additionally shown 
to exert a protective function through maintenance of the epithelial barrier, where epithelial 
transmigration of T. gondii and S. typhimurium is enhanced in TCRδ-/- mice. Epithelial permeability in 
TCRδ-/- mice is associated with a lack of occludin phosphorylation and claudin 3 as well as zona occludens-
1 proteins in tight junction complexes, and reconstitution of these mice with TCRVγ7 IELs was shown to 
be sufficient for restoration of epithelial barrier function [81]. Beside the aforementioned infectious 
models, γδ T IELs have also been implicated in resistance to Listeria monocytogenes and Encephalitozoon 
cuniculi infections [82-84]. A function for TCRγδ IELs in IBD development has been extensively 
investigated through the use of both chemically-induced models of colitis, including dextran sodium-
sulphate (DSS)- and trinitrobenzenesulfonic acid (TNBS)-induced colitis, and genetically induced models 
of IBD, including TNF∆ARE/+ ileitis and Il2-/--mediated colitis. Kühl et al. [85] extensively examined the 
consequence of γδ T cell depletion or deficiency in DSS-induced colitis, Il2-/--mediated colitis and TNF∆ARE/+ 
ileitis. Depletion of γδ T cells using a γδ T-cell depleting antibody aggravates DSS-induced colitis and 
TNFΔARE/+ ileitis. Similarly, TCRγδ-/- mice display exacerbated DSS-induced colitis. Il2-/- mice show 
increased mortality upon early (4 weeks of age), but not late (8 wks of age) γδ T cell depletion. Increased 
pathology in the gut of γδ T cell-depleted or deficient mice in all models was associated with an increase in 
lamina propria lymphocyte IFN-γ expression. As TCRγδ cells express very few IFN-γ transcripts, the 
authors hypothesize that TCRγδ cells regulate IFN-γ expression by αβ T cells through an as yet undefined 
mechanism. Complimentary studies by a number of groups have shown that TCRγδ cells may also exert a 
direct protective effect in IBD development and progression, through maintenance and repair of the 
intestinal epithelium. As such, Chen et al. [86] illustrated the importance of γδ T cell-produced 
keratinocyte growth factor-1 (KGF-1) in DSS-induced colitis, showing that both TCRγδ−/− mice and Kgf-/- 
mice have severe defects in repair of the intestinal epithelium following DSS treatment. More recently, 
Meehan et al. [87] showed that interaction of CD100 expressed by γδ-IELs, with plexin B2 on epithelial 
cells, is required for KGF-1 mediated epithelial repair following DSS-induced colitis. Inagaki-Ohara et al. 
[88] demonstrated that TCRδ−/− mice are highly susceptible to TNBS-induced colitis, and that adoptive 
transfer of γδ IELs to TCRδ−/− mice ameliorates TNBS-induced colitis. Roselli et al. [89] corroborated this 
result, showing that a probiotic-induced increase in γδ-positive IELs suppressed TNBS-induced colitis 
development in TNBS-treated mice. Taken together, this data illustrates a protective role for TCRγδ IELs 
in IBD development. A role for γδ T cells in cancer development and progression has also been illustrated. 
Matsuda et al. [90] showed that TCRδ-/- mice  are more susceptible to azoxymethane (AOM)-mediated 
colorectal cancer, and developed more adenocarcinomas as compared with TCRα-/- and WT mice. 
However, a study in adenomatous polyposis coli (Apc)Min/+ TCRδ-/- mice showed that these mice develop 
significantly less adenomas than control ApcMin/+ mice, suggesting that TCRγδ IEL may exert both 
beneficial and pathological roles in tumour development [91]. Additional data from human studies show a 
role for γδ T cells  in tumour immunity,  where γδ T cells are capable of recognizing stress- or 
transformation-induced cell ligands, such as tumour-expressed MIC-A and  MIC-B proteins [92,93]. 
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Unconventional TCRαβ CD8αα IEL are agonist-selected cells [26]. Despite their self-reactivity, these cells 
appear to have profound tolerogenic and regulatory functions [22,94]. As such, Saurer et al. [95] 
demonstrated that self-reactive TCRαβ CD8αα IEL isolated from mice expressing their cognate antigen 
had reduced expression of IL-2, IL-10 and IFN-γ when stimulated in vitro by plate-bound anti-CD3, as 
compared with TCRαβ CD8αα IEL isolated from mice lacking the cognate antigen. Alongside, in vivo LCMV-
induced activation of TCRαβ CD8αα IEL did not result in upregulation of pro-inflammatory cytokines or 
cytotoxicity, confirming the tolerogenic nature of these cells [95]. TCRαβ CD8αα IEL have also been 
attributed a role in the immune response to bacterial sepsis, where a study by Tung et al. [96] illustrated 
that sepsis is accompanied by increased expression of IL-2Rβ, IL-15Rα, and IFN-γ mRNA by TCRαβ CD8αα 
IELs.  With respect to IBD, a study by Poussier et al. [97] illustrated that TCRαβ CD8αα IEL are protective 
in the CD4+ T cell transfer model of induced colitis. Here, co-transfer of TCRαβ CD8αα IEL and CD4+ 
CD45RBhi splenic cells to SCID mice protected mice from colitis development, and this in contrast to co-
transfer of CD4+ CD45RBhi  cells with TCRαβ CD8αβ IEL. Protection was IL-10-mediated, as TCRαβ CD8αα 
IEL isolated from Il10-/- mice were unable to prevent colitis development [97]. Unconventional IEL have 
been shown to recognize a number of non-MHC class I-restricted ligands. With respect to TCRαβ CD8αα 
IEL, an early study by Gapin et al. [98] demonstrated that numbers of these cells are reduced in β2m-/- and 
TAP-/- mice as compared to WT mice, but a small population of cells remains. This suggests that at least 
some TCRαβ CD8αα IEL are not dependent upon MHC class I molecules. Indeed, Leishman et al. [99] 
showed that CD8αα can bind the non-classical MHC class-I molecule thymus leukemia antigen (TL). TL is 
abundantly expressed on IECs [100]. Interestingly, binding of CD8αα to TL modifies TCR-mediated cell 
responses upon antigen exposure, whereby stimulated-IEL proliferation decreased, and the cytotoxic 
killing capacity of TCRαβ CD8αα IEL was reduced [99]. Olivares-Villagomez et al. [101] corroborated these 
results in part, showing that colonic TCRαβ CD8αα IELs from TL-/- mice incorporated more BrdU, used as a 
proliferation marker, than  TCRαβ CD8αα IELs from TL+/+ mice. Thus, interaction of CD8αα with TL 
modifies the proliferation capacity of TCRαβ CD8αα IELs. Interestingly, TL absence does not influence 
DSS- or TNBS-induced colitis, wherein the epithelial barrier is breached. This suggests that TL expression 
on IECs may not be sufficient in these models to have a critical effect on colitis development [101]. Taken 
together, interaction of TCRαβ CD8αα IELs with TL appears to modulate IEL proliferation and function, 
aiding in maintenance of the ‘activated yet resting’ phenotype. Most recently, Huang et al. [102] have 
additionally shown that expression of TL by IECs is involved in the selection of mature TCRαβ CD8αβ 
memory cells that transiently express CD8αα. A function for TCRαβ CD8αα IELs in mediating intestinal 
tumour immune response has not been described to our knowledge. However, studies by Marsh et al. [91] 
and Matsuda et al. [75] demonstrate that numbers of CD8αα IELs are reduced in two models of colorectal 
cancer, namely ApcMin/+ mediated and AOM-induced colorectal cancer. 
v. Human intestinal intraepithelial T lymphocytes
IEL are abundantly present in both the murine and human intestine. Nonetheless, some differences 
between mouse and human IEL have been described.  With respect to IEL subset composition it is notable 
that TCRγδ IEL represent only a minor fraction (10%) of all IEL in the human gut [103]. As well as this, 
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TCRαβ CD8αα IEL are present in great numbers in the human foetal intestine, but are rare in human 
adults [104]. As such, unconventional IEL are less prevalent in the human intestine as compared with the 
murine gut. Importantly, this does not reflect a diminished importance of these IEL subpopulations in 
contributing to intestinal mucosal immunity. Testament to this, for example, is the increase in TCRγδ IEL 
in coeliac disease [105]. In this disease setting, Bhagat et al. [106] demonstrated that individuals on a 
gluten-free diet have an increased frequency of NKG2A-expressing TCRγδ IELs as compared to patients 
with active coeliac disease. Triggering of the TCR or NKG2A receptor increases TGF-β expression by these 
cells. Also, co-culture of NKG2A+ TCRγδ IELs with enterocytes and activated TCRαβ IELs decreases the 
percentage of cytotoxic CD8 TCRαβ IELs expressing IFN-γ, granzyme B and surface NKG2D. Thus, TCRγδ 
IEL exert a key suppressor/immunoregulatory function in human coeliac disease [105-107].  
2. Innate lymphoid cells
i. Nomenclature of innate lymphoid cells
ILCs are a recently discovered aggregation of lymphoid cells whose precise classification, development 
and functions are still a matter of debate. Nonetheless, a consensus regarding the nomenclature for ILCs 
was reached in 2013 (Fig. 3). In this nomenclature, ILCs may be divided into three groups: group 1, group 
2 and group 3 ILCs. Group 1 ILCs contain the well-known conventional NK (cNK) cells and ILC1 cells. 
Group 2 ILCs contain only ILC2 cells, which have previously been termed ‘natural helper cells’, ‘nuocytes’ 
and ‘innate helper 2 cells’ [108-110]. Group 3 ILCs are diverse and contain lymphoid tissue inducer (LTi) 
cells, as well as NKp46 negative (NCR-) and NCR+ ILC3 cells [111]. NCR+ ILC3 were previously assigned 
different names, including NK22 [112], NCR22 [113], NKR-Lti [114] and ILC22 cells [115-117]. 
It is currently unknown whether additional ILC subsets exist. Also, due to the apparent functional 
plasticity of some ILC subsets, classification of ILC populations may differ depending on the circumstances 
under which these are studied. 
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Fig. 3 Nomenclature of ILC subsets. Group 1, 2 and 3 ILCs are defined on the basis of their functional 
characteristics. Spits et al. (2013) [111]. 
ii. Development and classification of innate lymphoid cells
All lymphoid cells develop from a common lymphoid progenitor (CLP) [118] (Fig. 4). CLP are Lin- Id2- 
CD127+ α4β7- Flt3+ cells, and can give rise to all ILC subsets, including cNK cells, as well as B and T cells. 
Progenitor cells that can give rise to all ILCs, including cNK, but not to B/T cells have also been identified. 
These progenitor cells are highly similar to CLP, but express α4β7, and are therefore termed α-lymphoid 
progenitor (αLP) cells [118]. Several specific ILC precursors have been identified downstream of the αLP, 
all of which express the transcription factor Id2. Id2 is an antagonist of E proteins, which function as 
transcriptional activators and as such have the capacity to modulate gene transcription [119]. Testament 
to the importance of Id2 for the development of ILCs is the expression of Id2 by all known mature ILC 
populations [120,121]. Furthermore, deletion of Id2 abrogates the development of all ILCs, including cNK 
cells [108,113,122]. Two recently discovered Id2+ ILC precursors will be discussed here. Klose et al. [123] 
described the existence of an Id2+ common helper innate lymphoid progenitor (CHILP). The CHILP 
progenitor was first identified in the BM as being Lin- Id2+ CD127+ CD25- α4β7+. Moreover, CHILP are 
CD93- Flt3- and CD122-, distinguishing this progenitor from the CLP (CD93+ Flt3+) and committed NK cell 
progenitors (CD122+). CHILP are negative for RORγt, T-bet and Eomes, and show only low expression of 
GATA binding protein 3 (GATA-3), thus asserting the immature phenotype of these cells. To assess the 
differentiation potential of the CHILP progenitor, cells were purified and adoptively transferred into 
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alymphoid mice. Here, CHILP differentiated into GATA-3+ ILC2 cells, RORγt+ ILC3 cells, and Eomes- ILC1 
cells, but not into conventional Eomes+ cNK cells. Thus, CHILP progenitors can differentiate to all ‘helper’ 
ILC populations, but not to cytotoxic cNK cells. Another ILC progenitor was identified on the basis of 
transcription factor promyelocytic leukaemia zinc finger protein (PZLF) expression. PLZF+ Id2+ CD3ɛ- 
CD127+ CD117+ CD90+ α4β7+ progenitor cells are found in fetal liver and adult BM, and have the capacity 
to differentiate to CD127+ ILC1, ILC2 and ILC3 (except LTi) cells, but not LTi or cNK cells [124]. Thus, 
whereas CHILP give rise to all ILC3 (including LTi-ILC3) cells, PLZF+ Id2+ progenitors do not, 
demonstrating that PLZF+ Id2+ progenitors appear downstream of the CHILP, and highlighting a branching 
in the development of LTi-ILC3 and ‘other’ ILC3 cells. Interestingly, Klose et al. [123] were able to identify 
a subset of CHILP that expresses PLZF, suggesting that indeed PLZF+ Id2+ progenitors develop 
downstream of PLZF- Id2+ progenitors and represent cells with more restricted developmental potential. A 
specific ILC2 progenitor (ILC2P) has also been described as being Lin- Id2+ CD127+ CD25+ [120]. More 
committed ILC1 and ILC3 progenitor cells have yet to be discovered.  
Fig. 4 A model for ILC development. ILCs develop from a common lymphoid progenitor (CLP). The common 
ILC/NK cell precursor is contained within a population of cells that have the same phenotype as the CLP but 
also express the α4β7 integrin. Downstream of the common ILC/NK cell precursor is an Id2-expressing 
precursor that can give rise to all ILCs, including lymphoid tissue inducer (LTi) cells and an Id2+ PLZF+ 
precursor that is restricted to ILCs but is unable to develop into LTi cells. Some ILC3s may downregulate 
RORγt+ and upregulate T-bet expression to develop into IFNγ-producing cells. These IFN-γ-producing ILC1-
like cells are called ex-RORγt+ ILC3s. Artis and Spits (2015)[118] . 
ILC development takes place during fetal life and continues into adulthood [119]. Known sites for ILC 
development include the BM, fetal liver and fetal gut. With respect to the latter, a previous study by 
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Cherrier et al. [125] identified RORγt+ ILC3-restricted fetal liver precursors that migrate to the gut and 
subsequently differentiate to LTi cells.  
 
Mature ILC subsets are characterised by a lymphoid morphology and lack expression of rearranged 
antigen-specific receptors [116]. Further classification of ILC populations is based on transcription factor 
dependency and functional properties. For the purpose of this thesis, only ILC populations present in the 
gut are discussed below. 
 
Of all ILC populations, cNK cells are undoubtedly the best studied and most extensively characterised. 
Generally speaking, cNK cells may be defined by their developmental dependency on the transcription 
factors Eomes and nuclear factor interleukin-3 regulated (Nfil3). cNK cells are absent or severely reduced 
in Eomes-/- and Nfil3-/- mice, respectively [123]. cNK also strongly express T-bet, but Tbx21-/- mice show 
normal numbers of cNK, showing that development of cNK is not dependent on this transcription factor 
[123]. Furthermore, cNK cells require IL-15 for survival, and produce IFN-γ upon stimulation with the 
cytokines IL-12 and/or IL-18. NK cells are also highly granular, and contain lytic granules for exerting a 
cytotoxic function [116,126]. 
 
ILC1 cells, which together with NK cells constitute the group 1 ILCs, are perhaps the least well defined and 
studied of all ILC populations. In mice, three distinct gut ILC1 populations have been described in recent 
years [123,127,128]. The first of these is the intraepithelial ILC1 as defined by Fuchs et al. [127]. Here, 
ILC1 cells were isolated from the intestinal intraepithelial compartment of Rag1-/- mice. ILC1 cells were 
defined as CD3- Nkp46+ NK1.1+ CD160+ cells. Importantly, intraepithelial ILC1 cells lack expression of 
CD127, the Il7rα chain, which is expressed on the surface of most ILC cells. Development of intraepithelial 
ILC1 cells was shown to be dependent on the transcription factors T-bet and Nfil3, as Tbx21-/- and Nfil3-/- 
mice have strongly reduced numbers of intraepithelial ILC1s. Conversely, development was independent 
of RORγt and aryl hydrocarbon receptor (AhR), two transcription factors required for development of 
ILC3 cells. Setting these cells apart from cNK cells is the lack of dependence on the cytokine IL-15 for 
survival, where intraepithelial ILC1 cells are only minimally reduced in Il15rα-/- mice. As is common to all 
group 1 ILCs, intraepithelial ILC1 cells were shown to produce IFN-γ upon stimulation with IL-12 and IL-
15 [127]. A second ILC1 population was described by Klose et al. [123]. Here, ILC1 cells were identified in 
the lamina propria that are CD3- Nkp46+ NK1.1+ CD127+ CD27+. Furthermore, these cells have surface 
expression of the markers CD117 (c-kit) and CD90 (Thy-1), commonly expressed by ILCs. Lamina propria 
ILC1 cells are dependent on the transcription factor T-bet for their development, but independent of 
Eomes, thus corroborating that these cells are distinct from cNK cells. ILC1 cells are also RORγt-fate map 
(fm) negative, and thus are not “ex-ILC3s”. Interestingly, lamina propria ILC1 development was also found 
to be partially dependent on the transcription factors Nfil3 and GATA-3, which are required for NK cell 
development and ILC2/ILC3 development, respectively, suggesting a previously unappreciated role for 
these transcription factors in ILC1 cell development. In contrast to the intraepithelial ILC1 cells described 
by Fuchs et al. [127], lamina propria ILC1 cells as defined by Klose et al. [123] were shown to require IL-
15 for their maintenance and/or differentiation. Lamina propria ILC1 cells produce IFN-γ upon 
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stimulation with IL-12. Most recently, Van Kaer et al. [128] have described a new lymphoid ILC1-like 
population termed innate CD8α (iCD8α) cells. These cells, located within the intestinal epithelium, are 
characterised as CD3- CD8α+ CD103+ CD11bint CD11cint CD117- Nkp46- NK1.1-. As for the intraepithelial 
ILC1 population described by Fuchs et al. [127], iCD8α cells do not express CD127, and Il7rα-/- mice 
contain equal numbers of iCD8α cells as WT mice.  In contrast to previously described ILC1 populations, 
iCD8α cells are independent of T-bet and AhR, and express very low levels of RORγt. Thus, it remains to be 
determined which transcription factors are essential for the development of these cells. As is the case for 
lamina propria ILC1s [123], but unlike intraepithelial ILC1 cells [127], iCD8α cells are dependent on IL-15 
for their survival and/or maintenance, and are avid producers of IFN-γ upon IL-12 stimulation [128]. 
As previously mentioned, all ILC populations are considered to derive from a common Id2+ precursor. 
Using Id2GFP/+ reporter mice, iCD8α cells were shown to express Id2. However, Id2GFP/GFP mice, which lack 
Id2 expression, contain normal numbers of iCD8α cells. Furthermore, transfer of fetal liver cells from 
Id2GFP/GFP mice to irradiated WT recipients results in full reconstitution of the iCD8α pool, demonstrating 
that iCD8α development is Id2-independent. As such, despite exhibiting many characteristics of ILC1 cells, 
the classification of iCD8α cells as ILC1 cells is still under dispute [128]. 
Group 1 ILCs are highly heterogeneous, and defining what distinguishes cNK from ILC1 cells has become 
more challenging with the identification of new ILC1 subpopulations. To date, the developmental 
dependency of cNK cells, but not ILC1 cells, on the transcription factor Eomes, appears to constitute a true 
distinction between these cell types. In turn, dependency on the transcription factor T-bet is common to 
all group 1 ILCs except cNK. Moreover, a recent large-scale transcriptome analysis of cNK and ILC subsets 
revealed that expression of cd49a, Tmem176a and Tmem176b by ILC1s, but not cNK cells, may also be 
used to efficiently distinguish between these group 1 ILC populations [129]. Furthermore, whereas ILC1 
cells may develop from CHILP precursors, cNK cells do not [123]. 
Group 2 ILCs contain ILC2 cells, which may be characterised as Lin- ICOS+ Sca-1+ CD127+ CD117+ CD90+ IL-
25R+ IL-33R (also known as ST2)+ and thymic stromal lymphopoietin receptor (TSLPR)+ cells [111]. 
Furthermore, killer-cell lectin like receptor G1 (KLRG1) may constitute a good marker for identification of 
ILC2 cells, as KLRG1 is expressed by virtually all ILC2 in adult mice [120]. ILC2 cells have been identified 
in the gut lamina propria [120,130] and depend on the transcription factors GATA-3 and RAR-related 
orphan receptor alpha (RORα) for their development [120,131-133]. Hoyler et al. [120] illustrated a role 
for GATA-3 in ILC2 development by showing that all ILC2 cells are characterised by continuously high 
GATA-3 expression. Subsequently, using conditional Gata3∆ILC/T mice, it was shown that KLRG1+ GATA-3hi 
cells and KLRG1+ RORγt− cells (both representing ILC2 cells) are virtually absent in the lamina propria of 
GATA-3-deficient mice. In parallel, development of RORγt+ ILC was shown to be unaffected in Gata3∆ILC/T 
mice. Yagi et al. [134] confirmed the importance of GATA-3 for maintenance of ILC2 in vivo, similarly 
showing that Gata3flox/flox-CreERT2 mice have reduced numbers of KLRG1+ ILC2s, but not RORγt+ ILCs, in 
the small intestinal lamina propria following tamoxifen treatment. To investigate a role for RORα in ILC2 
development, Rorαsg/sg mice have been used. These mice have a spontaneous deletion in the Rora gene that 
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results in RORα deficiency [133]. Halim et al. [132] demonstrated that Rorαsg/sg mice, but not Rorc(γt)-/-, 
lack ILC2 cells in all tissues studied, including lung, small and large intestine. Alongside, Wong et al. [133] 
generated BM chimeras by transfer of CD45.2 Rorαsg/sg or WT BM cells into CD45.1 irradiated recipient 
mice. BM chimeras showed similar hematological repopulation, but transfer of Rorαsg/sg BM failed to 
generate ILC2 cells, in contrast to WT BM. Moreover, IL-25 injection of Rorαsg/sg mice did not result in 
expansion of ILC2 cells in these mice, as compared with ILC2 expansion in WT controls, confirming the 
importance of RORα for ILC2 development. Functionally, ILC2 cells are characterised by production of 
type 2 cytokines, most notably IL-5 and IL-13, but also IL-4, IL-6, IL-9 and granulocyte-macrophage 
stimulating colony factor (GM-CSF) upon stimulation of these cells by IL-25, IL-33 and/or TSLP [108-
110,132,135,136]. 
Group 3 ILCs are heterogeneous, and a number of different ILC3 populations have been identified. LTi 
cells have been extensively studied, and may be characterised as Lin- CD127+ CD4+/- CCR6+ CD117+ CD90+ 
IL-1R+ IL-23R+ cells [111,137]. These cells are negative for NKp46, a marker that is used to discriminate 
between several murine ILC3 subpopulations. Development of LTi cells is dependent on the transcription 
factors RORγt and AhR. Eberl et al. [138] showed that in fetal Rorc(γt)GFP/+ mice, only LTi cells express 
RORγt. Furthermore, whereas Rorc(γt)GFP/+ mice have normal development of lymph nodes and PPs, 
Rorc(γt)GFP/GFP mice lack these structures as well as LTi cells. Thus, demonstrating that RORγt is essential 
for the generation of LTi cells, and that LTi cells are necessary for the development of lymph nodes and 
PPs. Kiss et al. [139] showed that AhR is implicated in the postnatal expansion of LTi cells and in the 
formation of isolated lymphoid follicles (ILFs). Lee et al. [117] corroborated these results, demonstrating 
that Ahr-/- mice have markedly less LTi cells than WT mice, and lack cryptopatches and ILFs. Lymph nodes 
and PPs are formed during embryonic life, whereas cryptopatches and ILFs function following birth. As 
such, RORγt and AhR may influence the development of LTi cells and the formation of gut-associated 
lymphoid tissue (GALT) both prior to and following birth [140,141]. LTi cells produce IL-17 and IL-22 
upon stimulation with IL-1β and IL-23. Two additional subpopulations of ILC3 cells that can be 
distinguished are NCR- and NCR+ ILC3s, lacking or expressing the NKp46 receptor, respectively [111,137]. 
NCR- ILC3 cells are Lin- CD127+ CD4- CCR6- CD117- CD90+ Sca-1+ IL-1R+ IL-23R+ cells. These cells produce 
IL-17A, IL-22 and IFN-γ upon stimulation with IL-1β and IL-23. NCR+ ILC3s are Lin- CD127+ CD4- CCR6- 
CD117+ CD90+ IL-1R+ IL-23R+ cells [111,137]. These cells produce IL-22 upon stimulation with IL-1β and 
IL-23. Both NCR- and NCR+ ILC3 depend on RORγt for development. The requirement of RORγt for NCR- 
ILC3 development was illustrated by Buonocore et al. [142]. NCR- ILC3 express high levels of RORγt, and 
Rag-/- Rorc(γt)-/- mice show significantly reduced expression of IL-23R in the colon as compared to Rag-/-
mice, suggesting that RORγt may be important in the development of these cells. The requirement of 
RORγt for NCR+ ILC3 development was shown by Klose et al. [123] who demonstrated that Rorc(γt)-/- mice 
have significantly reduced numbers of NKp46+ NK1.1+ ILC3 as compared with WT mice. Additionally, 
NCR+ ILC3s depend on AhR and T-bet for their development [111,118]. Ahr-/- mice harbor a severely 
diminished population of CCR6- T-bet+ RORγt+ ILC3 cells [143]. Tbx21-/- mice, in turn, have normal 
development of CCR6+ LTi and CCR6- NKp46- RORγt+ (NCR-) ILC3 populations, but are devoid of CCR6- 
NKp46+ RORγt+ (NCR+) ILC3s [143]. It has been suggested that NCR- ILC3 cells may differentiate into NCR+ 
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ILC3s. As such, a study was performed in which genetically labeled ILC3 subsets were transferred into 
alymphoid mice. Results showed that CCR6+ LTi cells are a stable lineage. A subset of CCR6- NKp46- RORγt+ 
(NCR-) ILC3 cells, however, upregulated T-bet, lost RORγt and acquired NKp46 expression. Here, the 
commensal microbiota instructs T-bet expression, where germ-free and myeloid differentiation primary 
response gene 88  (Myd88)-/- toll/interleukin 1 receptor domain containing adaptor inducing IFN-β (Trif)-
/- mice have strongly reduced numbers of NCR+ ILC3 cells [143]. IL-12 and IL-15 have also been shown to 
accelerate RORγt loss in NCR+ ILC3s, where RORγt+ NCR+ ILC3 cells produce IL-22, but Rorc(γt)lo/- NCR+ 
ILC3 release IFN-γ [114]. Therefore, it appears that NCR- and NCR+ ILC3 cells constitute flexible ILC3 
populations that may alter in phenotype and function dependent on the gut environment. NCR+ ILC3s have 
been shown to produce IL-22 and IFN-γ upon stimulation with IL-1β and IL-23, but they do not produce 
IL-17A [111,115,118]. 
iii. Function of innate lymphoid cells
ILC are distributed throughout the length of the intestine, with group 1 ILC located within the epithelium 
as well as the lamina propria compartment. Group 2 and group 3 ILCs are mainly located within the 
lamina propria. Due to their strategic localisation, ILCs are able to respond rapidly to breaches of the 
intestinal barrier and may mount an important primary immune response to viral or bacterial infection, as 
well as contributing to IBD and intestinal tumourigenesis. 
Group 1 ILCs have been assigned a number of functions. NK cells, first described in 1975, are important 
players in frontline defense to infected and transformed cells [144,145]. In this, NK cells may function as 
either helper or cytotoxic cells, secreting IFN-γ and eliciting Th1-type immunity, or killing target cells. 
Killing is mediated through the secretion of perforins and granzymes, or through Fas/FasL-mediated 
caspase-dependent apoptosis [146]. NK cells have been implicated in protection against numerous 
infections. Ashkar et al. [147] showed that NK cells are involved in elimination of S. typhimurium infection, 
where Il15-/- mice have increased bacterial burdens, and depletion of NK cells in WT mice results in 
increased bacterial colonization. Schulthess et al. [148] demonstrated that lamina propria NK cells 
contribute to T. gondii infection, where IL-15 and IL-18 induction of NK cells results in CCL3 expression by 
these cells. NK CCL3 expression was indispensable for recruitment of inflammatory monocytes to the gut, 
where these cells aided in parasite control. As a last example, NK cells have also been shown to protect 
against Yersinia enterocolitica infection, where Trif-/- mice, which are defective in IFN responses and have 
impaired phagocytosis, present with greater Y. enterocolitica dissemination and mortality as compared to 
WT mice. Immunity to infection was mediated in part by IFN-γ+ NK cells, where induction of IFN-γ 
increased macrophage bactericidal activity to sufficient levels for elimination of Y. enterocolitica 
pathogens [149].  A function for NK cells in IBD was recently demonstrated by Hall et al. [150], as NK cell 
depletion in the model of DSS-induced colitis impairs survival and increases colonic inflammation. Here, 
NK cells were shown to downregulate cytokine and reactive oxygen species production by activated 
neutrophils, which attenuates inflammation and tissue injury in treated mice. A limited role for NK cells in 
the context of colorectal cancer development has also been suggested, where several studies have shown 
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that infiltration of tumours by NK cells, in combination with CD8+ T cells, improves survival rates [151-
154]. 
ILC1 cells have been designated various functions, ranging from defense against bacterial infections to 
mediating IBD development [118,123,127,128]. Intraepithelial ILC1 cells were shown to contribute to 
inflammation in the model of anti-CD40-mediated colitis [127]. In this model, injecting anti-CD40 antibody 
into immunodeficient Rag1-/- mice induces rapid and robust colitis development [155]. Thirty-six hours 
following anti-CD40 injection, intraepithelial ILC1 cells from Rag1-/- mice were shown to produce copious 
amounts of IFN-γ, contributing to gut inflammation. Moreover, depletion of both cNK and intraepithelial 
ILC1 cells with an anti-NK1.1 antibody reduced colon inflammatory cell infiltration and epithelial damage 
as compared to control mice, suggesting that IFN-γ producing intraepithelial ILC1 cells may contribute to 
colitis in this particular IBD model [127]. Lamina propria ILC1 cells have in turn been attributed an 
important role in the protection against T. gondii parasite infection [123]. Four days following oral gavage 
of EomesGFP/+ x Rorc(γt)-fm mice with T. gondii, ILC1 cells were shown to be the main producers of both 
IFN-γ and TNF-α in response to infection. Moreover, Tbx21-/- mice, which lack ILC1 cells but have normal 
cNK cell numbers, show little IFN-γ production and are subsequently unable to control parasite load and 
infection [123]. In this, ILC1 were demonstrated to be important for the recruitment of inflammatory 
monocytes to the gut, which were previously shown to be crucial in control of T. gondii infection [156]. 
Thus, ILC1 are significant players in the response and control of T. gondii parasite infection [123]. iCD8α 
ILC1-like cells function in defense against bacterial infections, and have the capacity to engulf and kill 
bacteria, as well as to process and present antigen [128]. This was illustrated by Van Kaer et al. [128] in an 
elegant study whereby FITC-labeled Citrobacter rodentium or Helicobacter pylori bacteria were co-
incubated with iCD8α cells. Fluorescence activated cell sorting (FACS) 4 h following incubation showed 
that iCD8α cells engulf bacteria, as measured by iCD8α-FITC expression. Addition of cytochalasin D, a 
phagocytosis inhibitor, abrogates the ability of iCD8α cells to engulf bacteria. Killing of bacteria by iCD8α 
cells was shown through incubation of these cells with C. rodentium bacteria for 4 or 24 h, where 
significantly fewer C. rodentium colonies were counted from plated cell lysates following 24 h as compared 
to 4 h of iCD8α-bacteria incubation [128]. Additionally, iCD8α cells had high expression of the cytokine 
osteopontin (OPN), which has been implicated in chemotaxis, wound healing and Th1-mediated immunity. 
Interestingly, Van Kaer et al. [128] showed that incubation of iCD8α with peptidoglycan or L. 
monocytogenes bacteria results in secretion of OPN by iCD8α cells, suggesting that iCD8α may also 
contribute to defense against bacterial infection through production of this Th1-type cytokine. Moreover, 
iCD8α cells were also shown to have the capacity for processing and presenting bacterial-derived antigen, 
suggesting that iCD8α cells may interact with cells of the adaptive immune system to modulate response 
to infection. Lastly, an in vivo role for iCD8α cells in control of bacterial infection was demonstrated in the 
C. rodentium infection model [128]. H2-T3−/− Rag2−/−-infected mice, which have fewer iCD8α cells than 
infected H2-T3+/+ Rag2−/− mice, showed significantly more weight loss and increased bacterial titers 6 days 
following infection. Alongside, the presence of iCD8α was shown to enhance IL-22 production by NKp46+ 
ILC3s, whereby IL-22 is important in protection against C. rodentium infection [128]. Overall, iCD8α cells 
were illustrated to have a crucial role in immunity to bacterial infections. 
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Group 2 ILCs have been attributed numerous functions, ranging from aiding in immunity to extracellular 
helminth infection, mediating eosinophil homeostasis and function, and have been shown to interact with 
adaptive immune cells [108-110,135,157-159]. A role for ILC2 cells in contributing to defense against N. 
brasiliensis nematode infection has been illustrated by a number of research groups [108-110]. These 
showed that ILC2 cells are the primary non-T cell source of IL-13, which is crucial for expulsion of the gut 
nematode [108,110]. In addition, Neill et al. [109] showed that ILC2 cells fail to expand in the absence of 
IL-25 and IL-33 signalling, resulting in a defect in N. brasiliensis helminth expulsion. This defect could be 
restored through adoptive transfer of WT, but not IL-13 deficient ILC2 cells. Thus, ILC2 cells are important 
effectors in type 2-mediated immunity to helminth infection. Additionally, ILC2 cells are proposed to play 
a protective role in Trichuris muris helminth infection, where ILC2 have been shown to express 
amphiregulin, a growth factor important in immunity to this helminth [135,159]. Recently, ILC2 cells were 
shown to respond rapidly to changes in nutrient levels in the intestine [157]. Here, IL-13 expression by 
ILC2s was shown to be suppressed as a result of fasting in mice. Alongside, IL-5 expression by ILC2s was 
shown to increase in response to vasoactive intestinal peptide, a neuropeptide that is induced upon 
feeding. Interestingly, IL-5 plays an important role in the development and survival of eosinophils. Thus, 
this research demonstrated for the first time that tissue ILC2 cells regulate eosinophil homeostasis and 
accumulation through cytokine expression, levels of which may be regulated by nutrient intake levels. 
Lastly, work by Oliphant et al. [158] has illustrated that ILC2 cells interact with cells of the adaptive 
immune response to co-ordinate type 2 immunity. In this context, ILC2 cells were shown to express 
ligands in an MHC class-II-restricted context, activating T cells to produce IL-2 (albeit with a lower 
efficiency than dendritic cells). In turn, IL-2 has the capacity to stimulate ILC2 proliferation and 
production of Th2-associated cytokines, which contributes to protection against the parasite N. brasiliensis 
[158]. 
Group 3 ILCs are diverse, not only in classification but also in function. These cells are important 
mediators of immunity in bacterial infection, contribute to host-microbiota homeostasis, are involved in 
organogenesis, and have been implicated in IBD and tumour immune response [20,141-143,160-165].  
LTi cells have been extensively studied and implicated in GALT formation before and after birth 
[138,141,166]. Briefly, PPs and MLN are believed to develop between embryonic days E13.5 to E15.5, 
whereas cryptopatches and ILFs develop following birth [137,140]. LTi cells aid in the formation of GALT 
through production of lymphotoxin (LT)α1β2 that binds to LTβ receptors expressed by stromal cells. 
Subsequently, stromal secretion of chemokines and upregulation of adhesion molecules results in 
attraction and binding of leukocytes, ultimately resulting in formation of secondary and tertiary lymphoid 
structures [167,168]. In addition to their important role in organogenesis, production of the cytokine IL-
22 by LTi cells was shown to be crucial for epithelial repair following host-versus-graft disease [169]. 
Furthermore, a study by Goto et al. [170] showed that LTi-derived IL-22, in co-operation with 
lymphotoxin, leads to fucosylation of the intestinal epithelium. Interestingly, disruption of epithelial 
fucosylation results in increased susceptibility to S. typhimurium infection. Thus, LTi cells also contribute 
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significantly to maintaining protective epithelial barrier function and mediating immune response to 
bacterial infections. 
NCR- and NCR+ ILC3 cells have been implicated in numerous immune-mediated processes. An important 
function for ILC3 cells was shown in innate immunity to C. rodentium infection [162,163]. In an early study 
by Satoh-Takayama et al., [163] NKp46+ RORγt+ ILC3 were shown to express IL-22. Resistance to C. 
rodentium infection is critically dependent on IL-22, where IL-22 promotes expression of antimicrobial 
peptides by intestinal epithelial cells [164,165]. As such, Rag2-/- Il2rβ-/- mice (lacking T/B and cNK cells, 
but retaining NCR+ ILC3 cells), were shown to be more resistant to C. rodentium infection than Rag2-/- 
Il2rg-/-  mice (additionally lacking NCR+ ILC3 cells), which rapidly succumb to infection. Thus, in the 
absence of cNK cells, NCR+ ILC3 cells provide sufficient IL-22 to protect mice from C. rodentium infection 
[163]. Later, Satoh-Takayama et al. [162] additionally demonstrated that Ncr1-/- Rag2-/- and Rag2-/- mice 
were equally resistant to C. rodentium infection, indicating that NKp46 is not required for the generation 
of IL-22+ ILC3s that mediate the defense against this pathogen. Taken together, both NCR- and NCR+ IL-22-
producing ILC3 are likely to play an important role in mediating defense to C. rodentium infection. A 
specific function for NCR+ ILC3 cells in mediating immunity to S. typhimurium has also been demonstrated 
by Klose et al. [143]. Here, NKp46+ T-bet+ RORγt-fm+ RORγtlo/-, but not NKp46- T-bet+ RORγt+ ILC3 cells 
were shown to be the main producers of IFN-γ in the control of S. typhimurium infection. Besides exerting 
an important role in innate immunity to bacterial invasion, both NCR- and NCR+ ILC3 cells have been 
shown to contribute to colitis development [114,142,161]. Buonocore et al. [142] identified a function for 
NCR- ILC3 cells in colitis, first showing that H. hepaticus-induced colitis in Rag-/- mice is characterised by 
an increase in RORγt+ ILC3 cells that express IL-22, IL-17A and IFN-γ. Subsequent depletion of these cells 
protects mice from colitis, illustrating that NCR- ILC3 cells are pathogenic in the context of H. hepaticus-
mediated colitis. In a second model of anti-CD40-mediated colitis, Buonocore et al. [142] additionally 
showed that depletion of NCR- ILC3 cells protected Rag-/- mice from colitis development, where 
pathogenicity of NCR- ILC3 was IFN-γ- rather than IL-17-dependent. Powell et al. [161] illustrated a 
function for NCR- ILC3 in a third model of colitis, namely Tbx21-/- Rag2-/- ulcerative colitis (TRUC). TRUC 
development in mice is dependent on IL-23-mediated IL-17A induction in the gut, where depletion of IL-
17A through administration of a neutralizing IL-17A or IL23p19 antibody significantly improves disease. 
Interestingly, TRUC mice were shown to harbor large numbers of IL-17A+ NCR- ILC3 cells, and depletion of 
CD90+ cells results in a sharp decrease in IL-17A-producing ILC3s, which protects TRUC mice from colitis 
development. Thus, IL-17A NCR- ILC3 cells have an important function in mediating TRUC [161]. A 
function for NCR+ ILC3 cells in colitis was illustrated by Vonarbourg et al. [114], who demonstrated that 
colon RORγt- NCR+ ILC3 may produce IFN-γ in response to IL-23. Here, in a model of anti-CD40-mediated 
colitis in Il15-/- mice, which lack cNK, IFN-γ production by NKp46+ cells was shown to mediate colitis. 
Moreover, following transfer of highly purified colonic lamina propria cells from RORγt-fm mice to 
alymphoid anti-CD40-treated mice, results indicated that NCR+ RORγt- (RORγt-fm+) ILC3, but not cNK 
(RORγt-fm-), are the main producers of IFN-γ. Thus, NCR+ ILC3 cells are important mediators of colitis 
development [114]. Although little research has been conducted with respect to a possible role for ILCs in 
cancer development, some preliminary studies exist that indicate a role for ILC3 cells in colorectal cancer 
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development and colon epithelial repair [160,171]. Transgenic overexpression of IL-23 in Rag1-/- mice 
induces the formation of intestinal adenomatous polyps [172]. Using this model, Chan et al. [160] 
demonstrated that tumourigenesis is mediated in part by IL-17A-expressing Thy1+ IL-23R+ NCR- ILC3 
cells, as tumour development is inhibited in Rag-/- Il17-/- mice. Alongside, Kirschberger et al. [173] showed 
that colon cancer in genetically susceptible 129SvEv.Rag−/− mice infected with Helicobacter hepaticus and 
treated with the carcinogen AOM is accompanied by accumulation of IL-17+ IL-22+ NCR- ILCs. Interestingly, 
depletion of these cells in mice with severe inflammation prevents the development of invasive colon 
cancer as compared to control mice [173]. Taken together, these studies highlight a previously 
unappreciated role for ILC3 cells in tumour development and cancer progression. Lastly, it is important to 
note that ILC3 cells have been shown to interact with the gut microbiota in regulating mucosal immunity 
[174,175]. For example, Sawa et al. [175] showed that germ-free or antibiotic-treated Rorc(γt)GFP/+ mice 
harbored similar numbers of RORγt+ ILC3 as WT mice,  however, IL-22 expression was greatly increased 
in these mice. Microbiota were subsequently shown to repress IL-22 expression by ILC3s indirectly 
through epithelial production of IL-25. Importantly, this mechanism was de-repressed by epithelial 
damage, allowing for epithelial repair upon damage to the intestinal barrier. Similarly, interaction 
between host microbiota and ILC3 cells may aid in creating a tolerogenic gut environment. As such, 
Mortha et al. [174] showed that intestinal microbiota elicit GM-CSF production by ILC3s.  This, in turn, 
enhanced DC and regulatory T-cell function, promoting intestinal homeostasis. Thus, host microbiota-ILC3 
interactions may be highly beneficial to promoting intestinal immune response. 
Developmental and functional plasticity between ILC1 and ILC3 cells has been demonstrated, and is linked 
with varying expression levels of the transcription factors RORγt and T-bet [114,143]. As such, 
differentiation of NCR- and NCR+ ILC3 cells to IFN-γ-producing CD127+ ILC1 cells may occur under 
influence of IL-2 and IL-12. In turn, the reverse differentiation of CD127+ ILC1 cells into IL-22-producing 
ILC3 cells may occur under the influence of IL-2, IL-23 and IL-1β. Functionally, this plasticity suggests that 
these cells may adapt their phenotype and function differently under specific disease or homeostatic 
conditions in the gut. As such, ILCs are optimally adapted to providing rapid and robust innate immune 
responses [114,143]. 
iv. Human innate lymphoid cells
All three groups of ILC cells are present in the human gut. Group 1 ILC cells, as is the case for mouse ILCs, 
are not yet well-defined. Although NK cells were identified many years ago, helper ILC1 cells have only 
recently been characterised. Human helper ILC1s include two subpopulations which can be distinguished 
on the basis of their localisation and cell surface marker expression profile. Intraepithelial ILC1s are 
characterised by a CD127low profile, and are CD103+ CD160+ CD56+ CD94+ NKp44+ cells. In contrast, 
lamina propria ILC1 are CD127high, and lack expression of CD56, CD94 and NKp44. Both intraepithelial and 
lamina propria ILC1 express high levels of T-bet and express IFN-γ when stimulated with IL-12 + IL-
15/IL-18. Group 2 ILCs are innate CD127+ CRTH2+ cells. Like murine ILC2 cells, human ILC2 cells depend 
on GATA-3 for their development and can be stimulated by IL-25, IL-33 and TSLP to express IL-5, IL-13 
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and amphiregulin. Human group 3 ILCs contain LTi cells, NCR+ (NKp44 in humans) and NCR- ILC3s. NCR+
and NCR- ILC3 are CD127+ CD117+ CCR6+ IL1βR+ IL23R+ cells.  As is the case for mouse ILC3s, human ILC3 
respond to IL-1β and IL-23 to secrete IL-22. Functional plasticity between human ILC1 and ILC3s has also 
been demonstrated [176-178]. 
IV. Ly49 receptors
NK cells express a wide array of cell surface receptors. Amongst these are several families of receptors, 
including the NKG2/CD94, CD69-related, NKRP1 and Ly49 receptor families [126]. Of importance to this 
thesis are the Ly49 receptor family members, and Ly49E in particular, which are discussed in more detail 
below. 
i. Activating and inhibitory Ly49 receptors
The Ly49 NK cell receptor family has been most extensively characterised in the mouse C57BL/6 strain, 
with a total of 15 Ly49 receptor genes identified. Ly49 genes are located distally on mouse chromosome 6, 
in a 620-kb cluster [126]. Seven Ly49 genes encode an inhibitory receptor, (ly49a, c, e, f, g, i and q), two 
Ly49 genes encode for an activating receptor (ly49d, h) and the remaining genes are pseudogenes [179]. 
Fig. 5 provides an overview of Ly49 receptor expression and functions known to date. Inhibitory Ly49 
receptors have been extensively implicated in the process of NK cell education. In NK cell education, NK 
cells become “licensed” and fully functional following the interaction of a self-specific inhibitory Ly49 
receptor with self-MHC-I. In agreement with this notion, NK cells from Ly49-deficient mice have an 
impaired “missing-self” response against MHC-I-deficient target cells [180]. Similarly, specific interaction 
of Ly49A with the non-classical MHC-I molecule H2-M3 has been implicated in NK cell education, where 
Ly49A+ NK cells from H2-M3-/- mice showed reduced expression of IFN-γ as compared to Ly49A+ NK cells 
isolated from WT H2-M3+/+ mice [181]. Ly49C/I have been implicated in leukemia, where use of a blocking 
Ly49C/I antibody was shown to be therapeutic in the treatment of disease [182]. With respect to Ly49Q, 
two independent studies showed that Ly49Q is expressed by plasmacytoid DCs. Subsequent analysis of 
Ly49Q-deficient mice demonstrated that plasmacytoid DCs isolated from these mice express decreased 
levels of TLR9-mediated IFN-α, and are more susceptible to MCMV-mediated infection as compared with 
wild-type littermates [183,184]. A possible explanation for this paradoxical stimulatory effect of Ly49Q on 
IFN-α expression levels was  proposed in that Ly49Q/DAP12 may negatively regulate TLR7/9 signal 
transduction, resulting in decreased IFN-α responses in Ly49Q-deficient mice [184]. Ly49Q is also 
expressed by macrophages, where cross-linking of this receptor induces cytoskeletal re-arrangements and 
cell spreading [185]. A function for the Ly49F receptor has, to our knowledge, not been described to date. 
Looking at a function of the two activating Ly49 receptors, a study by Mason et al. [186] demonstrated 
that expression of Ly49D by NK cells augments IFN-γ expression by these cells upon interaction of the 
receptor with its ligand H-2Dd. Interestingly, NK cells co-expressing Ly49D and the inhibitory receptor 
Ly49G exhibited decreased levels of IFN-γ as compared to cells expressing Ly49D alone, additionally 
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demonstrating the dominant inhibitory nature of the Ly49G receptor [186]. With respect to the activating 
receptor Ly49H, Ly49H-deficient mice were illustrated to have an increased susceptibility to MCMV-
infection. In accordance, Ly49H was shown to recognize specifically the MCMV viral protein m157, 
expressed on the surface of infected cells [187].  
Fig. 5 Schematic depiction of cell types expressing Ly49 receptors. The diversity of Ly49 receptors 
expressed by each cell type, and proposed functions for these receptors, are shown. (uNK, uterine NK cells; 
pDC, plasmacytoid.  Rahim et al. (2014) [188]. 
ii. Signalling mechanisms in Ly49 receptors
Structurally, Ly49 receptors are lectin-like receptors, which refers to the extracellular core c-type lectin-
like domain (CTLD), common to all Ly49 receptors. Ly49 receptors are expressed as 92-kDa disulphide-
linked homodimers [126].  
Activating Ly49 receptors are characterised by the presence of positively charged transmembrane 
residues. The presence of a positively charged residue allows for the interaction of the receptor with 
adaptor signalling chains, such as DAP12, DAP10, FcɛRIγ and CD3ζ, which facilitate the expression of the 
activating receptors. Furthermore, these signalling chains contain an immunoreceptor tyrosine-based 
activating motif (ITAM). Upon ligand binding, receptor cross-linking results in tyrosine phosphorylation at 
the ITAM. The phosphorylated ITAM tyrosine then recruits SYK or ZAP70 proteins for further 
downstream signalling, ultimately resulting in cell activation. In contrast, inhibitory Ly49 receptors are 
characterised by the presence of an immunoreceptor tyrosine-based inhibitory motif (ITIM) in the 
cytoplasmic domain. Following ligand binding, the ITIM is tyrosine phosphorylated by a SRC-family 
tyrosine kinase. The phosphorylated ITIM tyrosine subsequently recruits SH2-domain-containing protein 
tyrosine phosphatase 1, which mediates further downstream signalling, ultimately resulting in inhibition 
of cell activation (Fig 6) [126,189]. 
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Fig. 6 Signalling of activating and inhibitory mouse NK Ly49 receptors. Ly49 receptors are lectin-like 
glycoprotein receptors expressed as disulphide-linked homodimers on the cell surface. Upon triggering of a 
Ly49 inhibitory receptor, tyrosine phosphatase SHP-1 is recruited, where downstream signalling from SHP-1 
results in inhibition of NK cell activation. Upon triggering of an activating Ly49 receptor, the adaptor 
signalling chain DAP-12 ITAM is phosphorylated, resulting in subsequent recruitment and activation of Syk 
kinase. Downstream signalling from the activated Syk kinase will initiate NK cell activation. Dimasi and 
Biassoni (2005) [189]. 
iii. Ly49E
Ly49E is a unique member of the Ly49 NK receptor family, where the Ly49e gene is strongly conserved, in 
contrast to the allelic polymorphism observed for other Ly49 genes [190]. Furthermore, Ly49E is distinct 
from other members of this family on the basis of its structural properties, expression pattern and ligand 
recognition [126]. 
With respect to its structural properties, Ly49E is particular in displaying characteristics of both an 
activating and inhibitory NK receptor. In this sense, the intracellular domain of Ly49E contains an ITIM, 
characteristic of an inhibitory NK receptor. On the other hand, the Ly49E transmembrane domain also 
contains a positively charged residue, i.e. arginine. This would suggest that Ly49E can function as both an 
activating and/or inhibitory NK receptor. Ly49E, however, in contrast to other activating Ly49 receptors, 
has an arginine residue that is located at position 19 instead of position 10, as is the case for the activating 
receptors Ly49D/H. Previous studies have shown that the location of the charged residue within the 
transmembrane region is critical in the ability of the receptor to pair with the adaptor signalling chain 
[191].  Therefore, it is unlikely that Ly49E can function as an activating receptor.  
In contrast to other Ly49 receptors, Ly49E is expressed on a range of innate-like cells. With regard to NK 
cells, expression of other (non-Ly49E) Ly49 receptors commences at 1 week following birth, and adult 
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Ly49 receptor expression levels are reached at 6-8 weeks of age [192]. In contrast, Ly49E is highly 
expressed on fetal and neonatal NK cells, and Ly49E expression decreases from 2 weeks following birth, to 
reach low levels on adult NK cells [94,192-194]. An exception to this are DX5-negative NK cells in the liver, 
which express relatively high levels of Ly49E, also in adult mice. With respect to this, it was shown that up 
to 50% of fetal day (FD)17 NK cells, the majority of which are DX5-negative, express Ly49E [195]. Ly49E 
is also expressed by T cells, where 25-35% Ly49E expression has been observed in FD17 Vγ3 and adult 
Vγ3 skin intraepithelial T cells [192]. Furthermore, Ly49E expression by CD8αα-expressing IELs of the 
small intestine has been demonstrated, where 20-30% of TCRαβ CD8αα IELs and 10-20% of TCRγδ IELs 
express Ly49E [196]. 
Most Ly49 receptors have MHC-class I ligands. Ly49E, in contrast, is unique in its ability to be triggered by 
a non-MHC-class I-related ligand, i.e. urokinase plasminogen activator (uPA) [197]. Briefly, triggering of 
Ly49E by uPA was shown in vitro through the use of a BWZ.36 reporter cell line. In this model, BWZ.36 
cells express a hybrid Ly49 receptor, where the extracellular Ly49E domain is coupled to the 
transmembrane and intracellular domains of the activating Ly49H receptor. A DAP-12 signalling chain is 
also expressed (H/ED12 cells). As such, triggering of the chimeric Ly49E receptor will result in cell 
activation and signalling, and ultimately β-galactosidase production. Using this reporter model, uPA was 
selected from a cDNA library as the protein that triggers the Ly49E receptor, and this was confirmed by 
the demonstration that coated recombinant uPA strongly stimulates H/ED12 cells [197]. 
Interaction of uPA with Ly49E has been shown to inhibit NK cell function. In this context, IFN-γ 
production by NK cell lines that strongly express Ly49E, i.e. KY and NK03, is inhibited upon exposure to 
coated uPA. Importantly, addition of anti-Ly49E (Fab’)2 fragments restores IFN-γ production, showing the 
Ly49E specificity of uPA [197]. Additionally, coated uPA reduces the cytotoxicity of IL-2 cultured FD17 
thymocytes upon NK1.1-mediated stimulation, as assessed by CD107-surface expression. Thus, triggering 
of Ly49E by uPA inhibits the cytotoxic potential of fetal NK cells. With respect to other innate-like cell 
populations, data from our group also went on to show that IEL upregulate Ly49E expression following 
TCR-mediated stimulation of these cells [198]. However, a function for Ly49E expression by IEL remains 
to be determined. Importantly, uPA is a serine protease that has been implicated in a number of 
physiological processes, including tissue remodeling, tumour invasion and tumour metastasis, as well as 
development and progression of IBD [197,199-201].  
V. In vivo disease models for the study of Ly49E function on intestinal intraepithelial 
T lymphocytes and innate lymphoid cells 
To study the functional role of Ly49E expression on IEL and ILC cells, a wide range of in vivo disease 
models can be used. Listed below are in vivo disease models relevant to this PhD thesis, with a brief 
description of each model used. 
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IBD encompasses Crohn’s disease and ulcerative colitis. Whereas Crohn’s disease is characterised by a 
predominant Th1-type immune response, ulcerative colitis is characterised primarily by a Th2-type 
immune response. However, it should be mentioned that the Th1/Th2 nature of these disease is not clear-
cut, and an overlap in the pathogenesis of Crohn’s disease and ulcerative colitis exists [73]. Furthermore, a 
Th17-type immune response is also prominent to both Crohn’s disease and ulcerative colitis [202]. Three 
popular models for the study of Crohn’s disease and ulcerative colitis in mice are TNF∆ARE-mediated ileitis, 
DSS-induced colitis and TNBS-induced colitis.  
TNF∆ARE-mediated ileitis develops in mice that harbor a deletion of the AU-rich elements (ARE) of the Tnfa 
gene.  Deletion of the ARE 3’ UTR regulatory element results in loss of posttranscriptional regulation of 
TNF-α. As a result of deregulated expression, TNF-α levels are systemically increased, and TNF∆ARE/+ mice 
develop spontaneous IBD as well as inflammatory polyarthritis [203,204]. Similar to Crohn’s disease 
patients, intestinal inflammation in TNF∆ARE/+ mice is transmural and primarily localized to the terminal 
ileum [205,206]. The first symptoms of ileitis are detectable at 3 weeks of age, and disease is fully 
developed at 8 weeks of age [203,204].  
One of the most widely used mouse models of colitis, is that of DSS-induced colitis. DSS is a water soluble 
polysaccharide that is capable of establishing linkages with medium-chain-length fatty acids present in the 
colon lumen. Once complexed, DSS-fatty acid nanovesicles fuse with colonocyte membranes and are toxic 
to colon epithelial cells [207]. As a result, the intestinal barrier is breached and bacteria are capable of 
disseminating across the lumen into the gut. The spread of bacteria and bacterial products, in turn, 
triggers a response from both the innate and adaptive immune system [208,209]. DSS-treated mice 
develop inflammation that affects the mucosal layer of the intestinal wall (but is not transmural), where 
inflammation is primarily localized to the distal colon [210,211]. DSS-induced colitis is induced through 
the administration of DSS in drinking water to mice. Both acute and chronic intestinal inflammation can be 
modeled, depending on the concentration and frequency of DSS administration. Where acute DSS-induced 
colitis is characterised by a Th1 cytokine profile, with expression of cytokines such as TNF-α, IFN-γ, IL-1β 
and IL-12, chronic DSS-induced colitis exhibits a pre-dominant Th2 cytokine profile, with expression of IL-
4, IL-6 and IL-10 [208]. DSS-induced colitis is also modulated by signalling through the IL-23/IL-17 axis. In 
this model, IL-23 and IL-17A have been shown to improve disease outcome, whereas IL-17F exacerbates 
colitis [212,213]. As is the case for a number of murine models, susceptibility to DSS-induced colitis is 
influenced by the genetic background of mice, where  C3H/HeJ, NOD/Ltj, and NOD-SCID mouse strains are 
very susceptible to DSS-induced colitis, whereas C57BL/6 mice are more resistant [208,209].  
A second model commonly used for the study of colitis is that of TNBS-induced colitis, where TNBS is a 
chemical that haptenises colonic autologous and microbial proteins, rendering these immunogenic to the 
host [214]. TNBS is administered intrarectally in ethanol, and colitis induction is rapid. Intestinal 
inflammation in TNBS-induced colitis is transmural and localized to the distal colon [209,211]. 
Development of colitis is associated with high expression levels of Th1-type cytokines, where IFN-γ is key. 
Here, signalling through the IL-23 receptor, and IL-17A, were shown to improve disease outcome. As is the 
case for DSS-induced colitis, disease severity is dose-dependent. Also, genetic background influences the 
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degree of TNBS-induced colitis development, where SJL/J and BALB/c for example are highly susceptible 
to colitis, whereas C57BL/6 mice are relatively resistant [215-217].  
Importantly it should be noted that other models, such as the  Il10-/- mouse colitis model, or the T cell 
transfer model of colitis, show a deficiency in IL-23 and IL-17 to result in less severe colitis development 
[202]. These findings are in contrast to those observed for the DSS-induced and TNBS-induced colitis 
models. This highlights a key aspect of IBD development, where IL-23/IL-17 mediated immune responses 
can be both beneficial and pathogenic to colitis development [202,214]. 
For the study of intestinal cancer, we utilized two specific murine models: ApcMin-mediated intestinal 
cancer and AOM-induced colorectal cancer.  
ApcMin/+ mice are frequently used for the study of intestinal tumour development. These mice have a 
dominant mutation in the Apc gene, resulting in truncation of the gene product at amino acid 850, and the 
formation of non-functional Apc protein. Under normal circumstances, Apc is involved in the Wnt-
signalling pathway, where Apc is complexed with GSK3β/Actin/CKIα and is crucial for phosphorylation 
and degradation of β-catenin. In the absence of functional Apc protein, β-catenin accumulates, translocates 
to the nucleus in increased amounts, and subsequently deregulates target gene transcription. In this 
process, transcriptional activation of numerous genes is altered, including for example the known 
oncogenes c-Myc and Kras. As a result, ApcMin/+ mice develop many (up to 100) adenomatous polyps and 
adenomas throughout the length of the intestine, with most located in the small intestine. Tumour 
development can be noted as early on as 3-4 weeks of age, and progressively increases as mice age. 
Homozygous ApcMin mice are embryonic lethal, and as such cannot be used for intestinal tumour research 
[218,219].  
The AOM-induced colorectal cancer model is often used for the study of inflammation-driven colon cancer. 
Azoxymethane is a potent carcinogen, where a metabolite of AOM causes DNA mutations by altering 
nucleotides from G-C to A-T [220]. To induce carcinogenesis, mice are usually injected intraperitoneally 
with a single dose (10 mg/kg) of AOM. Subsequently, treatment is often supplemented with varying 
doses/cycles of DSS. In this context, inflammation-driven tumourigenesis takes place in the gut, with 
development of multiple adenomas and adenocarcinomas throughout the colon and rectum. Tumour 
development classically takes place over a period of 3-5 months, and serves as an excellent model for 
colorectal cancer development in humans [220,221]. 
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VI. Research objectives 
 
The intestinal epithelium, a polarised single-cell layer, is all that separates our ‘clean’ bodies from the 
‘dirty’ environment, containing potentially harmful pathogens. Therefore, the intestinal epithelium must 
be optimally equipped to react quickly and correctly to breaching. To enable it to carry out this function, a 
multitude of immune cells are interspersed between the epithelial cells that constitute this barrier.  
 
iELs have long been shown to reside in the intestinal epithelium, but a complete understanding of  IEL 
function and regulation is lacking. ILCs are a novel set of immune cells, and a subgroup of ILC1 cells have 
also been shown to reside in the intestinal epithelium. The function of these cells remains elusive.  
 
The Ly49E receptor has previously been shown to be expressed on innate-like cells, such as cNK cells, 
epidermal Vγ3 T cells, DX5- liver NK cells and CD8αα+ small intestinal IEL. A first objective of this thesis is 
to investigate whether Ly49E is expressed not only by small intestinal but also by colonic IEL. Previous 
studies have demonstrated differences in IEL subset composition and function between the small intestine 
and colon [1,222]. As such it is important to examine Ly49E expression in the colon as well as the small 
intestine, and to evaluate how Ly49E expression on IEL of both gut compartments translates to IEL 
function of these cells. Subsequently, the question of whether Ly49E expression influences IEL 
differentiation will be addressed. Here, Ly49E KO mice will be used to examine differences in IEL subset 
composition and cell surface receptor expression as compared to Ly49E WT. IEL will be isolated from 
naive mice and examined in a basal resting state. If Ly49E affects IEL development and/or function in the 
basal resting state, this knowledge will be of importance when the role of these cells in intestinal disease is 
subsequently studied.  
The second main aim of this thesis is to examine whether IEL Ly49E expression affects development 
and/or progression of inflammatory bowel diseases and intestinal tumour immune response. Here 
development refers to the establishment of disease, whereas progression refers to disease kinetics. With 
respect to inflammatory bowel diseases, disease progression may be measured through parameters such 
as the rate of weight loss, faecal consistency and occult blood, and the extent of mucosal inflammation. 
With respect to intestinal cancer development, disease progression may be evaluated through parameters 
such as the rate of tumour development and tumour size. A role for Ly49E expression by IEL in the 
development and/or progression of inflammatory diseases and intestinal tumour immune response will 
be examined for both IEL of the small intestine and colon. Where inflammatory bowel diseases are 
concerned, a role for IEL Ly49E expression in the small intestine will be examined through  the use of the 
TNF∆ARE/+ ileitis model, whereas a role for IEL Ly49E expression in the colon will be examined through the 
use of the DSS-induced and TNBS-induced colitis models. To study a possible role for Ly49E expression by 
IEL in the small intestinal tumour immune response, development of intestinal cancer in ApcMin/+ mice will 
be evaluated. For the study of a possible role for Ly49E expression by IEL in colon intestinal tumour 
immune response, development of colorectal cancer in AOM/DSS-treated mice will examined.  
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The third, and final, objective of this thesis is to investigate whether the Ly49E receptor is expressed by 
intestinal ILCs. To gain a full understanding of Ly49E function in intestinal mucosal immunity, it is 
important to have knowledge of all gut populations that express, and are possibly regulated by, this 
receptor. ILCs represent a novel innate immune population of which little is known to date, and as such it 
is of importance to examine whether Ly49E is also expressed by these cells.  
Taken together, the overall objective of this PhD thesis is to gain valuable insights into the functional role 
of the Ly49E receptor in the immune response of murine intestinal intraepithelial T cells and ILCs. With 
respect to inflammatory bowel diseases and tumour immune response, identifying a function of Ly49E 
expression by IEL may constitute a first step towards combating these intestinal diseases. With respect to 
ILC cells, examining Ly49E expression on murine ILC subpopulations will contribute to ILC knowledge and 
may provide additional clues as to a role for Ly49E in regulation of mucosal immunity.  
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Chapter 2: 
Results 
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Part I 
Paraffin-embedded section of colonic crypts from an Ly49E WT mouse 
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The Ly49E NK receptor is a unique inhibitory receptor, presenting with a high degree of conservation among mouse strains
and expression on both NK cells and intraepithelial-localised T cells. Amongst intraepithelial-localised T cells, the Ly49E
receptor is abundantly expressed on CD8aa-expressing innate-like intestinal intraepithelial lymphocytes (iIELs), which
contribute to front-line defense at the mucosal barrier. Inflammatory bowel diseases (IBDs), encompassing Crohn’s disease
and ulcerative colitis, have previously been suggested to have an autoreactive origin and to evolve from a dysbalance
between regulatory and effector functions in the intestinal immune system. Here, we made use of Ly49E-deficient mice to
characterize the role of Ly49E receptor expression on CD8aa-expressing iIELs in the development and progression of IBD.
For this purpose we used the dextran sodium sulphate (DSS)- and trinitrobenzenesulfonic-acid (TNBS)-induced colitis
models, and the TNFDARE ileitis model. We show that Ly49E is expressed on a high proportion of CD8aa-positive iIELs, with
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colonic iIELs does not influence the development or progression of inflammatory bowel diseases.
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Introduction
Inflammatory bowel diseases (IBDs), encompassing Crohn’s
disease and ulcerative colitis, are chronic and relapsing disorders
of the gastrointestinal tract [1]. Although the etiology of IBD is
incompletely understood, inflammatory bowel disorders are
believed to present in genetically predisposed individuals exposed
to undefined microbial and environmental triggers. In this, IBD
pathogenesis has been linked to deregulation of the fine
homeostatic balance that exists between the mucosal immune
system and commensal microbiota [2–5]. With the highest
worldwide prevalence, European figures show an estimated 1 in
200 people affected by ulcerative colitis, and 1 in 300 affected by
Crohn’s disease [6,7]. Current IBD treatment options include the
administration of anti-inflammatory drugs, immunosuppressives
and immunobiological agents [8,9]. For unresponsive patients,
surgical intervention may provide a temporary relieve from
symptoms. However, specificity is lacking in these modes of
treatment, and none are capable of inducing complete remission
[8,10]. Therefore, additional research is required to further
elucidate IBD mechanisms and facilitate the development of
specific and effective new therapies.
Intestinal intraepithelial lymphocytes (iIELs) are resident
lymphocytes of the intestinal epithelium, and constitute one of
the largest lymphocyte populations of the body [11]. In mice, five
main subpopulations of iIELs have been identified: CD4, CD8ab
and CD8aa T cell receptor (TCR)ab iIELs, and CD4/CD8
double-negative (DN) and CD8aa TCRcd iIELs. TCRab CD4
and TCRab CD8ab iIELs have been described as being ‘induced’
iIELs, whereas TCRab CD8aa, TCRcd DN and TCRcd CD8aa
iIELs are also referred to as ‘natural’ iIELs [12]. More recently,
Mucida et al. [13] have also described the existence of a sixth iIEL
subpopulation, the TCRab CD4 CD8aa double-positive (DP)
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e110015
iIELs. Numerous reports indicate an important role for iIELs in
maintaining mucosal homeostasis. In this context, iIELs have been
implicated in the recognition of stress signals [14], repair of the
intestinal epithelium [15–17], may function as memory cells [18],
show cytotoxic activity [19,20], and have autoreactive properties
[21,22]. In addition, iIELs are characterized by an ‘activated yet
resting’ phenotype [20], suggesting the capacity to respond rapidly
to in vivo stimuli and the need for tight regulation of iIEL effector
function. However, exact mechanisms involved in iIEL regulatory
and effector functions remain largely unknown.
Unique to iIELs is the large number of cells expressing the
CD8aa homodimer [23]. Recently, our group showed that
Ly49E, an inhibitory receptor, is abundantly expressed on
CD8aa-expressing iIELs of the small intestine [24]. We demon-
strated that iIELs expressing inhibitory Ly49 receptors, including
Ly49E, are hyporesponsive to TCR-mediated stimulation [24].
Importantly, in vitro TCR-triggering results in upregulation of
Ly49E receptor expression on iIELs [25]. Furthermore, we were
able to show that the Ly49E receptor can be triggered by the non-
MHC-related protein urokinase plasminogen activator (uPA).
Interestingly, several studies have indicated a role for uPA in IBD,
with increased levels of tissue uPA present in Crohn’s disease and
ulcerative colitis patients as compared to healthy controls [26,27].
Thus, we hypothesized that Ly49E expression on CD8aa-
expressing iIELs constitutes a novel mechanism through which
iIEL function can be regulated. To test our hypothesis in vivo, we
have generated Ly49E knockout (KO) mice on a C57BL/6
background. Here, we investigated a role for Ly49E expression on
iIELs in the context of IBD development and progression, making
use of the dextran sodium sulphate (DSS)- and trinitrobenzene-
sulfonic-acid (TNBS)- induced colitis models, and the TNFDARE
ileitis model. Our results indicate that Ly49E expression on both
small intestinal and colonic CD8aa-expressing iIELs is abundant.
However, abrogation of Ly49E expression on iIELs of the small
intestine and colon does not influence development or progression
of IBD.
Materials and Methods
Mice
The generation of Ly49E KO mice on a C57BL/6 background
was outsourced to Ozgene (Bentley DC, WA, Australia), and the
targeting strategy is explained elsewhere [28]. Heterozygous
Ly49EWT/KO mice were interbred to obtain homozygous
Ly49EWT/WT and Ly49EKO/KO mice. TNFDARE/WT mice were
a kind gift from Dr. G. Kollias (Institute for Immunology,
Biomedical Sciences Research Center ‘‘Alexander Fleming,’’
Attica, Greece). Heterozygous TNFDARE/WT (Ly49EWT/WT) mice
were bred to homozygous (TNFWT/WT) Ly49EKO/KO mice in
order to obtain TNFDARE/WT Ly49EWT/KO offspring. Male
TNFDARE/WT Ly49EWT/KO and female TNFWT/WT Ly49EWT/
KO offspring were bred to obtain homozygous TNFDARE/WT
Ly49EWT/WT and TNFDARE/WT Ly49EKO/KO mice. All mice
were housed and bred in our animal facility, and all animal
experimentation was performed after approval and according to
the guidelines of the Ethical Committee for Experimental Animals
at the Faculty of Medicine and Health Sciences of Ghent
University (Ghent, Belgium).
Genotyping of mice
Genomic DNA was extracted from tail tissue samples, according
to the REDExtract-N-Amp Tissue PCR Kit (Sigma-Aldrich, St.
Louis, MO, USA). PCR amplification of genomic DNA for the
TNF locus was carried out with the following primers: forward-
59CCTTCCTCACAGAGCCAGC-39 and reverse-59-AATTAC-
GGTTAGGCTCCTGTTTCC-39. Following agarose gel electro-
phoresis, TNFDARE and wild-type (WT) alleles yield bands of 626
and 560 bp, respectively. PCR amplification of genomic DNA for
the Ly49E locus was carried out making use of the following
primers: for the WT allele, forward-59-TCGCTTGGAATCTT-
CTGTTTC-39 and reverse-59TCCTCACCTGGACTGCAAT-
C-39; for the KO allele, forward-59GGAATAATTGCTGTTAC-
CATTAG in combination with reverse-59TCCTCACCTGGA-
CTGCAATC-39. Ly49E WT and KO alleles yield bands of 1070
and 1200 bp, respectively.
DSS-induced colitis
Colitis was induced in 8-week old mice by administering 4%
(w/v) DSS (molecular weight 36,000–50,000, MP Biomedicals,
Cleveland, USA) in drinking water and allowing mice to drink ad
libidum for 7 days. Following 7 days of DSS treatment, drinking
water containing DSS was replaced by normal drinking water and
mice were allowed to recover. Control mice received normal
drinking water only.
Assessment of the disease activity index in DSS-induced
colitis
The disease activity index (DAI) was scored as follows: weight
loss, score 0–5 (0: ,1% change in weight, 1: 1–5% change in
weight, 2: 6–10% change in weight, 3: 11–15% change in weight,
4: 16–20% change in weight, 5: .20% change in weight),
appearance, score 0–2 (0: healthy appearance, 1: unkempt fur
coat, 2: arched back), fecal consistency, score 0–2 (0: normal, 1:
soft pellets, 2: diarrhea) and fecal occult blood, score 0–5, using the
ColoScreen Hemoccult test (Helena Laboratories, Texas, USA) (0:
Hemoccult negative, 1: Hemoccult +, 2: Hemoccult ++, 3:
Hemoccult +++, 4: Hemoccult ++++ or marked bleeding, 5:
visible indications of rectal bleeding and prolapse). An individual
score was assigned to each mouse on a daily basis.
TNBS-induced colitis
Prior to administration of TNBS, mice were sedated through
intraperitoneal injection with a mixture (2.5 ml/g body weight) of
ketamine (50 mg/ml: 4 volumes) and xylazine (2%: 1 volume). For
induction of TNBS-induced colitis, mice were rectally adminis-
tered a solution (0.1 ml/mouse) of 2.5% (w/v) TNBS (Sigma-
Aldrich) in 50% ethanol solution. Control mice received a solution
(0.1 ml/mouse) of PBS in 50% ethanol solution. Mice were kept in
a vertical position for 1 min to prevent rectal leakage.
iIEL isolation
iIELs from 8-to-14 week old mice were isolated as follows.
Briefly, intestines were removed and cleaned of mesenteric fat.
Peyer’s patches were excised, and intestines were rinsed with
DPBS to clear intestines of fecal content. Subsequently, intestines
were opened longitudinally, cut into 0.5-cm pieces, and transferred
to a 50-ml conical tube. Intestines were incubated twice for
20 minutes at 37uC in Ca/Mg-free Hank’s Balanced Sodium
Solution (HBSS; Invitrogen, Carlstad, CA, USA) containing 5%
FCS, 1 mM ethylenediaminetetraacetic acid (EDTA; Invitrogen)
and 1 mM dithiotreitol (Sigma-Aldrich) at slow rotation. Cell
suspensions were passed through a 40-mm cell strainer (Falcon,
Becton Dickinson, Franklin Lakes, NJ, USA) and pelleted by
centrifugation at 480 g. Pellets were resuspended in 44% Percoll
(GE Healthcare, Buckinghamshire, UK) on an underlay of 67%
Percoll, and centrifugated for 20uC at 2000 g. iIELs were collected
from the 44%/67% Percoll interface, washed twice with
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phosphate buffered saline (PBS) for 5 minutes at 840 g, and
resuspended in RPMI 1640 medium supplemented with 10%
FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM
glutamine, 1 mM sodium pyruvate, 100 mM non-essential amino
acids (all Invitrogen) and 50 mM 2-mercaptoethanol (Sigma-
Aldrich).
Antibodies
mAbs used for staining of iIELs were as follows: anti-TCRb
(APC/Cy7-conjugated, clone H57.597), anti-CD4 (peridinin
chlorophyll protein/Cy5.5-conjugated, clone GK1.5), anti-CD8b
(peridinin chlorophyll protein/Cy5.5-conjugated, clone
YTS156.7.7), all from BioLegend, San Diego, CA, USA. Anti-
TCRd (PE- or FITC-conjugated, clone GL3), anti-Ly49D (FITC-
conjugated, clone 4E5), anti-Ly49C/I (PE-conjugated, clone 5E6),
anti-NKG2D (PE-conjugated, clone CX5), anti-CD69 (biotin-
conjugated, clone H1.2F3), were obtained from Becton Dickinson,
Franklin Lakes, NJ, USA. Anti-CD8a (PE/Cy7-conjugated, clone
53–6.7) from eBioscience, San Diego, CA, USA. Anti-Ly49G2-
producing hybridoma (clone 4D11) was from ATCC and antibody
was biotin- or FITC-conjugated in-house. Anti-Ly49A (biotin-
conjugated, clone JR9-318; kindly provided by Dr J. Roland
(Paris, France)), anti-Ly49E/C (biotin- or FITC-conjugated, clone
4D12, made and labeled in-house) [29] and anti-Ly49E/F (FITC-
conjugated, clone CM4; kindly provided by Dr C. G. Brooks
(Newcastle on Tyne, UK) [30]. mAb 4D12 (Ly49C/E) in
combination with mAb CM4 (Ly49E/F) were used to identify
Ly49C-expressing cells (CM42/4D12+), Ly49E-expressing cells
(CM4+/4D12+) and Ly49F-expressing cells (CM4+/4D122). In B6
(H-2b) mice, mAb 5E6 stains Ly49I, whereas Ly49C is very hard
to detect [31]. Anti-Ly49H (biotin-conjugated, clone 3D10; kindly
provided by Dr. W. Yokoyama, St.Louis, MO, USA)) and anti-
NKG2A/C/E (FITC-conjugated, clone 3S9, generated and
labeled in-house) [29].
Prior to staining, cells were blocked with anti-FccRII/III
(unconjugated, clone 2.4G2, kindly provided by Dr J. Unkeless,
Mount Sinai School of Medicine, New York, USA). Propidium
iodide was used to discriminate live and dead cells. Flow cytometry
was performed using a BD LSRII flow cytometer, and samples
were analysed with FACSDiva Version 6.1.2 software (BD
Biosciences).
Histology
For histological analysis, tissue sections of the distal ileum and
distal colon were fixed in 4% formaldehyde solution (VWR,
Radnor, Pennsylvania, USA) and embedded in paraffin. 5 mm
paraffin-embedded sections were stained with hematoxylin and
eosin (Sigma-Aldrich). Intestinal inflammation was scored blindly
by two independent observers using a validated scoring system, as
previously described [32].
Statistics
Statistical analysis was carried out using PASW Statistics 22
Software (SPSS, Chicago, IL, USA). Data was analysed using the
non-parametric two-tailed Mann-Whitney U-test or ANOVA, as
indicated. A P value #0.05 was considered statistically significant.
Results
Ly49E KO mice have normal iIEL population frequencies
and NK receptor expression
As the function of Ly49E expression on iIELs of the intestine is
currently unknown, we initially sought to clarify whether Ly49E
expression on iIELs affects differentiation of intestinal iIELs. In
this respect, we found that total numbers of iIELs present in the
small intestine of Ly49E WT and Ly49E KO mice
(8.68610662.50 vs. 6.60610661.15 iIELs, respectively) and
colon of Ly49E WT and Ly49E KO mice (0.32610660.10 vs.
0.46610660.20) were similar. Furthermore, iIEL subpopulation
frequencies, and the total number of cells in each iIEL
subpopulation, did not differ significantly between Ly49E WT
and Ly49E KO mice (Fig. 1A and 1B, and data not shown). We
and others have previously shown that several NK receptors are
expressed on the surface of small intestinal iIELs. In particular,
Ly49E is expressed on a higher proportion of CD8aa-positive
iIELs than other Ly49 receptors [24,33]. Here, we show that
several NK receptors are also expressed on the surface of colonic
CD8aa-positive iIELs. As for small intestinal iIEL expression, a
high proportion of colonic iIELs express the Ly49E receptor.
Surprisingly, the frequency of Ly49E-expressing colonic TCRcd
CD8aa-positive iIELs exceeds the frequency of Ly49E-expressing
TCRcd CD8aa-positive iIELs in the small intestine, whereas we
found the proportion of Ly49E-expressing TCRab CD8aa-
positive iIELs in the small intestine and colon to be comparable.
As expected, Ly49E expression is absent on iIELs of Ly49E KO
mice. Small intestinal and colonic iIEL NK receptor expression
was unchanged between Ly49E WT and Ly49E KO mice
(Fig. 2A and 2B). Furthermore, co-expression of Ly49 receptors
on the iIEL surface was unaltered between Ly49E WT and Ly49E
KO mice (Fig. 2C and 2D). Ly49E expression on CD8aa-negative
iIELs was low or absent (data not shown).
Ly49E expression on CD8aa-expressing iIELs of the colon
does not influence DSS-induced colitis
To study a possible role for Ly49E expression on colonic
CD8aa-expressing iIELs in the context of colitis, we performed
DSS-induced colitis with Ly49E WT and Ly49E KO mice. DSS
was administered to mice in drinking water for a period of 7 days,
after which DSS-containing water was replaced by normal
drinking water. Mice were analysed on a daily basis for a total
of 11 days. As shown in Fig. 3A, we observed no difference in
relative weight loss between Ly49E WT and Ly49E KO mice.
Additionally, we analysed the DAI on a daily basis. Here, we
observed no significant difference between the DAI of Ly49E WT
and Ly49E KO mice between days 0–11 (p$0.35; Mann-Whitney
test) (Fig. 3B). This was corroborated by histological scores of
distal colon formalin fixed paraffin-embedded (FFPE-) sections
obtained from Ly49E WT and Ly49E KO mice at days 7, 9 and
11 following colitis induction, which indicate a similar degree of
inflammation for Ly49E WT and Ly49E KO mice (Fig. 3C and
3D). Studying a role for Ly49E expression on colonic iIELs, we
analysed iIEL subpopulation frequencies and iIEL NK receptor
and activation marker expression at days 0, 7 and 11 of DSS-
induced colitis. As illustrated, iIEL subpopulation frequencies and
iIEL NK receptor and activation marker expression were
unchanged on days 7 and 11 as compared to untreated mice on
day 0, and were unchanged between Ly49E WT and Ly49E KO
mice (Fig. 4A, 4B and 4C). Hall et al. [34] recently reported an
increased frequency of NKG2D expression on NK cells in DSS-
induced colitis. As iIELs have a number of innate-like properties
and are crucial to front-line defense of the intestinal mucosal
barrier [12,18–22], we examined whether iIELs upregulate
NKG2D expression upon DSS-induced colitis. Using littermate
DSS-treated and control mice, we observe a trend towards
upregulation of NKG2D expression on TCRab CD8aa-positive
iIELs and TCRcd CD8aa-positive iIELs in DSS-induced colitis,
but this was not significant (p$0.083; Mann-Whitney test).
NKG2D expression between Ly49E WT and Ly49E KO
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DSS-treated mice was comparable (Fig. 5A and 5B). Thus, Ly49E
expression on colonic CD8aa-expressing iIELs does not appear to
influence DSS-induced colitis development or progression.
Ly49E expression on CD8aa-expressing iIELs of the colon
does not affect TNBS-induced colitis
A second frequently used model in the study of mucosal
immunity is that of TNBS-induced colitis. Here, we show that
colitis induction in both Ly49E WT and Ly49E KO occurred
rapidly, with the first cases of mortality noted at 5 and 3 days post-
treatment for Ly49E WT and Ly49E KO mice, respectively.
Seven days following TNBS-colitis induction, 50% of mice had
died in both Ly49E WT and Ly49E KO-treated groups, and the
decision was made to terminate treatment and euthanize the
remaining mice (Fig. 6A). Maximum weight loss for Ly49E WT
and Ly49E KO mice occurred at day 5 and day 3, respectively,
following the start of treatment, and weight loss differences
between Ly49E WT and KO mice were not significant (Mann-
Whitney test) on all days analysed (Fig. 6B). FFPE-sections of the
distal colon of Ly49E WT and Ly49E KO mice were obtained
72 h following induction of colitis, and scored as described. As
shown in Fig. 6C and 6D, colonic inflammation in the colon of
both Ly49E WT and Ly49E KO treated mice was comparable in
severity. A role for Ly49E expression on colonic CD8aa-
expressing iIELs was investigated by comparing iIEL numbers,
iIEL subpopulation frequencies and iIEL NK receptor expression
of Ly49E WT and Ly49E KO-treated mice 72 h after treatment
start. Here, we found the total number of iIELs, iIEL subpopu-
lation frequencies and iIEL NK receptor expression to be
unchanged between Ly49E WT and Ly49E KO mice 72 h after
treatment initiation as compared to healthy control mice (data not
shown). Therefore, we conclude that Ly49E expression on colonic
CD8aa-expressing iIELs does not alter TNBS-induced colitis
development or progression.
TNFDARE/WT Ly49EWT/WT and TNFDARE/WT Ly49EKO/KO mice
display similar ileitis development and progression
To study the role of Ly49E expression on small intestinal iIELs
in the context of ileitis development and progression, we employed
the TNFDARE model of ileitis. Harbouring a deletion of the TNF
39 AU-rich elements, TNFDARE/WT mice develop spontaneous
ileitis that highly resembles human Crohn’s disease [35,36]. Here,
we bred Ly49E WT and Ly49E KO mice to heterozygous
TNFDARE/WT mice in two rounds, generating TNFDARE/WT
Ly49EWT/WT and TNFDARE/WT Ly49EKO/KO offspring. Moni-
toring weight progression of TNFDARE/WT Ly49EWT/WT and
TNFDARE/WT Ly49EKO/KO mice, and their littermate controls,
we noted decreased weights for TNFDARE/WT mice as compared
to TNFWT/WT mice, as expected. Furthermore, we observed no
significant difference in weight progression of TNF DARE/WT
Ly49EWT/WT versus TNFDARE/WT Ly49EKO/KO mice between 5
and 14 weeks of age (Fig. 7A). Subsequently, we analysed iIEL
numbers, subpopulation frequencies, NK receptor and activation
marker expression in TNFDARE/WT Ly49EWT/WT and TNFDARE/
WT Ly49EKO/KO mice and their littermate controls at the age of
10 weeks, by which time ileitis is fully developed. Total numbers of
iIELs isolated from the small intestine of TNFDARE/WT Ly49EWT/
WT and TNFDARE/WT Ly49EKO/KO mice were similar
(8.57610662.73 vs. 9.57610663.39 iIELs, respectively). Studying
iIEL subpopulation frequencies, we noted a significant increase in
TCRab CD4 iIELs (p#0.001; ANOVA), and a significant
decrease in TCRab CD8aa iIELs (p#0.001; ANOVA), in the
intestines of TNFDARE/WT Ly49EWT/WT and TNFDARE/WT
Ly49EKO/KO mice as compared to their littermate controls.
However, no differences were observed in iIEL subpopulation
frequencies between TNFDARE/WT Ly49EWT/WT and TNFDARE/
WT Ly49EKO/KO mice (Fig. 7B). Similarly, we noted no significant
differences in the NK receptor expression of iIELs from
TNFDARE/WT Ly49EWT/WT and TNFDARE/WT Ly49EKO/KO
mice (data not shown). To confirm that iIELs were activated in
this TNFDARE ileitis model, we stained iIELs for expression of the
activation marker CD69. Small intestinal iIELs from TNFDARE/
Figure 1. iIEL subpopulation frequencies in the small intestine and colon of Ly49E WT versus Ly49E KO mice. A) iIEL subpopulation
frequencies in the small intestine of Ly49E WT versus Ly49E KO mice. TCRab and TCRcd iIEL population frequencies are shown as a percentage of the
total iIELs present in the small intestine and colon of Ly49E WT versus Ly49E KO mice. TCRab CD4, TCRab CD8ab and TCRab CD8aa iIEL
subpopulation frequencies are shown as a percentage of the total TCRab iIELs. TCRcd DN and TCRcd CD8aa iIEL subpopulation frequencies are
shown as a percentage of the total TCRcd iIELs. B) iIEL subpopulation frequencies in the colon of Ly49E WT versus Ly49E KO mice. Representation of
iIEL subpopulation frequencies is the same as for Fig. 1A. iIEL subpopulation frequencies are shown as mean values (n = 5, small intestine; n = 5, colon,
where each value is derived from a pool of 3 mice).
doi:10.1371/journal.pone.0110015.g001
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WT Ly49EWT/WT and TNFDARE/WT Ly49EKO/KO mice expressed
significantly higher CD69 levels as compared to their littermate
controls for both TCRab CD8aa and TCRcd CD8aa iIELs (p#
0.001; ANOVA). However, CD69 expression levels were compa-
rable between TNFDARE/WT Ly49EWT/WT and TNFDARE/WT
Ly49EKO/KO mice, and between control Ly49E WT and Ly49E
KO mice (Fig. 7C). All experiments were repeated with mice at 14
weeks of age, and similar results were obtained (data not shown).
Together, this data suggests that Ly49E expression on small
intestinal iIELs does not affect ileitis development or progression.
Discussion
In this paper we show that the Ly49E NK receptor is
abundantly expressed on CD8aa-expressing iIELs of the small
intestine as well as the colon. Herein, the frequency of Ly49E-
expressing colonic CD8aa-positive iIELs is greater than the
frequency of Ly49E-expressing small intestinal CD8aa-positive
iIELs. Because of the relatively high Ly49E expression on iIELs,
we initially sought to investigate whether Ly49E expression
influences iIEL differentiation or the iIEL NK receptor expression
profile. In this regard, we show that Ly49E KO mice have
unchanged iIEL subpopulation frequencies and a similar NK
receptor expression profile to Ly49E WT. Thus, we show that
Ly49E expression on iIELs does not affect the development or NK
receptor expression profile of basal resting iIELs.
Upon iIEL activation, a number of reports have demonstrated a
function for these cells in regulating the development and
progression of ulcerative colitis. Recently, Meehan et al. [37]
illustrated that interaction of CD100 on cd-iIELs with plexin B2
on epithelial cells is required for keratinocyte-growth factor (KGF-
1)-mediated epithelial repair following DSS-induced colitis. A role
Figure 2. iIEL NK receptor expression in the small intestine and colon of Ly49E WT versus Ly49E KOmice. A) NK receptor expression on
TCRab CD8aa iIELs and TCRcd CD8aa iIELs in the small intestine of Ly49E WT versus Ly49E KO mice. B) NK receptor expression on TCRab CD8aa iIELs
and TCRcd CD8aa iIELs in the colon of Ly49E WT versus Ly49E KO mice. C) Co-expression of Ly49 receptors on the iIEL surface of TCRab CD8aa iIELs
and TCRcd CD8aa iIELs in the small intestine of Ly49E WT versus Ly49E KO mice. Numbers indicate the percentage of cells expressing or co-
expressing the indicated Ly49 receptors, and are representative of 3 mice. D) Co-expression of Ly49 receptors on the iIEL surface of TCRab CD8aa
iIELs and TCRcd CD8aa iIELs in the colon of Ly49E WT versus Ly49E KO mice. Numbers indicate the percentage of cells expressing or co-expressing
the specific Ly49 receptors, and are representative of 3 mice. iIEL NK receptor expression is presented as the mean 6SD (n = 5, small intestine; n = 5,
colon, where each value represents the mean of a pool of 3 mice).
doi:10.1371/journal.pone.0110015.g002
Figure 3. Clinical symptoms of DSS-induced colitis in Ly49E WT versus Ly49E KO mice. Colitis was induced in Ly49E WT and Ly49E KO
mice by administration of DSS in drinking water for 7 days. Thereafter, mice received normal drinking water. Ly49E WT and Ly49E KO mice were
scored and compared at the indicated days. A) Relative weight loss (mean 6SD; n = 71). The reference weight was taken as the weight on day 0, at
the start of the experiment. B) Disease activity index (mean 6SD; n = 71). C) Colon histological score (mean 6SD; n= 6 on day 7, n = 5 on day 9 and
n= 10 on day 11). D) Representative hematoxylin/eosin-stained paraffin sections of the distal colon.
doi:10.1371/journal.pone.0110015.g003
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Figure 4. iIEL NK receptor expression upon DSS-induced colitis in Ly49E WT versus Ly49E KO mice. A) Colon iIEL subpopulation
frequencies (mean 6SD; n = 5 on day 0, n = 3 on day 7 and n= 4 on day 11, where each value is derived from a pool of 3 mice). TCRab CD4, TCRab
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for iIELs in TNBS-induced colitis has been shown by Inagaki-Ohara
et al. [38], who demonstrated that cd T cell-deficient (Cd2/2) mice
show high susceptibility to TNBS-induced colitis at young age, and
that subsequent transfer of cd IELs to Cd2/2 mice ameliorates
TNBS-induced colitis. Roselli et al. [39] corroborated this result by
illustrating that a probiotic-induced increase in cd-positive iIELs
suppresses TNBS-induced colitis development in treated mice. Most
recently, Jiang et al. [40] were able to show that adoptive transfer of
iIELs to NOD22/2 mice, harboring a strongly reduced number of
iIELs, significantly reduced the susceptibility to TNBS-induced
colitis. Together, these reports suggest an important role for iIELs in
the regulation and prevention of ulcerative colitis.
Alongside, NK receptor expression has been implicated in
colitis development. Hall et al. [34] showed that NKG2A
expression on NK cells protected mice from DSS-induced colitis
development, where NK cells downregulated reactive oxygen
species and cytokine production by activated neutrophils through
direct cell-to-cell contact involving the NK cell inhibitory receptor
NKG2A. Additional data from human studies supports a possible
role of NK receptor expression in ulcerative colitis development
and progression. In this context, the frequency of KIR2DL1 and
KIR2DL3 genotypes was shown to be lower in ulcerative colitis
patients as compared to control individuals [41–43]. Moreover, it
was shown that KIR2DL1/HLA-C2 interaction negatively
correlates with IBD development [44]. Inversely, KIR2DL2 and
KIR2DS2 expression was linked to an increased incidence of
ulcerative colitis [45]. Interestingly, several studies have suggested
KIR receptors to be the human equivalent of Ly49 receptors in
mice [46–48]. Taken together, these studies illustrate that NK
receptor expression on colonic NK cells and some T cell subsets
may influence the course of colitis development. However, to our
CD8ab and TCRab CD8aa iIEL subpopulation frequencies are shown as a percentage of the total TCRab iIELs. TCRcd DN and TCRcd CD8aa iIEL
subpopulation frequencies are shown as a percentage of the total TCRcd iIEL. B) Colon iIEL NK receptor and activation marker expression on TCRab
CD8aa iIELs and TCRcd CD8aa iIELs (mean6SD; n = 5 on day 0, n = 3 on day 7 and n= 4 on day 11, where each value represents the mean of a pool of
3 mice). C) Colon iIEL NK receptor expression on TCRab CD8aa iIELs and TCRcd CD8aa iIELs on day 7 following induction of DSS-induced colitis.
Numbers indicate the percentage of cells expressing the indicated Ly49 receptors, and are each representative of 5 mice. Representative data are
shown on the left. Mean fluorence intensity (MFI) values for each receptor are shown on the right.
doi:10.1371/journal.pone.0110015.g004
Figure 5. iIEL NKG2D expression upon DSS-induced colitis in Ly49E WT and Ly49E KO mice. Colitis was induced in Ly49E WT and Ly49E
KO littermate mice by administration of DSS in drinking water for 7 days. A) NKG2D expression on TCRab CD8aa iIELs. B) NKG2D expression on TCRcd
CD8aa iIELs. N = 2 for control mice, n = 3 for DSS-treated mice.
doi:10.1371/journal.pone.0110015.g005
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knowledge, a role for NK receptor expression on iIELs, in the
context of ulcerative colitis, had not previously been investigated.
Recently, our group demonstrated that expression of inhibitory
Ly49 receptors on iIELs promotes hyporesponsiveness of these
cells [24], and that in vitro TCR-triggering results in upregulation
of Ly49E receptor expression on iIELs, indicating a negative
feedback loop [25]. Thus, we hypothesized that Ly49E expression
on colonic CD8aa-expressing iIELs might provide a new
mechanism through which iIEL function can be regulated in
colitis development and progression. Here, we show that Ly49E
expression on colonic CD8aa-expressing iIELs does not influence
the development or progression of DSS-induced colitis and TNBS-
induced colitis. Relative weight progression, disease activity index
scores, and histological scoring of FFPE-embedded colon sections
showed no significant difference in DSS-induced colitis progres-
sion between Ly49E WT and Ly49E KO mice. Furthermore, iIEL
numbers, iIEL subpopulation frequencies and iIEL phenotype
were unaltered throughout DSS-induced colitis progression in
Ly49E WT versus Ly49E KO mice. Similarly, survival rates,
relative weight progression and iIEL kinetics were not statistically
significant in TNBS-induced colitis between Ly49E WT and KO
mice.
A role for iIELs in ileitis, as modeled by the mouse TNFDARE
model, has been reported by Apostolaki et al. [49], who showed
that intestinal inflammation in TNFDARE/WT mice is associated
with a reduced presence of CD8aa-expressing iIELs. As in
ulcerative colitis, human data studies show a negative influence of
KIR2DL2/KIR2DL3 in Crohn’s disease development and a
protective effect for the KIR2DL1/HLA-C2 interaction [41–44].
Here, we crossed Ly49E WT and Ly49E KO mice to
heterozygous TNFDARE/WT mice in two rounds, generating
TNFDARE/WT Ly49EWT/WT and TNFDARE/WT Ly49EKO/KO
offspring for the study of the role of Ly49E expression on iIELs
in ileitis development and progression. Our results show that
TNFDARE/WT Ly49EWT/WT and TNFDARE/WT Ly49EKO/KO
mice display with similar ileitis disease kinetics. Concurrent with
results from Apostolaki et al. [49], we observe a significant
decrease of TCRab CD8aa iIELs in the small intestine of
TNFDARE/WT mice compared to their littermate controls.
Alongside, we note a significant increase of TCRab CD4 iIELs
in TNFDARE/WT mice compared to their littermate controls.
Furthermore, we show activation of TNFDARE/WT small intestinal
iIELs in ileitis, with significantly higher CD69 expression in
TNFDARE/WT mice as compared to littermate controls. However,
we observe no significant differences in iIEL numbers, subpopu-
lation frequencies, NK receptor expression or activation marker
expression between TNFDARE/WT Ly49EWT/WT and TNFDARE/
WT Ly49EKO/KO mice, illustrating that Ly49E expression on small
intestinal CD8aa-expressing iIELs does not influence ileitis
development or progression.
Conclusively, we report that Ly49E expression is abundant on
iIELs of the small intestine and colon. In this, Ly49E is expressed
on a high proportion of CD8aa-expressing iIELs. However,
Figure 6. TNBS-induced colitis in Ly49E WT versus Ly49E KO mice. Colitis was induced in Ly49E WT and Ly49E KO mice by intra-rectal
administration of TNBS. Mice were analysed at the indicated days. A) Survival (n = 16). B) Relative weight loss (mean 6SD; n = 16). The reference
weight was taken as the weight on day 0, at the start of the experiment. C) Colon histological score (mean 6SD; n= 5). D) Representative
hematoxylin/eosin- stained paraffin sections of the distal colon.
doi:10.1371/journal.pone.0110015.g006
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Ly49E expression on CD8aa-expressing iIELs does not influence
the development or progression of inflammatory bowel diseases.
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Part II
250 µm 
Tumour formation in the colon of an 
azoxymethane-treated Ly49E KO mouse. 
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Abstract 
Ly49E is a member of the Ly49 family of natural killer (NK) receptors and is distinct from other members 
of this family on the basis of its structural properties, expression pattern and ligand recognition. 
Importantly, Ly49E receptor expression is high on small intestinal and colonic intraepithelial lymphocytes 
(IELs). Intestinal IELs are important regulators of the mucosal immune system and contribute to front-line 
defense at the mucosal barrier, including anti-tumour immune response. Whereas most Ly49 receptors 
have major histocompatibility complex (MHC) class-I ligands, we showed that Ly49E is instead triggered 
by urokinase plasminogen activator (uPA). uPA has been extensively implicated in tumour development, 
where increased uPA levels are linked to poor prognosis. As such, we investigated the role of Ly49E 
receptor expression on intestinal IELs in the anti-tumour immune response. For this purpose we 
compared Ly49E wild-type (WT) mice to Ly49E knockout (KO) mice in two established tumour models: 
ApcMin/+-mediated and azoxymethane-induced intestinal cancer. Our results indicate that Ly49E 
expression on IELs does not influence the development or progression of intestinal cancer.  
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Introduction 
Colorectal cancer represents the third most common type of cancer worldwide [1,2]. Of all cases, 10-30% 
are hereditary, such as familial adenomatous polyposis coli and hereditary non-polyposis colon cancer. 
The majority, however, can be attributed to non-familial sporadic mutations and colitis-associated cancer 
[3]. For patients, treatment options today are limited. Curative resection in combination with chemo- or 
radiotherapy is standard, but recurrence rates are high, and up to 50% [4]. Alongside, a variety of new 
immunotherapies have been developed, including peptide-, whole tumour lysate-, dendritic cell- and viral 
vector-based vaccines. Adoptive cell transfer, including chimeric antigen receptor therapy, and antibody-
based therapies have also been introduced [5]. However, all currently available therapies struggle with 
low efficiency and limited success rates [5]. Therefore, sustained and additional research to elucidate the 
mechanisms that operate in intestinal cancer progression and development are crucial to improve 
outcome in therapies. 
Intestinal intraepithelial lymphocytes (IELs) are key to maintaining intestinal homeostasis. Strategically 
positioned within the intestinal epithelium, these cells have been implicated in the recognition of stress 
signals [6] and repair of the intestinal epithelium [7]. Furthermore, IELs have been attributed a role in 
intestinal tumour immune response as demonstrated by a number of in vitro and in vivo studies. 
Cytotoxicity of  intestinal IELs towards epithelial cell tumours was first reported in 1993 [8]. Later, Ebert 
et al. [9] showed that interaction of CD2 on the IEL surface with tumour-expressed CD58 induces 
expression of IL-8, TNF-α and IFN-γ by IELs, with a resulting enhanced anti-tumour response. 
Additionally, binding of IEL-expressed NKG2D to tumour MIC and ULBP ligands may trigger Fas-mediated 
lysis of tumour cells [10]. Moreover, Baker et al. [11] showed that colorectal cancers preferentially retain 
intestinal IEL rather than peripherally derived CD8 T cells. Together, these data illustrate that IELs, and 
NK receptors expressed on the IEL cell surface, play an important role in mediating intestinal tumour 
immune response.  
Ly49E is an inhibitory member of the Ly49 natural killer (NK) receptor family [12], characterised by a 
unique expression profile. Ly49E expression is high on tissue-resident lymphocytes, including CD8αα-
positive IEL [13,14]. IELs expressing inhibitory Ly49 receptors, including Ly49E, are hyporesponsive to 
TCR-mediated stimulation [13]. Importantly, in vitro TCR-triggering results in upregulation of Ly49E 
receptor expression on IELs [15]. Furthermore, whereas all other inhibitory Ly49 receptors have MHC 
class-I ligands, Ly49E is triggered by the non-MHC-related protein urokinase plasminogen activator (uPA) 
[16]. Importantly, uPA has been implicated in tumour development in general, and colorectal cancer in 
particular, as an increase in tumour uPA expression has been noted in the colorectal adenoma-carcinoma 
transition [17-22]. Also, in a clinical setting, increased uPA levels have been linked to poor patient 
prognosis [23,24]. Indeed, targeted uPA antibodies and inhibitors have been shown to reduce tumour 
growth, cancer cell spread and metastasis [25,26].  
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With the recent finding that uPA triggers the inhibitory Ly49E receptor, along with the observed 
constitutive expression of Ly49E on intestinal IELs and its additional upregulation upon TCR-mediated 
activation, we hypothesize that Ly49E receptor expression by IELs affects their in vivo immune response 
against intestinal tumours. If this hypothesis is correct, uPA produced by tumour cells would not only 
promote tumour invasion and metastasis, but would also be used as a novel tumour escape mechanism 
from host innate-like T cells. We tested this hypothesis by comparing Ly49E KO to Ly49E WT mice in two 
intestinal tumour models, ApcMin/+-mediated and azoxymethane (AOM)-induced intestinal cancer.  
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Materials and Methods 
Mice 
The generation of Ly49E KO mice on a C57BL/6 background was outsourced to Ozgene (Bentley DC, WA, 
Australia), and the targeting strategy is explained elsewhere [27]. Heterozygous ApcMin/+ mice were 
purchased from Jackson Laboratories (Bar Harbor, ME, USA). For the generation of ApcMin/+ Ly49E WT and 
ApcMin/+ Ly49E KO mice, male ApcMin/+ Ly49EWT/WT mice were first bred to female Apc+/+ Ly49EKO/KO mice, 
after which male heterozygous ApcMin/+ Ly49EWT/KO offspring were bred to female heterozygous Apc+/+
Ly49EWT/KO offspring to generate ApcMin/+ Ly49EWT/WT, ApcMin/+ Ly49EKO/KO, Apc+/+ Ly49EWT/WT and Apc+/+
Ly49EKO/KO mice at the expected ⅛ Mendelian ratio. All mice were housed and bred in our animal facility, 
and all animal experimentation was performed after approval by and according to the guidelines of the 
Ethical Committee for Experimental Animals at the Faculty of Medicine and Health Sciences of Ghent 
University (Ghent, Belgium). 
Genotyping of mice 
Genomic DNA was extracted from tail tissue samples using the REDExtract-N-Amp Tissue PCR Kit (Sigma-
Aldrich, St. Louis, MO, USA). PCR amplification of genomic DNA from the Apc locus was carried out with 
the following primers: forward-5’-TGAGAAAGACAGAAGTTA-3’ and reverse-5’-TCCACTTTGGCATAAGGC-
3’. Following agarose gel electrophoresis, the ApcMin allele yields a band of 313 bp, whereas the Apc WT 
allele does not yield a band due to primer mismatch.  PCR amplification of genomic DNA for the Ly49E 
locus was carried out making use of the following primers: for the WT allele, forward-5’-
TCGCTTGGAATCTTCTGTTTC-3’ and reverse-5’TCCTCACCTGGACTGCAATC-3’; for the KO allele, forward-
5’GGAATAATTGCTGTTACCATTAG in combination with reverse-5’TCCTCACCTGGACTGCAATC-3’. Ly49E 
WT and KO alleles yield bands of 1070 and 1200 bp, respectively. 
Azoxymethane-induced colorectal cancer 
Azoxymethane-induced colorectal cancer was induced in 7 to 11-week old mice. At day 0, mice were 
intraperitoneally injected with 10 mg/kg azoxymethane (AOM) (Sigma-Aldrich, St. Louis, MO, USA). At day 
7 of treatment, mice were administered 2.5% (w/v) dextran sodium sulphate (DSS) (molecular weight 
36,000-50,000, MP Biomedicals, Cleveland, OH, USA) in drinking water and mice were allowed to drink ad 
libitum for 7 days. Following 7 days of DSS treatment, drinking water containing DSS was replaced by 
normal drinking water and mice were allowed to recover. At days 28 and 39, a second and third DSS-
treatment cycle was initiated, and mice were administered 2% DSS in drinking water. Once more, mice 
were allowed to drink ad libitum for 7 days, following which drinking water containing DSS was replaced 
by normal drinking water and mice were allowed to recover. Control mice were not treated with 
azoxymethane, but were subjected to DSS treatment in an identical manner to azoxymethane-treated 
mice. 
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Assessment of mouse weight, intestinal length and tumour load/distribution 
Mice were weighed weekly, and at each time point of analysis. After sacrifice by cervical dislocation, the 
small intestine or colon was removed and intestinal length was determined. Intestines were then cleaned 
of all mesentery and cut open longitudinally for microscopic analysis of tumour load, size and distribution. 
The maximal tumour diameter was used to determine tumour size. For tumour distribution, intestines 
were cut into three equal-sized segments and the number of tumours per segment was noted. 
Isolation of tumour-infiltrating intestinal IELs 
Tumour-infiltrating IELs were isolated as follows. Briefly, the small intestine or colon was removed and 
cleaned of mesenteric fat. Peyer’s patches were excised and intestines were rinsed with DPBS to remove 
fecal content. Subsequently, intestines were opened longitudinally and screened for tumour load and 
distribution. Tumour-rich sections of the small intestine, or dissected colonic and colorectal tumours, 
were cut into 0.5-cm pieces, and incubated twice for 20 minutes at 37°C in Ca/Mg-free Hank’s Balanced 
Sodium Solution (HBSS; Invitrogen, Carlstad, CA, USA) containing 5% FCS, 1 mM 
ethylenediaminetetraacetic acid (EDTA; Invitrogen) and 1 mM dithiotreitol (DTT; Sigma-Aldrich) at slow 
rotation. Between the first and second incubation, intestinal pieces were collected and cut into 1 mm-
fragments with surgical scalpel blades to ensure complete dissection of tumours. Following incubation, 
cell suspensions were passed through a 40-µm cell strainer (Falcon, Becton Dickinson, Franklin Lakes, NJ, 
USA) and pelleted by centrifugation at 480 g. Pellets were resuspended in 44% Percoll (GE Healthcare, 
Buckinghamshire, UK) on an underlay of 67% Percoll, and centrifuged for 20 min  at 2000 g. IELs were 
collected from the 44%/67% Percoll interface, washed twice with phosphate buffered saline (PBS) for 5 
minutes at 840 g, and resuspended in RPMI 1640 medium supplemented with 10% FCS, 100 U/ml 
penicillin, 100 µg/ml streptomycin, 2 mM glutamine, 1 mM sodium pyruvate, 100 µM non-essential amino 
acids (all Invitrogen) and 50 µM 2-mercaptoethanol (Sigma-Aldrich). Small intestinal and colonic IELs 
were isolated from control mice according to the same protocol. 
Antibodies 
mAbs used for staining were as follows: anti-TCRβ (APC/Cy7-conjugated, clone H57.597), anti-CD4 
(peridinin chlorophyll protein/Cy5.5-conjugated, clone GK1.5), anti-CD8β (peridinin chlorophyll 
protein/Cy5.5-conjugated, clone YTS156.7.7), all from BioLegend (San Diego, CA, USA). Anti-TCRδ (PE- or 
FITC-conjugated, clone GL3), obtained from Becton Dickinson, (Franklin Lakes, NJ, USA). Anti-CD8α 
(PE/Cy7-conjugated, clone 53-6.7) from eBioscience (San Diego, CA, USA). Anti-Ly49C/E (biotin- or FITC-
conjugated, clone 4D12, made and labeled in-house) [28] and anti-Ly49E/F (FITC-conjugated, clone CM4; 
kindly provided by Dr C. G. Brooks (Newcastle on Tyne, UK)) [29]. mAb 4D12 (Ly49C/E) in combination 
with mAb CM4 (Ly49E/F) were used to identify Ly49E-expressing cells (CM4+/4D12+), Ly49C-expressing 
cells (CM4-/4D12+) and Ly49F-expressing cells (CM4+/4D12-). Prior to staining, cells were blocked with 
anti-FcγRII/III (unconjugated, clone 2.4G2, kindly provided by Dr J. Unkeless, Mount Sinai School of 
Medicine, New York, NY, USA). Propidium iodide was used to discriminate live and dead cells. Flow 
cytometric analysis was performed using a BD LSRII flow cytometer, and samples were analysed with 
FACSDiva Version 6.1.2 software (BD Biosciences). 
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Immunohistochemistry 
For histological analysis, tumour-rich sections of the distal ileum and distal colon were fixed in 4% 
formaldehyde solution (VWR, Radnor, PA, USA) and embedded in paraffin. 5 µm formalin-fixed paraffin-
embedded sections were stained with hematoxylin and eosin (Sigma-Aldrich) for analysis of tumour 
morphology. Alternately, sections were immersed in target retrieval solution, pH6 (Dako, Glostrup, 
Denmark) for 20 min at 95°C for antigen retrieval. Subsequently, sections were stained for 
immunofluorescent analysis of tumour-infiltrating lymphocytes. Antibodies used for immunofluorescent 
staining were polyclonal rabbit anti-human/mouse CD3 (Dako) and Dylight649 donkey anti-rabbit 
(BioLegend). Cell nuclei were counterstained by mounting with ProLong Gold anti-fade reagent with DAPI 
(Invitrogen). Stained sections were analysed on a Leica TCS SPE (Leica Microsystems, Wetzlar, Germany)
using the LAS4 and LASAF software. 
uPA ELISA 
Tumours were microscopically dissected and weighed. Subsequently, tumours were lysed in buffer 
composed of 1 part PBS/1 part caspase lysis buffer/2 parts blocking buffer (0.1 M Tris, 0.15 M NaCl, 3% 
BSA, pH 7.4), on a Precellys24 tissue homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France). 
The uPA content of the tumour lysates was determined using the Mouse uPA Total ELISA Kit (Innovative 
Research, Novi, MI, USA). Results are expressed as ng uPA per mg of tumour tissue.  
Statistics 
Statistical analysis was carried out using PASW Statistics 22 Software (SPSS, Chicago, IL, USA). Data were 
analysed using the non-parametric two-tailed Mann-Whitney U-test, or the Kruskall-Wallis test. A P value
≤ 0.05 was considered statistically significant. 
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Results 
Mouse weight, small intestinal length and tumour load is unaltered in ApcMin/+ mice on an Ly49E KO 
background 
To study the role of Ly49E in intestinal cancer development and progression in ApcMin/+ mice, we 
generated ApcMin/+ Ly49E WT and ApcMin/+ Ly49E KO littermates. When mice were weighed at 14 weeks of 
age, mouse weight did not differ significantly between ApcMin/+ Ly49E WT and ApcMin/+ Ly49E KO 
littermates, nor between ApcMin/+ and control Apc+/+ littermates (Fig 1A). A putative link between Dvl2 
gene expression and small intestinal length in ApcMin mice has been reported [30]. To investigate whether 
Ly49e gene expression influences intestinal length in ApcMin mice, we analysed small intestinal length in 
ApcMin/+ Ly49E WT and ApcMin/+ Ly49E KO littermates at 14 weeks of age, when tumour load was highest. 
As illustrated in Fig 1B, small intestinal length was unchanged between ApcMin/+ Ly49E WT and ApcMin/+ 
Ly49E KO littermates, and between ApcMin/+ and control Apc+/+ mice. When analyzing the small intestine 
tumour load during aging, there was a clear increase in tumour load as mice aged from 8 to 14 weeks of 
age. However, tumour numbers were comparable between ApcMin/+ Ly49E WT and ApcMin/+ Ly49E KO 
littermates at all time-points analysed (Fig 1C). Tumour distribution, i.e. in the proximal, middle or distal 
parts of the small intestine, was also similar for ApcMin/+ Ly49E WT and ApcMin/+ Ly49E KO littermates 
(data not shown). As expected, no intestinal tumours were detected in Apc+/+ mice (data not shown). 
Tumour-infiltrating T cells and tumour uPA expression levels are similar between ApcMin/+ Ly49E WT and 
ApcMin/+ Ly49E KO mice
To examine possible differences in tumour-infiltrating T lymphocytes in ApcMin/+ Ly49E WT and ApcMin/+ 
Ly49E KO littermates, we first stained tumour sections for CD3+ infiltrating T cells. As illustrated in Fig 2A, 
tumour-infiltrating T cells were clearly present, but we did not observe discernible differences in the 
numbers of tumour-infiltrating T cells between ApcMin/+ Ly49E WT and ApcMin/+ Ly49E KO mice. To 
investigate possible changes in subpopulations of tumour-infiltrating T lymphocytes between ApcMin/+ 
Ly49E WT and ApcMin/+ Ly49E KO littermates, tumour-infiltrating IEL were isolated from tumour-rich 
tissue and population frequencies were analysed, and compared to IEL subpopulations of Apc+/+ littermate 
mice. At 14 weeks of age, we noted a slight increase in TCRαβ lymphocytes, and decrease in TCRγδ 
lymphocytes, for ApcMin/+ mice compared to Apc+/+ mice. TCRαβ and TCRγδ lymphocyte frequencies were 
not different in tumour-infiltrating T lymphocytes of ApcMin/+ mice on an Ly49E WT versus Ly49E KO 
background. Within the TCRαβ lymphocyte fraction, we observed no differences between the CD4, CD8αβ 
and CD8αα subpopulations. Within the TCRγδ lymphocyte fraction, double-negative (DN: CD4-, CD8-) and 
CD8αα cell frequencies were unchanged (Fig 2B). The frequency of Ly49E-expressing TCRαβ and TCRγδ 
IELs did not differ significantly between ApcMin/+ Ly49E WT and Apc+/+ Ly49E WT littermates (data not 
shown). We have previously shown that uPA triggers Ly49E and that this results in inhibition of 
cytotoxicity as well as cytokine production of Ly49E-expressing lymphocytes [16]. Furthermore, extensive 
research has shown that uPA is critical in tumour development and metastasis [24,25,31].  To investigate 
a putative link between Ly49E and tumour uPA expression levels, we analysed uPA expression levels in 
lysates of intestinal tumours from ApcMin/+ Ly49E WT versus ApcMin/+ Ly49E KO mice. As illustrated in Fig 
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2C, tumour uPA expression levels were comparable between ApcMin/+ Ly49E WT and ApcMin/+ Ly49E KO 
mice.  
Mouse weight, colon length and colon tumour load are similar between azoxymethane (AOM)-treated 
Ly49E WT and Ly49E KO mice
To induce tumour formation in the colon, Ly49E WT and Ly49E KO mice were administered 10 mg/
kg AOM and subsequently subjected to 3 cycles of dextran sodium sulphate (DSS) treatment, eliciting
colitis-associated colorectal cancer. Mice were analysed at 14, 16 and 22 weeks following the start of
treatment. At 22 weeks, mouse weight was unchanged between AOM-treated and untreated control 
mice. Moreover, we did not observe weight differences between AOM-treated Ly49E WT and AOM-
treated Ly49E KO mice (Fig 3A). As severe colitis is linked to colon shortening [1], we analysed colon 
length in untreated and AOM-treated mice. Colon length was not significantly different in AOM-treated 
Ly49E KO as compared to AOM-treated Ly49E WT mice, nor in AOM-treated versus untreated mice (Fig 
3B). When analyzing colon tumour load, we observed that tumours of varying size developed. 
Overall, tumour load increased as treatment progressed. However, tumour load was comparable 
between AOM-treated Ly49E KO and AOM-treated Ly49E WT mice (Fig 3C).  We did not note 
significant differences in tumour size (Fig 3D). Alongside, tumour distribution was similar for AOM-
treated Ly49E KO as compared to Ly49E KO mice, with tumour development almost exclusively 
restricted to the middle and distal colon (data not shown), as has been reported previously [32]. 
Tumour-infiltrating T cell frequencies and tumour uPA expression levels are unchanged in AOM-
treated Ly49E WT versus Ly49E KO mice
As illustrated in Fig 4A, immunofluorescent staining of tumour sections shows that there were no 
discernible differences in the frequencies of tumour CD3+ infiltrating cells between AOM-treated Ly49E 
WT and AOM-treated Ly49E KO mice. Following dissection of colorectal tumours, the frequencies of 
tumour-infiltrating T lymphocyte subsets were analysed. We observed a strong and statistically significant
increase in the frequency of TCRαβ and a decrease of TCRγδ tumour-infiltrating lymphocytes, as 
compared to IELs from untreated mice. Within the TCRαβ lymphocyte fraction of tumour-infiltrating 
lymphocytes there was an increase in conventional CD4 lymphocytes, and a corresponding decrease in the 
frequency of non-conventional CD8αα lymphocytes. Surprisingly also, within the TCRγδ lymphocyte 
fraction, we noted a sharp increase in the frequency of DN lymphocytes and a corresponding decrease in 
CD8αα lymphocytes (Fig 4B and 4C). However, we could not find differences in lymphocyte population 
frequencies in AOM-treated Ly49E WT versus AOM-treated Ly49E KO mice. Lastly, we analysed uPA
expression by tumours of varying size, isolated from AOM-treated mice (Fig 4D). Tumour uPA expression 
increased steadily as tumours grew larger in size. In 3-4 mm and in ≥ 5 mm tumours, there was also a 
trend towards higher uPA expression in AOM-treated Ly49E WT versus Ly49E KO mice, but this was not 
significant. 
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Discussion 
ApcMin/+ mice were first described in 1990, and have been used extensively since for the study of intestinal 
cancer development [33]. In humans, 80% of sporadic colorectal cancers have a mutation in the Apc gene 
[34].  Moreover, mutations in Apc are present in familial adenomatous polyposis coli (FAP) [34].  Here, we 
studied a possible role for Ly49E in cancer development using ApcMin/+ mice crossed onto an Ly49E KO 
background. To investigate if Ly49E affects mouse weight, we weighed ApcMin/+ Ly49E WT and ApcMin/+ 
Ly49E KO mice at 14 weeks of age, when tumour load reached a plateau, as similarly observed by Puppa et 
al. [35]. Our results show no differences in body weight, suggesting that ApcMin/+ -mediated pathology in 
these mice is similar. This was confirmed by the absence of a difference in small intestinal length between 
ApcMin/+ Ly49E WT and ApcMin/+ Ly49E KO littermates. ApcMin/+ Ly49E WT and ApcMin/+ Ly49E KO mice 
developed numerous 1-2 mm adenomatous polyps along the duodenal to ileal axis, with a 100% 
penetrance. As has been previously reported, and in contrast to human colorectal cancers [33,36], 
tumours developed almost exclusively in the small intestine and were not detected in the colon. Tumour 
load increased with age and was not significantly different in ApcMin/+ Ly49E WT as compared to ApcMin/+ 
Ly49E KO mice, indicating that adenoma formation and growth is not affected by Ly49E expression. 
Immunofluorescent staining showed that global T cell infiltration is comparable between ApcMin/+ Ly49E 
WT and ApcMin/+ Ly49E KO mice. Marsh et al. [37] have previously shown that both ApcMin/+ TCRβ-/- and 
ApcMin/+ TCRδ-/- mice develop less tumours than ApcMin/+ mice, implicating a role for both TCRαβ and 
TCRγδ cells in tumourigenesis. Examining tumour lymphocyte infiltration in ApcMin/+ Ly49E WT and 
ApcMin/+ Ly49E KO littermates and comparing these to IELs of Apc+/+ littermate controls, we observed 
slightly increased frequencies of TCRαβ cells, and decreased frequencies of TCRγδ cells. The latter is in 
agreement with Marsh et al. [37] who similarly recovered fewer TCRγδ cells from ApcMin/+ as compared to 
Apc+/+ mice. Frequencies of the CD4, CD8αα and/or CD8αβ subpopulations of TCRαβ and TCRγδ cells were 
unaltered between ApcMin/+ and Apc+/+ mice. Moreover, we observed no differences in infiltrating 
lymphocyte composition between ApcMin/+ Ly49E WT and ApcMin/+ Ly49E KO mice. Taken together, our 
data illustrate that Ly49E does not influence the number or frequencies of tumour-infiltrating 
lymphocytes in ApcMin/+ mice.  
Ploplis et al. [38] showed that ApcMin/+ Plau-/- mice, which have an additional uPA deficiency, have a lower 
tumour load than ApcMin/+ (Plau+/+) mice. Our lab showed that uPA triggers the Ly49E receptor, thereby 
inhibiting cytokine production and cytotoxicity [39]. Furthermore, Ly49E expression on intestinal 
intraepithelial cells is high [13], where Ly49E is primarily expressed by CD8αα-expressing IELs, and 
expression is higher for the colon as compared to the small intestine [14]. As such, we wished to explore a 
possible link between Ly49E and tumour immunosurveillance. It has been shown that the immune 
response not only protects against tumour development but can also select for tumour cells of lower 
immunogenicity [40]. If this also applies to the ApcMin/+ model, tumours in Ly49E WT mice would be 
enriched for uPA production, whereas this would not be the case for tumours in Ly49E KO mice. However, 
our results show no significant difference in tumour uPA expression levels between ApcMin/+ Ly49E WT 
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and ApcMin/+ Ly49E KO mice, indicating that interaction between Ly49E and uPA is not involved in small 
intestinal ApcMin/+ tumour evasion of the immune response. 
The AOM-induced colorectal cancer model accurately recapitulates the aberrant crypt foci-adenoma-
carcinoma sequence and allows for the development of adenocarcinomas in a relatively short time span 
[32,41]. This in contrast to ApcMin/+ mice, where adenomas rarely progress to invasive adenocarcinoma’s 
[34]. Thus, whereas ApcMin/+ mice are excellent for study of the mucosa-adenoma transformation, study of 
AOM-treated mice may provide additional information with regard to adenoma-carcinoma 
transformation. Furthermore, tumours develop almost exclusively in the middle to distal colon, mimicking 
human colorectal cancer [32]. To explore a possible role for Ly49E in later stages of colorectal cancer 
development, we treated Ly49E WT and Ly49E KO mice with AOM and monitored tumour development. 
Suzuki et al. [42] have previously shown that AOM does not influence body weight of mice, as compared to 
untreated mice. Similarly, we did not observe a difference in body weight between AOM-treated as 
compared to untreated mice, or between AOM-treated Ly49E KO and AOM-treated Ly49E WT mice. We 
observed no significant difference in colon length for AOM-treated Ly49E KO mice as compared to AOM-
treated Ly49E WT mice. Following 14-22 weeks of AOM/DSS treatment, AOM-treated mice developed on 
average 5-10 tumours. Tumour distribution was similar for AOM-treated Ly49E KO mice as compared to 
AOM-treated Ly49E WT mice. Tumour load was comparable between AOM-treated Ly49E WT and Ly49E 
KO mice, and this for all time-points analysed. Also, we did not observe a difference in numbers of
tumours of any particular size.  
Immunofluorescent staining of tumour sections from AOM-treated Ly49E WT and Ly49E KO mice showed 
that total T cell infiltration was comparable. Matsuda et al. [43] previously showed that the frequency of 
tumour-infiltrated TCRγδ cells is lower in well-to-moderately differentiated colorectal adenocarcinoma as 
compared to healthy colon IELs. Moreover, tumour-infiltrating lymphocytes were found to be 
predominantly CD4+ and TCRαβ+ [43]. Analyzing the frequencies of tumour-infiltrating lymphocytes in 
AOM-treated and untreated control mice, we similarly noted a significant decrease in the frequency of 
TCRγδ lymphocytes in colorectal tumours of AOM-treated mice. Alongside, we noted an increase in the 
frequency of TCRαβ lymphocytes, with a significant increase in the frequency of conventional TCRαβ CD4 
and CD8αβ cells. In contrast, the frequency of CD8αα lymphocytes was significantly decreased in both the 
TCRαβ and TCRγδ cell fractions. However, no differences in infiltrating lymphocyte populations were 
observed between AOM-treated Ly49E WT and Ly49E KO mice, suggesting that Ly49E expression does 
not influence the total number or frequency of subpopulations of tumour infiltrating lymphocytes.  
uPA has been extensively implicated in the development of colorectal cancer development, where 
increased levels of both plasma and tissue uPA are present in patients with colorectal cancer [44]. 
Furthermore, increased uPA activity has been demonstrated for adenocarcinomas as compared with 
adenomatous polyps, showing that uPA expression levels correlate with colorectal cancer staging [45]. 
Examining uPA expression in tumours of varying size, we noted a gradual increase in relative tumour uPA 
expression as tumour size increased. There was a trend towards higher uPA expression in tumours from 
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AOM-treated Ly49E WT as compared to Ly49E KO mice, but this was not significantly different. Thus, we 
have no evidence that Ly49E expression on intestinal IELs results in immunoediting of AOM-induced 
colorectal cancer cells. 
Overall, we have shown that intestinal cancer, as modeled in ApcMin/+ mice or through AOM/DSS 
treatment, is accompanied by significant changes in the gut. Specifically, study of tumour-infiltrating 
lymphocytes shows that these cells are predominantly CD4 and CD8αβ TCRαβ cells. In contrast, the 
frequency of CD8αα-positive cells is reduced. Ly49E, expressed by IELs of the small intestine and colon, 
did not influence the frequencies of subpopulations of tumour-infiltrating lymphocytes in either model 
studied. Furthermore, Ly49E, triggered by uPA, did not influence relative tumour uPA expression levels. 
Thus, conclusively, Ly49E expression on intraepithelial T lymphocytes does not affect the development or 
progression of intestinal cancer. 
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Fig. 1 Apc-mediated intestinal cancer on a Ly49E KO background (A) Body weight of ApcMin/+ Ly49E 
WT and ApcMin/+ Ly49E KO mice (mean ± SEM; n = 10 for ApcMin/+ Ly49E WT, n = 5 for ApcMin/+ Ly49E KO) 
and control Ly49E WT and Ly49E KO littermates (mean ± SEM; n = 6) at 14 weeks of age. (B) Length of the 
small intestine in ApcMin/+ Ly49E WT and ApcMin/+ Ly49E KO mice (mean ± SEM; n = 5 for ApcMin/+ Ly49E 
WT, n = 3 for ApcMin/+ Ly49E KO) and Ly49E WT and Ly49E KO littermates (mean ± SEM; n = 3) at 14 
weeks of age. (C) Tumour load in the small intestine of ApcMin/+ Ly49E WT and ApcMin/+ Ly49E KO mice at 
8, 10 and 14 weeks of age. n.s. = not significant. 
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Fig. 2 Tumour-infiltrating T cells and tumour uPA expression in ApcMin/+ Ly49E WT versus ApcMin/+
Ly49E KO mice (A) Haematoxylin/eosin-(H&E) (upper), and CD3- (lower) stained paraffin tumour 
sections from ApcMin/+ Ly49E WT and ApcMin/+ Ly49E KO mice. Scale bar: 250 µm, x100 magnification. (B) 
Small intestinal tumour-infiltrating IEL subpopulation frequencies in ApcMin/+ Ly49E WT and ApcMin/+
Ly49E KO mice, and small intestinal IEL subpopulation frequencies from control littermates, at 14 weeks 
of age (mean ± SEM; n = 6). TCRαβ CD4, TCRαβ CD8αβ and TCRαβ CD8αα IEL subpopulation frequencies 
are shown as a percentage of the total TCRαβ IELs. TCRγδ DN and TCRγδ CD8αα IEL subpopulation 
frequencies are shown as a percentage of total TCRγδ IEL. (C) Tumour uPA expression in tumours from 
ApcMin/+ Ly49E WT and ApcMin/+ Ly49E KO mice at 14 weeks of age. n.s. = not significant. 
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Fig. 3 Azoxymethane-induced colorectal cancer on a Ly49E KO background (A) Body weight of AOM-
treated Ly49E WT and Ly49E KO mice (mean ± SEM; n = 8 for AOM-treated Ly49E WT, n = 7 for AOM-
treated Ly49E KO) 22 weeks following the start of treatment, and of untreated mice at a similar age (mean 
± SEM; n = 5). (B) Colon length of AOM-treated Ly49E WT and Ly49E KO mice (mean ± SEM; n = 8 for 
AOM-treated Ly49E WT, n = 7 for AOM-treated Ly49E KO) 22 weeks following the start of treatment, and 
of untreated mice at a similar age (mean ± SEM; n = 4). (C) Colon tumour load in AOM-treated Ly49E WT 
and Ly49E KO mice at 14, 16 and 22 weeks following the start of treatment. (D) Average number of 
tumours, when tumours are classified according to size, in AOM-treated Ly49E WT and Ly49E KO mice at 
14, 16 and 22 weeks following the start of treatment (mean ± SEM; n = 3 at 14 weeks, n = 6 at 16 weeks 
and n = 5 at 22 weeks). n.s. = not significant. 
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Fig. 4 Tumour-infiltrating T cells and tumour uPA expression in azoxymethane-treated Ly49E WT 
versus Ly49E KO mice (A) Haematoxylin/eosin-(H&E)- (upper), and CD3- (lower) stained paraffin 
tumour sections from AOM-treated Ly49E WT and Ly49E KO mice. Scale bar: 250 µm, x100 magnification. 
(B) Colon tumour-infiltrating IEL subpopulation frequencies in AOM-treated Ly49E WT and Ly49E KO 
mice 14-22 weeks following the start of treatment, and colon IEL subpopulation frequencies from 
untreated Ly49E WT and Ly49E KO mice (mean ± SEM; n = 5 for AOM-treated mice; n = 3 for untreated 
mice). TCRαβ CD4, TCRαβ CD8αβ and TCRαβ CD8αα IEL subpopulation frequencies are shown as a 
percentage of the total TCRαβ IELs. TCRγδ DN and TCRγδ CD8αα IEL subpopulation frequencies are 
shown as a percentage of the total TCRγδ IEL. (C) Dot plots are shown for CD4/CD8β versus CD8α 
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expression in colon tumour infiltrating IEL in AOM-treated Ly49E WT and Ly49E KO mice, and colon IEL 
from untreated Ly49E WT and Ly49E KO mice. Numbers indicate the percentage of cells in each quadrant. 
Dot plots are representative for n = 5 AOM-treated mice and n = 3 untreated mice. (D) Tumour uPA 
expression in tumours of varying size from AOM-treated Ly49E WT and Ly49E KO mice at 14-22 weeks 
following the start of treatment. n.s. = not significant. 
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Part III
Innate lymphoid cells of the small intestine 
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Abstract 
Ly49E is an Ly49 receptor family member with unique characteristics, including its preferential 
expression on innate lymphocytes. On T cells, it is expressed by both innate-like epidermal Vγ3 T cells and 
intestinal intraepithelial CD8αα+ T lymphocytes. Regarding NK cells, Ly49E expression is low on 
conventional NK cells, but high on tissue-resident CD49a+ liver NK cells. As CD49a+ liver NK cells have 
recently been shown to have innate lymphoid cell type 1 (ILC1)-like properties, we investigated whether 
Ly49E is expressed on intestinal ILC populations. Here, we show that numbers of Ly49E-expressing 
conventional intestinal ILC1 and ILC3 are low. In contrast, Ly49E is expressed by a subpopulation of the 
recently characterised innate (iCD8α) lymphocytes, and defines a new and unique NKp46-negative innate 
lymphoid population that can be minimally characterised as NKp46- CD8αα- Ly49E+. This population is 
positive for CD49a and CD103, expresses T-bet but not Eomes, and requires IL-15 signalling for survival. 
Further transcriptome analysis of these cells revealed a gene profile closely related to ILC1 and NK cells. 
However, NKp46- CD8αα- Ly49E+ cells are unique and distinct from NK cells and previously described 
intraepithelial and lamina propria ILC1 populations. Importantly, these cells are avid IFN-γ producers, 
suggesting that this novel population may contribute to Th-1 mediated immunity. 
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Introduction 
In recent years, several new innate lymphoid cell (ILC) populations have been described [1]. Characterised 
by the absence of rearranged antigen-specific receptors, these cells have been classified into group 1, 2 
and 3 ILCs, where each group appears to mirror a respective T helper cell population [2-4]. Group 1 ILC 
cells comprise NK cells and ILC1 cells that are defined by dependence on the Eomes or T-bet transcription 
factors, respectively. These cells have the capacity to respond to interleukin (IL)-12, IL-15 and IL-18 to 
produce interferon (IFN)-γ [2,3]. ILC2 cells are defined by dependence on GATA-3 and the capacity to 
respond to IL-33, IL-25 and thymic stromal lymphopoietin (TSLP) to produce type 2 cytokines, such as IL-
5 and IL-13. Lastly, ILC3 cells are defined by dependence on RORγt and the capacity to respond to IL-1β 
and IL-23 by the production of IL-17 and/or IL-22 [2-5].  
Abundant at mucosal barrier surfaces [3,4], ILCs have been attributed important roles in a number of 
immunological processes. Whereas ILC1 cells have been implicated in the control of intracellular parasite 
infections [3,6] and gut inflammation [2,7], ILC2 cells are important in the clearance of helminth [8,9] and 
viral infections [10], and in the progression of asthma and lung allergies [11-15]. ILC3 cells, in turn, 
contribute to tertiary lymphoid organogenesis [16], the containment of commensal bacteria [17] and 
clearance of bacterial infections in the gut [18-22], and have been implicated in the pathology of 
inflammatory bowel disease [7,23,24]. It should be noted that some of the described functions are 
attributable to “ex-RORγt” ILC3s [7,25], where bidirectional functional plasticity between ILC1 and ILC3 
classes in response to distinct environmental stimuli was recently demonstrated by Bernink et al. [26]. 
Whereas group 2 ILCs appear to be the most homogeneous cells, considerable heterogeneity exists within 
group 1 and 3 ILCs [5,15]. In the gut, a distinction can be made within group 1 ILCs between conventional 
natural killer (cNK) cells, lamina propria [3] and intraepithelial ILC1s [2], and “ex-RORγt” ILC3s [7,25]. 
Within group 3 ILCs, four subsets can be distinguished: CD4- NKp46- and CD4+ NKp46- lymphoid tissue 
inducer (LTi)-like ILC3s, and NKp46- RORγt+ and NKp46+ RORγt+ ILC3s [4]. Recently, Van Kaer et al. also 
described the existence of innate CD8αα (iCD8α) cells, a new innate lymphoid population resident in the 
intestinal epithelium [27]. 
Ly49E is a unique member of the Ly49 NK receptor family, with preferential expression on innate 
lymphocytes. In this respect, the Ly49E receptor is expressed on innate-like epidermal Vγ3 T cells as well 
as intestinal CD8αα+ intraepithelial T lymphocytes [28-30]. Alongside, Ly49E expression is low on 
conventional (c)NK cells from adult mice [31], but is highly expressed on CD49a+ liver NK cells [32]. 
Interestingly, the latter have recently been shown to have ILC1-like properties [4,33]. As such, we 
investigated whether Ly49E is expressed on intestinal ILC populations. In this paper we show that, 
whereas Ly49E expression is low on conventional ILC1 and ILC3 populations, Ly49E is expressed by a 
subpopulation of the recently described innate CD8α (iCD8α) lymphocytes, and in addition defines a novel 
intraepithelial NKp46-negative lymphoid population. This novel intestinal intraepithelial NKp46-negative 
Ly49E+ lymphoid population requires IL-15-, but not IL-7-mediated signalling, and has a gene expression 
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profile that is closely related to both lamina propria ILC1 and NK cells. Importantly, stimulation with the 
cytokines IL-12, IL-15 and IL-18 results in robust expression of IFN-γ, confirming that these cells are ILC1-
like and may contribute to Th1-mediated immune responses. 
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Materials and Methods 
Mice 
C57BL/6 wild-type (WT), BALB/c NOD-SCID, and C57BL/6 Rag-/- and Rag-/- γc-/- were purchased from 
Charles River (Wilmington, MA, United States). Eomes-/- (Eomesfl/fl x T-Cre) [34,35], Tbx21-/- [36], Il7ra-/-
[37], Il15ra-/- [38] and RORγt fate map (fm) (Rorc(γt)-CreTg x Rosa26RYfp/+) mice [39] were on a C57BL/6 
background. All animal experimentation was performed after approval and according to the guidelines of 
the Ethical Committee for Experimental Animals at the Faculty of Medicine and Health Sciences of Ghent 
University (Ghent, Belgium) and the Landesuntersuchungsamt Koblenz (Mainz, Germany). 
Intestinal intraepithelial and lamina propria lymphocyte isolation 
For intestinal intraepithelial lymphocyte isolation, small intestines were removed and cleaned of 
mesenteric fat. Peyer’s patches were excised, and intestines were rinsed with Dulbecco’s phosphate-
buffered saline (DPBS) to clear fecal content. Subsequently, intestines were opened longitudinally, cut into 
0.5-cm pieces, and incubated twice for 20 minutes at 37°C in Ca/Mg-free Hank’s Balanced Sodium Solution 
(HBSS; Invitrogen, Carlstad, CA, USA) containing 5% foetal calf serum (FCS), 1 mM 
ethylenediaminetetraacetic acid (EDTA; Invitrogen) and 1 mM dithiotreitol (Sigma-Aldrich; Saint-Louis, 
MO, USA) at slow rotation. Cell suspensions were passed through a 40-µm cell strainer (Becton Dickinson 
Biosciences, Franklin Lakes, NJ, USA) and pelleted by centrifugation at 480 g. Cell pellets were 
resuspended in 44% Percoll (GE Healthcare, Buckinghamshire, UK) on an underlay of 67% Percoll, and 
centrifuged for 20 min at 2000 g. Intraepithelial lymphocytes were collected from the 44%/67% Percoll 
interface, washed twice with phosphate buffered saline (PBS) for 5 minutes at 480 g, and resuspended in 
RPMI 1640 medium supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM 
glutamine, 1 mM sodium pyruvate, 100 µM non-essential amino acids (all Invitrogen) and 50 µM β-
mercaptoethanol (Sigma-Aldrich) (further indicated as ‘complete RPMI medium’). For lamina propria 
lymphocyte isolation, small intestinal pieces were collected following two rounds of intraepithelial 
lymphocyte isolation and cut into fine pieces with a scalpel. Subsequently, the remaining tissue was 
incubated three times for 20 minutes at 37°C in Ca/Mg-free HBSS solution containing 2% FCS, collagenase 
D (0.5 mg/ml; Roche, Basel, Switzerland), DNase I (0.5 mg/ml; Roche) and dispase (50 U/ml; BD 
Biosciences). Cell suspensions were passed through a 40-µm cell strainer and pelleted at 480 g. Pellets 
were resuspended in 40% Percoll on an underlay of 80% Percoll, and centrifuged for 25 min at 1328 g. 
Lamina propria lymphocytes were collected from the 40%/80% interphase, washed twice with PBS and 
resuspended in complete RPMI medium. 
Immunofluorescence staining and antibodies 
Following isolation, cells were blocked with anti-FcγRII/III (unconjugated, clone 2.4G2, kindly provided 
by Dr J. Unkeless, Mount Sinai School of Medicine, New York, NY, USA). Cells were subsequently stained 
with the following antibodies: anti-CD45.2 (APC-Cy7; 104), anti-CD45 (PE-Cy7; 30-F11), anti-CD3 (PE-
Cy7; 145-2C11), anti-CD5 (PE-Cy7; 53-7.3), anti-CD19 (PE-Cy7; 1D3), anti-Ly6G (PE-Cy7; RB6-85C), anti-
CD127 (PerCP-Cy5.5; A7R34), anti-CD27 (FITC or PE; LG.7F9), anti-NKp46 (PE; 29A1.4), anti-NK1.1 
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(PerCP-Cy5.5; PK136), anti-CD160 (APC; CNX46-3), anti-CD8α (eFluor450; 53-6.7), anti-CD103 (PE; 2E7), 
anti-Sca-1 (PE; D7), anti-CD122 (PE; TM-β1), anti-Eomes (PE; Dan11mag), anti-T-bet (PE; 4B10), anti-
RORγt (PE; AFKJS-9), all purchased from eBioscience (San Diego, CA, USA). Anti-CD3 (Pacific Blue; 500A2), 
anti-CD4 (PE; L3T4), anti-CD8β (PE; H35-17.2), anti-CD8α (APC; 53-6.7), anti-NK1.1 (APC; PK136), anti-
NKp46 (AlexaFluor647; 29A1.4), anti-CD49a (PE; Ha31/8), anti-CD49b (PE; DX5), anti-CD11c (APC; HL3), 
anti-CD117 (PE; 2B8), anti-CD90.2 (PE; 53-2.1), anti-NK1.1 (PE; PK136), anti-NKG2D (PE; CX5), anti-
CD127 (PE-CF594; SB/199) and anti-IFN-γ (PE; XMG1.2) antibodies were purchased from BD Biosciences 
(Franklin Lakes, NJ, USA). Anti-CD4 (PerCP-Cy5.5; GK1.5) and anti-CD8β (PerCP-Cy5.5; YTS156.77) were 
bought from BioLegend (San Diego, CA, USA). Anti-CD11b (PE; M1/70.15.11.5) was obtained from 
Miltenyi (Bergisch Gladbach, Germany). Anti-Ly49A (biotin-conjugated; JR9-318; kindly provided by Dr J. 
Roland (Paris, France)), anti-Ly49E/C (biotin-conjugated; 4D12, made and labeled in-house) [31] and 
anti-Ly49E/F (biotin or FITC-conjugated; clone CM4; labeled in-house and kindly provided by Dr C. G. 
Brooks (Newcastle on Tyne, UK) [40]. mAb 4D12 (Ly49C/E) in combination with mAb CM4 (Ly49E/F) 
were used to identify Ly49E- (CM4+/4D12+), Ly49C- (CM4-/4D12+) and Ly49F-expressing cells (CM4
+/4D12-). Anti-Ly49A/D (biotin-conjugated; clone 12A8; ascites kindly provided by Dr. J. Ortaldo (National 
Cancer Institute, Frederick, MD, USA), labeled in-house), anti-Ly49H (biotin-conjugated; clone 3D10; 
kindly provided by Dr. W. Yokoyama, (St.Louis, MO, USA)), anti-Ly49G (biotin-conjugated;  4D11;  from 
ATCC and labeled in-house), and anti-NKG2A/C/E (biotin-conjugated; clone 3S9; generated and labeled 
in-house) [31]. Biotinylated antibodies were subsequently detected by streptavidin (APC-Cy7- or V500- 
conjugated, purchased from eBioscience or BD Biosciences, respectively). 
For intracellular staining, cell membrane staining was performed first, following which cells 
were incubated in Cytofix/Cytoperm (BD Biosciences) and stained for cytokines. Intranuclear 
staining of transcription factors was performed using the Foxp3-staining kit (eBioscience). 
For surface stainings, propidium iodide was used to discriminate live and dead cells. For intracellular and 
intranuclear stainings, Live/Dead Fixable Aqua Staining (Molecular Probes, Eugene, OR, USA) was 
used. Flow cytometry was performed using a BD LSRII flow cytometer, and samples were analysed with 
FACSDiva Version 6.1.2 software (BD Biosciences) or FlowJo 8.7.1 (FlowJo, Ashland, OR, USA). 
Cell sorting and cytospin 
CD3- CD45+ NKp46- CD8αα- Ly49E+ and CD3- CD45+ NKp46- CD8αα+ Ly49E+ cells were sorted to high purity 
(>98%) from the small intestinal intraepithelial lymphocyte fraction of NOD-SCID mice using a BD 
FACSAria III cell sorter (BD Biosciences). For cytospins, cells were spun onto a glass slide, fixed and 
stained with Giemsa.  
Microarray 
CD3- CD45+ CD8αα- Ly49E+, CD3- CD45+ CD8αα+ Ly49E+ and CD3- CD45+ CD8αα+ Ly49E- cells were sorted to 
high purity (>98%) from the small intestinal intraepithelial lymphocyte fraction of NOD-SCID mice using a 
BD FACSAria III cell sorter (BD Biosciences). RNA was isolated using the RNeasy Plus Micro Kit (Qiagen, 
Hilden, Germany). Amplification and hybridization was carried out with the Ovation Pico WTA V2 kit 
(NuGen Technologies, San Carlos, CA, USA) and the Affymetrix Mouse Gene 1.0ST Array (Affymetrix, Santa 
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Clara, CA, USA). Samples were subsequently analysed using R/Bioconductor. All samples passed quality 
control, and the Robust Multi-array Average procedure was used to normalize data within arrays 
(probeset summarization, background correction and log2-transformation) and between arrays (quantile 
normalization). Only probesets that mapped uniquely to one gene were kept, and for each gene, the 
probeset with the highest expression level was retained. Correlation heatmaps were made by clustering 
the samples via the Ward method, and correlation was used to determine the distance between the 
samples. Microarray data and RNA Seq data were merged by first normalising and filtering the microarray 
data and the RNA Seq data separately. Quantile normalisation and ComBat were then used to correct for 
batch effects. 
In vitro cell stimulation 
Intestinal intraepithelial lymphocytes were isolated from NOD-SCID mice and cultured in complete RPMI 
medium in the presence of IL-12 (20 ng/ml; R&D Systems), and/or IL-15 (10 ng/ml; R&D), and/or IL-18 
(2.5 ng/ml; Medical and Biological Laboratories, Nagoya, Japan) for 15 h. Brefeldin A (Golgistop, BD 
Biosciences) (1 µg/ml) was added during the last 12 h. Cells were harvested and stained as described. 
Statistical analysis
Statistical analysis was carried out using PASW Statistics 22 Software (SPSS, Chicago, IL, USA) or 
GraphPad Prism5 Software. Data were analysed using the non-parametric two-tailed Mann-Whitney U-
test. A P value ≤ 0.05 was considered statistically significant.  
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Results 
Ly49E is mainly expressed on NKp46-negative intestinal intraepithelial lymphocytes 
We have previously shown that the Ly49E receptor is expressed on several innate-like cell populations in 
adult WT C57BL/6 mice, including intestinal intraepithelial CD8αα+ T cells, epidermal Vγ3 T cells and 
tissue-resident liver CD49a+ CD49b- NK cells [28-30,32]. Recent years have seen the discovery of a number 
of new innate lymphoid populations, i.e. the ILCs, with particular diversity of these cells in the small 
intestine [4]. As such, we set out to investigate whether Ly49E is expressed on small intestinal ILC subsets. 
We show that Ly49E was expressed only by a small subpopulation of intraepithelial NKp46+ NK1.1+ ILCs, 
where 2-5% of cNK expressed Ly49E, and where Ly49E expression was even lower on ILC1 and almost 
absent on ILC3 cells. Similarly, Ly49E expression was relatively low on lamina propria NKp46+ NK1.1+ 
ILCs, where expression was 3-4% on cNK, and also lower on ILC1 and ILC3 cells (Fig. 1A). Importantly, 
Ly49E expression was most abundant on the NKp46- subpopulation of intraepithelial CD3- CD45+ cells. 
Whereas the percentage of Ly49E-expressing cells in the total CD3- CD45+ NKp46- population was 
relatively low (Fig. 1A), the absolute number of these cells was seven-fold higher as compared to the 
Ly49E-expressing CD3- CD45+ NKp46+ intestinal intraepithelial fraction (Fig. 1B). Even higher absolute 
numbers of CD3- CD45+ NKp46- Ly49E+ intraepithelial cells were present in the small intestine of Rag-/- 
and NOD-SCID mice (Fig. 1C and 1D), confirming the innate nature of these cells. Therefore, for practical 
purposes, all future experiments were performed with cells isolated from the small intestinal 
intraepithelial lymphocyte fraction of Rag-/- and NOD-SCID mice. 
NKp46-negative intraepithelial Ly49E+ cells have an ILC-like/non-NK surface phenotype and a granular 
lymphoid morphology
Based on CD4, CD8β and CD8α expression, two main subpopulations of CD3- CD45+ NKp46- Ly49E+ cells 
could be distinguished, that were CD8αα+ and CD8αα-, respectively (Fig. 2A). We further performed a 
detailed phenotypic characterization of these two populations, and of spleen NK cells for comparison. Both 
CD8αα- and CD8αα+ Ly49E-expressing populations were CD49a+ CD103+ (Fig. 2B), suggestive of a tissue-
resident intraepithelial ILC phenotype [2,4]. Furthermore, both populations were CD127- CD11bint CD11cint 
CD117- CD90- Sca-1- CD122int. Interestingly, whilst CD8αα+ Ly49E+ cells were negative for CD160, NK1.1 
and NKG2A/C/E, the CD8αα- Ly49E+ population showed intermediate expression of these NK cell markers. 
We could not detect expression of NKG2D or other (non-Ly49E) Ly49 receptors on either of these 
populations (Fig. 2B). In this, CD8αα+ Ly49E+ cells strongly resembled innate CD8α (iCD8α) cells, as 
recently described by Van Kaer et al. [27]. Thus, CD8αα+ Ly49E+ cells may define a subpopulation of iCD8α 
cells, whereas CD8αα- Ly49E+ cells define a previously undescribed intraepithelial population with innate-
type surface marker expression. Cytospins of highly purified CD8αα- Ly49E+ and CD8αα+ Ly49E+ 
intraepithelial lymphocytes, and of CD3+ Ly49E+ intraepithelial T cells for comparison, showed that the 
Ly49E-expressing cells had a lymphoid morphology. Intriguingly, both CD8αα- Ly49E+ and CD8αα+ Ly49E+ 
cells were highly granular (Fig. 3). 
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Intestinal intraepithelial NKp46-negative CD8αα- Ly49E+ and CD8αα+ Ly49E+ cells have a distinct 
transcription factor  expression profile and dependency 
ILCs may be classified into group 1, 2 or 3 ILCs on the basis of transcription factor expression and 
dependency. Intracellular staining of intestinal intraepithelial CD8αα- Ly49E+ and CD8αα+ Ly49E+ cells 
revealed that both populations lacked Eomes expression, in contrast to NK cells, but expressed T-bet. 
Whereas a very small proportion of CD8αα- Ly49E+ cells was RORγt positive, CD8αα+ Ly49E+ cells did not 
express RORγt (Fig. 4A). When CD8αα- Ly49E+ and CD8αα+ Ly49E+ cells were isolated from RORγt-fate map 
(fm) mice, the results indicated that a fraction of cells from each subpopulation was RORγt-fm positive 
(Fig. 4B). As intracellular RORγt staining of CD8αα- Ly49E+ and CD8αα+ Ly49E+ cells from NOD-SCID mice 
yielded fewer, or no, RORγt-positive cells, respectively (Fig. 4A), this suggests that some of the observed 
RORγt-fm-positive cells are “ex-ILC3” cells that have lost RORγt expression [7,26]. To analyse transcription
factor dependency, the cell numbers of intestinal intraepithelial CD8αα- Ly49E+ and CD8αα+ Ly49E+ cells, 
and as control the cNK, ILC1 and ILC3 populations, were determined in Eomes-/- and Tbx21-/- versus WT 
mice. Normal numbers of CD8αα- Ly49E+ and CD8αα+ Ly49E+ cells were present in Eomes-/-mice. In turn, 
Tbx21-/- mice had strongly reduced numbers of CD8αα+ Ly49E+ cells, whereas the number of CD8αα- Ly49E
+ cells was unaffected. The control populations showed the expected transcription factor dependency, as 
NK cells were virtually absent in Eomes-/- mice, whereas ILC1 and ILC3 populations were strongly reduced 
or absent, respectively, in Tbx21-/- mice (Fig. 4B). 
NKp46-negative CD8αα- Ly49E+ and CD8αα+ Ly49E+ cells are dependent on IL-15, but not IL-7 signalling 
Previous studies have shown that ILCs require signalling through the common gamma chain (γc) for their 
survival [7,41,42]. To investigate the cytokine dependency of intestinal intraepithelial CD8αα- Ly49E+ and 
CD8αα+ Ly49E+ cells, we determined their cell numbers in γc-/-, Il7ra-/- and Il15ra-/- mice. As shown in Fig. 
5, CD8αα- Ly49E+ cells were increased in number in Il7ra-/- mice, and absent in Il15ra-/- and in γc-/- mice. 
This is in agreement with the absence of CD127 on the cell membrane of these cells, but intermediate 
levels of CD122 expression (Fig. 2B). Increased ILCs numbers have previously been reported in the gut of 
Il7r-/- mice [3,25]. CD8αα+ Ly49E+ cells were similarly independent of IL-7 and dependent on IL-15 
signalling (Fig. 5), as previously reported for iCD8α cells [27]. 
NKp46-negative CD8αα- Ly49E+ cells have a group 1 ILC-like transcriptome 
To gain a better understanding of the lineage relationship and potential function of NKp46-negative 
Ly49E+ cells, we carried out a global transcriptome analysis of sorted CD8αα- Ly49E+, CD8αα+ Ly49E+ and 
CD8αα+ Ly49E-  intestinal intraepithelial NKp46- cell populations, and aligned our data with that of 
publicly available gene expression data of intestinal iCD8α cells and ILC subsets, including NK cells [4,27]. 
Hierarchical clustering revealed that CD8αα- Ly49E+ cells clustered with NK and ILC1 lamina propria 
subsets. CD8αα+ Ly49E+ cells, in turn, clustered with iCD8α cells, as expected, and thus represent a 
subpopulation of this innate lymphoid population (Fig. 6A). Principal component analysis (PCA) 
confirmed that CD8αα- Ly49E+ cells clustered with lamina propria NK and ILC1 cells (Fig. 6B). More 
detailed gene expression analysis of CD8αα- Ly49E+ and CD8αα+ Ly49E+ cell subsets showed that both 
populations express high levels of the transcription factor Id2, which is required for development of all ILC 
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subsets [15]. Furthermore, in accordance with our flow cytometric data, Tbx21 (T-bet) expression levels 
were high and comparable to those of NK and intestinal intraepithelial and lamina propria ILC1 
populations.  In contrast to CD8αα+ Ly49E+ cells, CD8αα- Ly49E+ cells also showed increased transcript 
levels of the transcription factors Rorc, Nfil3, Ahr and Rora, where transcript numbers were in the same 
range as those of lamina propria NK and/or ILC1 cells (Fig. 6C). Cytokine and cytokine receptor 
expression profiles indicate that both CD8αα- Ly49E+ and CD8αα+ Ly49E+ cells express high levels of the 
chemokines CCL3 (MIP1α) and CCL5 (RANTES), whereas only CD8αα- Ly49E+ cells showed increased 
expression of the chemokine receptor CCR9 (Fig. 6D). CD8αα- Ly49E+ cells also showed increased 
expression of Ifng and Tnf as compared to CD8αα+ Ly49E+ cells. Additionally, CD8αα- Ly49E+ cells differed 
significantly from CD8αα+ Ly49E+ cells in the expression of cytokine receptors, where CD8αα- Ly49E+ cells 
highly expressed the Il18r1, Il2ra and Il7r genes, whereas only low expression of these genes could be 
detected in CD8αα+ Ly49E+ cells. Il2rb and Il12rb were expressed at high and intermediate levels, 
respectively, in both populations. CD8αα- Ly49E+ cells expressed Grzma, Grzmb and Prf1, but levels were 
lower than in CD8αα+ Ly49E+, NK and ILC1 cells (Fig. 6E). Finally, comparative analysis of the expression 
levels of genes of the recently described NK cell-distinct ILC core signature [4] showed that these genes 
were mainly expressed by CD8αα- Ly49E+ cells (Fig. 6F upper panel), whereas the majority of NK-specific 
signature genes were only expressed at low levels (Fig. 6F lower panel). Transcriptome analysis of CD8αα+
Ly49E- cells showed that the gene expression profile of these cells is indistinguishable from that of CD8αα+
Ly49E+ cells, and highly similar to that of iCD8α cells (Fig. 6A-F). In summary, we show that CD8αα+ 
Ly49E+ cells likely presents a subpopulation of iCD8α cells. In contrast, transcriptome analysis of CD8αα- 
Ly49E+ cells reveals that these cells have a unique transcriptional profile that displays characteristics of 
core ILC subsets and a close correlation with both intestinal ILC1 and NK cell expression profiles. 
CD8αα-  Ly49E+ cells are avid producers of IFN-γ 
As CD8αα- Ly49E+ cells displayed intermediate and strong expression of Il12rb, Il2rb and Il18ra, 
respectively, we stimulated intestinal intraepithelial lymphocytes in vitro with IL-12, IL-15 and/or IL-18 
and determined IFN-γ expression. Whereas CD8αα+ Ly49E+ cells expressed moderate levels of IFN-γ 
following stimulation with IL-12 + IL-15 + IL-18, CD8αα- Ly49E+ cells were avid producers of IFN-γ (Fig. 
7A). These results suggest that CD8αα- Ly49E+ cells, similarly to NK and ILC1 cells, may be involved in 
mediating Th1-type immunity.  
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Discussion 
The intestinal epithelium harbors a number of lymphocyte populations, including innate-like and adaptive 
T cells, NKp46-expressing NK and ILC1 cells, and the recently described iCD8α cells [2,27]. In this paper 
we show that the intestinal epithelium is also home to a new and unique CD3- innate population that can 
be minimally characterised as NKp46- CD8αα- Ly49E+ cells. Further study of these cells revealed a 
lymphoid morphology and a CD103+ CD127- surface phenotype. CD103 is expressed by intestinal 
epithelium-homing leukocytes, including T cells and iCD8α cells [2,27,29]. As such, CD103 expression 
reflects the intraepithelial localization of innate lymphoid CD8αα- Ly49E+ cells. CD127 surface expression 
may be used to identify ILCs, except NK cells, in many mouse tissues [4]. CD8αα- Ly49E+ cells did not 
express cell surface CD127. However, microarray analysis revealed large numbers of Il7r transcripts in 
these cells, suggesting that Il7r expression may not, or not sufficiently, be translated onto the protein level 
in these cells to allow flow cytometric detection. As intraepithelial ILC1 and iCD8α cells have also been 
shown to lack detectable surface expression of  CD127 [2,27], it is worthwhile to consider that absence of 
CD127 on the surface membrane of these three cell populations may be a feature of their intraepithelial 
localization, whereas ILCs located in the lamina propria do express cell surface CD127 [3]. This notion is 
further corroborated by data from human studies which have also described the existence of 
intraepithelial CD103+ ILC1 cells that are CD127lo/- [43]. 
Specification of intestinal innate lymphoid CD8αα- Ly49E+ cells by hierarchical clustering and PCA analysis 
indicated that CD8αα- Ly49E+ cells had a unique transcriptional profile that showed some similarities to 
NKp46+ NK and NKp46+ ILC1s, but differed from ILC2 and ILC3 subsets. Detailed cytokine and effector 
molecule gene expression analysis confirmed a group 1 ILC profile for CD8αα- Ly49E+ cells, with the 
presence of large numbers of transcripts for Ccl5, Ifng, Tnf, Gzma and Gzmb. We also demonstrated that 
CD8αα- Ly49E+ cells were IL-15-dependent for their development and/or maintenance. As NK cells as well 
as lamina propria ILC1, but not intraepithelial ILC1 cells, are dependent on IL-15 signalling [2,3,27], these 
data further support the group 1 ILC-like nature of CD8αα- Ly49E+ cells. However, intestinal CD8αα-
Ly49E+ intraepithelial lymphocytes are not NK cells. Robinette et al. [4] recently identified the NK cell-
distinct ILC core signature, i.e. a set of transcripts common to ILC1 cells from all tissues that are more 
highly expressed than in NK cell subsets, and that also show high expression in ILC2 and ILC3 subsets. 
Analysis of CD8αα- Ly49E+ cells showed strong expression of the NK cell-distinct ILC core signature genes 
whereas, vice versa, CD8αα- Ly49E+ cells displayed low expression of NK cell-specific signature genes. 
There are several other indications that CD8αα- Ly49E+ cells are not NK cells. Contrary to NK cells, these 
cells have an NKp46- NK1.1-/low phenotype and express CD49a, a marker present on tissue-resident ILC1 
cells and absent on NK cells [3,4]. In addition, these cells do not express typical NK receptors, including 
NKG2D and NKG2A/C/E, and, most importantly, CD8αα- Ly49E+ cells develop independently of Eomes, as 
testified by the presence of normal numbers of these cells in Eomes-/- mice. Furthermore, there are 
important differences between the intestinal intraepithelial CD8αα- Ly49E+ cells described in the present 
paper and the previously described intestinal intraepithelial and lamina propria ILC1 cells. Fuchs et al. [2] 
identified murine intestinal intraepithelial ILC1 cells. In contrast to CD8αα- Ly49E+ cells, intraepithelial 
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ILC1 cells have an NKp46+ NK1.1+ phenotype and are negative for CD103. In addition, intraepithelial ILC1 
cells are dependent on T-bet and largely independent of IL-15Rα, which is opposite to what we observed 
for CD8αα- Ly49E+ cells. Klose et al. [3] described lamina propria ILC1 cells. Moreover, and also in contrast 
to CD8αα- Ly49E+ cells, lamina propria ILC1 cells have an NKp46+ NK1.1+ phenotype. In addition, these 
cells express CD127, CD90 and CD117, markers that are not expressed by CD8αα- Ly49E+ cells. Finally, 
lamina propria ILC1 cells are also dependent on T-bet. Thus, although CD8αα- Ly49E+ cells have group 1 
ILC characteristics, including their overall transcriptional profile, these cells have several crucial 
differences as compared to NK cells and previously described intestinal ILC1 cells, and are therefore a new 
and unique intestinal intraepithelial ILC1-like population.  
A role for both intraepithelial and lamina propria ILC1 cells in mediating Th1-type immune response has 
been demonstrated [2,3]. Intestinal intraepithelial NKp46-negative CD8αα- Ly49E+ cells expressed Il12r 
Il2rb and, in comparison to NKp46-expressing NK and NKp46+ ILC1 cells, expressed even higher Il18r1 
levels, which may reflect their ability to be readily stimulated by IL-18 in conjunction with IL-12 and/or 
IL-15 to express IFN-γ. We evaluated IFN-γ production by these cells following incubation in the presence 
of IL-12 alone, IL-12+IL-15 or IL-12+IL-15+IL-18. Whereas IL-12 alone induced IFN-γ, there was a 
progressive increase when IL-15 and IL-15+IL-18 were added. Flow cytometric analysis of the 
transcription factor expression of CD8αα- Ly49E+ cells revealed that these cells did not express Eomes 
protein, but did express high T-bet levels. Taken together with the IFN-γ production capacity, these data 
are in agreement with an ILC1-like phenotype of CD8αα- Ly49E+ cells. Intriguingly, Tbx21-/- mice had 
normal numbers of CD8aa- Ly49E+ cells in the gut, indicating that T-bet is not required for the 
development of these cells. Thus, it remains to be elucidated which transcription factor(s) are required for 
development of CD8αα- Ly49E+ cells.  
In parallel, we showed that intestinal intraepithelial CD8αα+ Ly49E+ cells represent a fraction of iCD8α 
cells. CD8αα+ Ly49E+ cells had a CD45+ CD11bint CD11cint CD103+ c-kit- NKp46- NK1.1- phenotype, as also 
described for iCD8α cells by Van Kaer et al. [27]. Furthermore, we showed that these cells express CD49a, 
suggesting a tissue-resident ILC1-like phenotype [2-4]. CD8αα+ Ly49E+ cells had a lymphoid morphology 
and were granular, in accordance with high expression of Grzma and Grzmb, as reported by Van Kaer et al. 
[27]. As well as this, CD8αα+ Ly49E+ cells were dependent on IL-15-mediated signalling, and total numbers 
were strongly reduced in γc-/- mice. CD8αα+ Ly49E+ expressed Id2, as do iCD8α cells. However, although 
our microarray data indicated lower T-bet expression levels for CD8αα+ Ly49E+ as compared to CD8αα- 
Ly49E+, lamina propria NK and ILC1 cells, CD8αα+ Ly49E+ cells were T-bet dependent, whereas iCD8α are 
reportedly T-bet independent [27].  
As such, we have defined a novel intestinal intraepithelial ILC1-like population, which is distinct from the 
previously described NKp46+ NK1.1+ CD160+ intraepithelial ILC1 population described by Fuchs et al. [2] 
and the NKp46+ NK1.1+  CD127+ lamina propria ILC1 population described by Klose et al. [3], and also 
distinct from NK cells. This new intestinal intraepithelial ILC1-like population, which may be minimally 
characterised as NKp46- CD8αα- Ly49E+, requires IL-15 mediated signalling for development and/or 
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survival. Furthermore, we demonstrated that these cells display robust IFN-γ expression following in vitro 
activation.  Lastly, we find that Ly49E is expressed on a subset of iCD8α cells. Thus, we show that Ly49E 
expression is not restricted to intestinal intraepithelial T lymphocytes, but may also be used to identify 
ILC1-like populations in the gut. Of interest, a recent paper by Dadi et al. [44] describes the presence of 
non-circulating innate-like T cell receptor αβ and γδ lymphocytes, in addition to ILC1-like cells, in 
mammary tissue. Both mammary innate-like T cells and ILC1-like cells express NK1.1, CD103 and CD49a, 
express high T-bet levels, are negative for CD127 and are IL-15 dependent. Thus, these cells show many 
similarities to the novel intestinal NKp46- CD8αα- Ly49E+ population described in this paper. Most 
intriguingly, mammary-resident innate-like T cells and ILC1-like cells express Ly49E [44]. We can thus 
conclude that Ly49E receptor expression is characteristic for, and restricted to, specific tissue-resident 
innate(-like) lymphocyte populations, including intestinal intraepithelial NKp46- CD8αα- Ly49E+ cells, 
intestinal iCD8α cells [27], intestinal innate-like CD8αα+ T lymphocytes [28,29,45], liver CD49a+ NK cells 
[32] that were recently shown to be ILC1-like [4], skin epidermal Vγ3 T lymphocytes [30], and mammary 
gland innate-like T and ILC1-like cells [44].  
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Fig. 1 NKp46+ and NKp46- lymphocytes in the intestinal epithelium and lamina propria express 
Ly49E. (A) Flow cytometric analysis of small intestinal intraepithelial and lamina propria lymphocytes 
from wild-type (WT) mice. cNK, ILC1, ILC3 and NKp46-negative cells were gated as indicated, and 
analysed for Ly49E expression. (B) Absolute numbers (mean ± SEM; n = 5)) of small intestinal
intraepithelial NKp46+ cNK, ILC1 and ILC3 cells, and NKp46- cells in WT mice. The absolute number of 
Ly49E-expressing cells within these lymphocyte populations is also shown. (C) Flow cytometric analysis 
of small intestinal intraepithelial lymphocytes from WT, Rag-/- and NOD-SCID mice. NKp46- cells were first 
gated for Ly49E expression, wherein CD3 and CD45 expression was further analysed. (D) Absolute
numbers (mean ± SEM; n = 5) of CD3- CD45+ NKp46- Ly49E+ cells in the small intestinal epithelium of 
C57BL/6, Rag-/- and NOD-SCID mice. Statistical analysis was performed using the two-tailed Mann-
Whitney U-test. *** indicates a significant difference with p<0.001. (A,C) Numbers in the dot plots 
represent the percentage of cells in the indicated gate or quadrant. Data are representative for 5 different 
experiments.  
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Fig. 2 Surface marker expression of NKp46-negative CD8αα- Ly49E+ and CD8αα+ Ly49E+ 
lymphocytes in the intestinal epithelium. (A) CD8αα- and CD8αα+ subpopulations were identified in 
CD45+ NKp46- Ly49E-expressing intestinal intraepithelial lymphocytes from Rag-/- mice, as indicated. (B) 
Surface-expression profile of CD8αα- Ly49E+ (red line) and CD8αα+ Ly49E+ (blue line) cells, gated as in 
(A), and stained with the indicated antibodies. The black line represents spleen NK cell staining. Data are 
representative of three independent experiments. 
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Fig. 3 CD8αα- Ly49E+ and CD8αα+ Ly49E+ intestinal intraepithelial cells have a lymphoid 
morphology. CD8αα+ Ly49E+ and CD8αα- Ly49E+ cells, additionally gated as CD3- CD45+ NKp46-, were 
sorted to high purity (>98%) from the small intestinal intraepithelial lymphocyte fraction of NOD-SCID 
mice. Intestinal intraepithelial CD3+ CD45+ Ly49E+ T lymphocytes were sorted from WT mice. Cells were 
fixed and stained with Giemsa.  
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Fig. 4 Transcription factor expression and dependency of CD8αα- Ly49E+ and CD8αα+ Ly49E+ 
lymphocytes in the intestinal epithelium. (A) Expression of the transcription factors Eomes, T-bet and 
RORγt by intestinal intraepithelial CD8αα- Ly49E+ (red line) and CD8αα+ Ly49E+ lymphocytes (blue line), 
and spleen NK cells (black line), isolated from NOD-SCID mice. (B) Analysis of small intestinal 
intraepithelial CD8αα- Ly49E+ (red line) and CD8αα+ Ly49E+ lymphocytes (blue line), and spleen NK cells 
(black line), from RORγt-fate map (Rorc(γt)-CreTg x Rosa26RGfp/+) reporter mice. The expression of RORγt-
fate map (fm) is shown in the indicated populations. (A,B) Data are representative of three independent 
experiments. (C)  Absolute numbers (mean ± SEM; n = 2-3) of the indicated cell populations in the small 
intestinal epithelium of wild-type (WT), Eomes-/- and Tbx21-/- mice. Statistical analysis was performed 
using the two-tailed Mann-Whitney U-test. ** and *** indicate a significant difference with p<0.01 or 
p<0.001, respectively. 
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Fig. 5 Intestinal intraepithelial CD8αα- Ly49E+ and CD8αα+ Ly49E+ cells are dependent on IL-15 
signalling. (A) Absolute numbers (mean ± SEM; n = 3) of CD8αα- Ly49E+ and CD8αα+ Ly49E+ lymphocytes 
isolated from the small intestinal epithelium of WT, Il7ra-/-, Il15ra-/- and yc-/- mice, as indicated. Statistical 
analysis was performed using the two-tailed Mann-Whitney U-test. *** indicates a significant difference 
with p<0.001. 
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Fig. 6 Intestinal intraepithelial CD8αα- Ly49E+ lymphocytes present with a group 1 ILC 
transcription profile. (A-F) Intestinal CD8αα- Ly49E+, CD8αα+ Ly49E+ and CD8αα+ Ly49E- innate 
lymphocytes, additionally gated as CD3- CD45+, were sorted to high purity (>98%) from NOD-SCID mice in 
3 different experiments. Transcriptome analysis was performed on these triplicates and was compared to 
publicly available gene expression data of spleen, liver, intraepithelial (IEL) and/or lamina propria (LPL) 
NK, ILC1, ILC2, NKp46+ ILC3, and CD4- or CD4+ ILC3 lymphoid tissue inducer (LTi) cells (see materials and 
methods). (A) Hierarchical clustering of the indicated populations based on the 15 percent genes with the 
greatest variability. (B) Principal component analysis (PCA) of the selected populations. Numbers along 
axes indicate relative scaling of the principal variables. (C-F) Comparative analysis of gene expression by 
the selected cell populations.  
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Fig. 7 CD8αα- Ly49E+ innate lymphocytes express IFN-γ. (A) Intestinal intraepithelial lymphocytes 
were isolated from NOD-SCID mice and stimulated with the indicated cytokines, after which IFN-γ 
expression was determined. Numbers in the right quadrant represent the percentage of IFN-γ-expressing 
cells in the indicated population. Results are representative of 3 independent experiments. 
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Chapter 3:
General discussion and future 
perspectives 
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Discussion and future perspectives 
Part I 
The Ly49E receptor is a unique receptor expressed on a number of innate-like lymphoid cell populations. 
Among these are NK and intestinal IEL cells, as well as our newly identified intestinal intraepithelial 
NKp46-negative ILC1-like population.  
Previous and current studies in our lab have identified Ly49E receptor expression patterns, and also 
identified uPA as capable of triggering the Ly49E receptor.  Our data indicate that Ly49E functions as an 
inhibitory NK receptor. As such, research at our lab showed that IFN-γ expression by several NK cell lines 
is reduced upon exposure to coated recombinant uPA [197]. Furthermore, NK1.1-mediated stimulation of 
FD17 NK cell cytotoxicity could similarly be reduced following incubation of these cells with uPA. Thus, 
triggering of Ly49E by uPA inhibits NK cell activation and function [197].  
Interestingly, additional data shows that IELs upregulate Ly49E expression following stimulation. TCR-
mediated stimulation increases Ly49E expression on TCRγδ CD8αα IEL from 12% to as much as 60%, 
indicating the existence of a negative feedback loop. Furthermore, our lab demonstrated that Ly49E 
expression is regulated by two different pathways wherein two different Ly49E promotors are active. 
More specifically, basal constitutive expression of Ly49E on resting cells is mainly driven by Pro2, 
whereas induced Ly49E expression on activated cells is driven by Pro3 [198]. 
Taken together, we hypothesized that basal Ly49E expression and TCR-induced upregulation of Ly49E on 
IELs might play an important role in tempering the mucosal immune response after initial activation, thus 
preventing intestinal autoimmunity and pathology.  
To test our hypothesis, we examined two profound pathological systems in which uPA has previously 
been implicated, i.e. IBD and intestinal tumourigenesis. By comparing Ly49E WT to Ly49E knock-out (KO) 
mice in several established murine disease models, we examined whether Ly49E expression on IELs 
influences development and progression of these diseases. Here, development refers to the establishment 
of an intestinal disease, whereas progression refers to disease kinetics. 
Taveirne et al. [196] previously showed that Ly49E is expressed on the surface of small intestinal IEL. 
However, at the start of this thesis, it was unknown whether Ly49E is also expressed by IELs of the colon, 
and whether IEL Ly49E expression affects differentiation of small intestinal and colonic IELs. We showed 
that Ly49E is indeed expressed by colonic IELs, and that Ly49E expression was almost exclusively 
restricted to CD8αα+ IELs, as was the case for the small intestine. In this, we found that Ly49E expression 
by TCRαβ CD8αα IELs was comparable between the small intestine and the colon. Ly49E expression by 
TCRγδ CD8αα IEL, in turn, was higher in the colon compared to the small intestine. Additionally, we 
studied IEL subpopulation frequencies and NK receptor expression on IEL isolated from Ly49E WT and 
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Ly49E KO mice. Here we found that IEL subpopulation frequencies and expression of other NK receptors 
were similar between Ly49E WT and Ly49E KO mice, indicating that IEL differentiation and homeostasis 
is unaffected by Ly49E expression. Furthermore, we found that the cytokine expression profile of resting 
small intestinal IEL from Ly49E KO mice was similar to that of Ly49E WT mice (unpublished data). 
Together, this suggests that Ly49E expression does not affect IEL development or function when these 
cells are in a basal resting state.  
A number of studies have shown a role for IEL in mediating immunity to ileitis and colitis. In this, both IEL 
numbers as well as IEL receptor-ligand interactions have been shown to contribute to protection from IBD 
development [53,87-89,150]. Alongside, an increase in uPA expression has been noted in IBD patients 
[223,224]. With the noted upregulation of Ly49E on CD8αα+ IELs upon TCR-mediated stimulation, we 
postulated that Ly49E expression by IELs may be involved in regulating the immune response in IBD. 
Studying a possible role for Ly49E expression by IEL in the development or progression of DSS-induced 
colitis, we noted that Ly49E KO mice developed colitis as did Ly49E WT mice. Examining disease 
progression through parameters such as the rate of weight loss, the disease activity index, and gut 
histology at defined time-points (prior to disease development, at the peak of colitis development and 
during disease recovery/remission) we observed no significant differences in colitis development or 
progression between Ly49E KO as compared to Ly49E WT mice. Furthermore, IEL subpopulation 
frequencies/receptor expression in DSS-treated Ly49E WT and Ly49E KO mice were similar. Thus, colitis 
development and progression was unchanged in Ly49E KO as compared to Ly49E WT mice in this murine 
IBD model. Similarly, we found comparable colitis development and progression in Ly49E WT and Ly49E 
KO mice using the TNBS-induced colitis model, where we monitored the mortality rate, weight loss, colon 
histology and IEL subpopulation frequencies/receptor expression. Thus, we concluded that Ly49E 
expression by colonic IEL does not influence colitis development or progression. Because we reasoned 
that IEL from the colon may carry out different functions as compared to small intestinal IEL, we also 
examined a possible role for Ly49E receptor expression on small intestinal IEL in the context of ileitis. By 
crossing Ly49E mice onto the TNF∆ARE background, we generated TNF∆ARE/+ Ly49E WT and TNF∆ARE/+ 
Ly49E KO mice. Although we observed severe ileitis development in these mice and noted IEL activation 
(as observed by an increase in CD69 expression), we found similar levels of intestinal inflammation and 
no differences in IEL subpopulation frequencies/receptor expression between TNF∆ARE/+ Ly49E WT and 
TNF∆ARE/+ Ly49E KO mice. Therefore, we conclude that Ly49E expression on small intestinal IEL does not 
influence ileitis development.  
The IBD colitis models selected for the study of Ly49E function on IELs were chosen on the basis of 
previous studies showing an involvement of innate and γδ T cells, as well as NK cell receptors, in the 
pathogenesis of DSS-induced and TNBS-induced colitis [53,88,89,150]. As IEL are innate-like cells, and a 
significant proportion of IEL express the γδ T cell receptor, these models were deemed good candidates 
for study. Furthermore, DSS-induced and TNBS-induced colitis models are excellent models for the study 
of intestinal barrier function/mechanisms. The intraepithelial localisation of IELs [4], the previously 
shown role for IELs in mediating intestinal barrier repair [86,88], and the interaction of CD8αα expressed 
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on IEL with the epithelial cell ligand TL [99], all suggest that these cells have an important role in 
regulating epithelial barrier function. As such, again, the DSS-induced and TNBS-induced models provided 
the right environment in which to study the regulatory role of the Ly49E receptor in IEL function. 
However, it should be noted that studies of Rag1-/- mice in the context of DSS-induced [225] and TNBS-
induced colitis [226] indicate a limited role for adaptive immunity in these colitis models, and as such 
alternative colitis models could also be considered for the study of the immunological response. Here, the 
Il10-/- model and the T cell transfer models of colitis have both been shown to involve T cell responses 
[214]. Il10-/- mice develop spontaneous inflammation of the colon characterised by an inflammatory 
infiltrate made up of lymphocytes, macrophages and neutrophils. Inflammation in this model is initially 
driven by a Th1/Th17-response but, for currently unknown reasons, is replaced by a more Th2-driven 
response over time [214]. Alongside macrophages, Foxp3+ T regulatory cells are the main drivers of 
disease in this model, where a more migratory and pro-inflammatory phenotype of intestinal 
macrophages arises due to the absence of IL-10 [227], and where deletion of IL-10 specifically from T 
regulatory cells has been shown to be sufficient for the induction of colitis [228]. In the T cell transfer 
model, transfer of CD4+ CD45RBhi T cells to immunodeficient mice is sufficient for the induction of colitis in 
recipient mice [229]. Both Th1 and Th17-mediated immune responses have been implicated in this 
pathology [230]. Here too, T regulatory cells are crucial in preventing pathology, as transfer of CD4+ 
CD45RBlo cells does not induce colitis in immunodeficient mice, where the mature CD4+ CD45RBhi cell 
population was shown to harbour Foxp3+ T regulatory cells that suppress the development of 
inflammation in this model [229,231]. The T cell transfer model requires an immune-deficient 
background, where Ly49E KO mice were available on an immune competent C57BL/6 background. 
Furthermore, inflammation in the  Il10-/- and T cell transfer models is mediated to a large extent by 
conventional T cells and T regulatory cells, that either do not express Ly49E or only display low Ly49E 
expression. Therefore, we considered these models less suitable for the study of IEL Ly49E function. 
However, it is not unforeseeable that IEL can interact with lamina propria lymphocytes to mediate colitis 
development, and as such these models could be considered for future study of IEL function in colitis. 
With respect to ileitis development, pathogenesis in TNFΔARE/+ mice is known to be mediated by both CD4 
and CD8 T cells. Adoptive transfer of CD4 T cells from TNFΔARE/+ mice into Rag1-/- mice transfers disease to 
recipient mice [232]. A role for CD8 T cells was demonstrated in the expansion of pro-inflammatory CD8+ 
CD44hi cells in TNFΔARE/+ mice. Interestingly, however, a subset of CD8+ CD103+ T cells was shown to 
attenuate ileitis in Rag1-/- mice co-transferred with pathogenic CD4 T cells, demonstrating that CD8 T cells 
have an important immunoregulatory function in disease development [232]. As IEL are CD103+ cells, and 
the majority of Ly49E+ IEL express the CD8αα homodimer [1], we selected TNFΔARE/+ -mediated ileitis as a 
suitable model for the study of IEL Ly49E function in the small intestine. However, an alternative is 
present in the SAMP1/Yit ileitis model. The SAMP1/Yit model was generated by twenty generations of 
brother-sister mating of a senescence-accelerated mouse line, and is characterised by the spontaneous 
development of inflammation in the ileum [233]. CD4 T cells are key to ileitis development, where transfer 
of activated CD4 T cells from ileitic mice into immunodeficient SCID mice transfers colitis. An increased 
frequency of CCR9+ CD8 T cells is also detected in early ileitis [234]. Together, this implicates both CD4 
and CD8 T cell responses in mediating pathogenesis in this model. However, due to the difficulty of 
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breeding selective brother-sister pairs in combination with obtaining the correct Ly49E genotype, the
TNFΔARE/+ -mediated ileitis was chosen for evaluation of IEL Ly49E function. 
Part II 
uPA is an integral part of the plasminogen system, whereby plasminogen is converted to active plasmin. 
Plasmin, in turn, triggers a downstream cascade of extracellular matrix breakdown, ultimately resulting in 
tissue degradation. This process is beneficial in the context of tissue remodeling, however, may become 
detrimental in the process of tumour development and metastasis [223,235,236]. uPA has been linked to 
colorectal cancer development and progression [223,235-238]. As uPA was shown to trigger the Ly49E 
receptor [197], we wished to explore a possible role for Ly49E expression on IELs in mediating intestinal 
tumour immune response. Thus, we examined Ly49E WT and Ly49E KO mice in two models of intestinal 
cancer progression: ApcMin/+ -mediated intestinal cancer and AMO-induced colorectal cancer. We first 
examined tumour formation in mice through examination of the tumour load and tumour distribution in 
the small intestine and colon, respectively. Secondly, we studied tumour development at the cellular level 
in two ways: through immunofluorescent staining of tumour-infiltrating CD3+ T cells, and through 
measurement of tumour uPA expression levels.  Crossing Ly49E WT and Ly49E KO mice onto the ApcMin/+
background, we found that these mice developed numerous spontaneous adenomas by 14 weeks of age. 
However, tumour load and distribution were similar for ApcMin/+ Ly49E KO as compared to ApcMin/+ Ly49E 
WT mice. At the cellular level, this was complemented with data showing no difference in T cell tumour 
infiltration or tumour uPA expression levels between ApcMin/+ Ly49E WT and ApcMin/+ Ly49E KO mice. 
Therefore, we concluded that IEL Ly49E expression does not affect adenoma formation in the small 
intestine of these mice.  
The ApcMin/+ model is limited, however, in that it does not allow for the study of adenocarcinoma 
formation [239]. Thus, it remained possible that Ly49E exerts a function during the adenoma-carcinoma 
transition, or at a later stage. AMO-treated Ly49E WT and Ly49E KO mice developed fully differentiated 
adenocarcinomas. However, here too, we did not observe differences in tumour load or distribution, T cell 
tumour infiltration or tumour uPA expression levels, and this for all tumour sizes analysed. Thus, we 
conclude that IEL Ly49E expression does not influence the development of adenomas nor 
adenocarcinomas in the gut.  
An unexplored aspect of this research is the role of IEL Ly49E receptor expression in the process of 
intestinal metastasis. Patients with intestinal cancers may develop additional metastatic tumours at 
multiple sites, including the peritoneum, liver, lung, brain and bone. Of these, the liver and lungs are the 
most frequent sites of metastasis [240,241]. Moreover, uPA has been extensively implicated in metastasis 
[238], and as such it would be relevant to investigate whether putative Ly49E-uPA interactions on IELs 
influence the metastatic ability of intestinal tumour cells. ApcMin/+ mice do not develop metastatic 
tumours, and metastasis in AMO-induced colorectal cancer has, to our knowledge, not been described 
[242]. Two currently available mouse models could be used to study the role of Ly49E in intestinal 
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metastasis. The first focuses on Smad3, where Smad3 is an intracellular protein active in, and required for, 
TGF-β signalling. In the intestine, TGF-β signals inhibit proliferation of the colonic epithelium, preventing 
aberrant proliferation that may result in tumour formation.  Thus, Smad3-/- mice spontaneously develop 4-
6 colonic tumours between 18 to 24 weeks of age, where tumours range from adenomatous polyps to 
invasive carcinomas. Metastasis to the thoracic and mesenteric lymph nodes is also observed in these 
mice, mimicking human colorectal cancer metastasis, which often initiates in the lymphatics and spreads 
to regional lymph nodes [243,244]. As such, crossing Ly49E KO mice onto a Smad3-/- background would 
allow for a comparative analysis of metastasis in these mice.  Alternately, Hung et al. [245] developed the 
Apcflox/flox/LSL-KrasG12D model [245]. In this model, mice in which exon 14 of the Apc gene is homozygous 
floxed (Apcflox/flox) are crossed to mice that are heterozygous for the KrasG12D allele (KrasG12D/+). As for the 
ApcMin/+ model, an inactivating Apc mutation is sufficient for the induction of tumour formation in these 
mice. An additional activating mutation in the Kras proto-oncogene promotes progression from adenomas 
to carcinomas and ultimately metastasis. Apcflox/flox/LSL-KrasG12D mice are surgically incised and the distal 
colon is infected with adenovirus expressing the Cre enzyme. Following infection, these mice develop 
primary tumours in the distal colon only, where tumours differentiate as both adenomas and carcinomas 
20 weeks following infection. Approximately 20% of mice also develop liver metastases starting 24 weeks 
following adeno-cre injection. Thus, this model accurately recapitulates human colorectal cancer 
development and progression on a number of levels: tumour development is localized to the colon, 
metastasis to the liver may occur, and tumourigenesis is the result of Apc and Kras gene mutations, where 
Apc and Kras genes are often mutated in human colorectal cancer cases [245]. A last additional advantage 
of this model is the low tumour load (+/- 3.6 tumours), which is coupled with a low lethality of mice and 
allows for the longitudinal study of metastases [245]. Thus, an excellent way to investigate a role for 
Ly49E in intestinal metastasis would be to cross Ly49E KO mice to Apcflox/flox/LSL-KrasG12D mice, 
generating Apcflox/flox/LSL-KrasG12D Ly49E WT and Apcflox/flox/LSL-KrasG12D Ly49E KO mice for a 
comparative study.  
Another aspect that should be considered in studying a role for IEL Ly49E expression in intestinal disease 
development and progression through the use of full Ly49E KO mice, is the possibility that observed 
differences in disease development and/or progression may not be due to Ly49E expression by IELs, but 
may also be the result of Ly49E expression by other intestinal cell populations. In order to ensure that 
observed differences in phenotype between Ly49E KO and Ly49E WT mice are solely due to Ly49E 
expression/function on IEL, it would therefore be advisable to confirm any phenotype in a cell-specific 
Ly49E KO mouse. For this, one could breed mice carrying a floxed Ly49E exon to mice carrying the Cre-
enzyme under control of an IEL-specific promotor. Our lab is already in possession of a mouse carrying a 
floxed Ly49E exon. A promotor that is specific to IEL is unknown to date as far as we are aware, however, 
use of the Lck (T-cell specific) promotor would allow for deletion of Ly49E specifically in all T cells. As 
lamina propria T cells express little or no Ly49E (unpublished data), differences between Ly49E WT and 
an Lck-Cre x Ly49E KO mouse are likely to be the result of a loss of Ly49E expression by IEL.  
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Part III 
NK and LTi innate lymphoid cells were first described in the late 70’s. Therefore, it is quite surprising that 
additional ILC subsets were only discovered more recently. Today, three groups of ILCs are defined: group 
1, 2 and 3 ILCs. These ILCs are particularly abundant at mucosal surfaces, and the presence of all three ILC 
groups has been demonstrated in the gut [116,129,246]. As such, the intestine represents an ideal 
environment for the study of ILC diversity, function and plasticity.  
With the recent identification of the ILC populations, and the knowledge that Ly49E is expressed on 
innate-like cell populations, we set out to explore whether the Ly49E receptor is expressed by intestinal 
ILCs (CD3-) in addition to intestinal IELs (CD3+). Ly49E staining of CD3- CD19- gated intraepithelial 
lymphocytes from WT C57BL/6 mice, and of total intraepithelial lymphocytes from T/B-deficient Rag-/- 
and NOD-SCID mice, revealed that Ly49E is indeed expressed by a non-T/B intestinal intraepithelial 
subset. Additional surface staining revealed that these intraepithelial non-T/B Ly49E+ cells could be 
divided into two subpopulations, i.e. CD8α+ and CD8α- populations. CD8α+ Ly49E+ cells were shown to be a 
subset of the recently described iCD8α cells [128]. These innate lymphoid cells have an intraepithelial 
localisation and are characterised as CD3- CD8α+ CD103+ CD11bint CD11cint CD117- Nkp46- NK1.1-. iCD8α 
cells do not express CD127, and are reliant on IL-15-, rather than IL-7, -mediated signalling. Furthermore, 
these cells are independent of the transcription factors T-bet and AhR, and have low/absent levels of 
RORγt. iCD8α cells have a unique transcriptome and are avid producers of IFN-γ upon IL-12 stimulation 
[128]. 
In contrast, CD8α- Ly49E+ cells presented with a phenotype uniquely different from all previously 
reported ILC populations. Indeed, CD8α- Ly49E+ cells did not express CD127, CD90 and CD117, markers 
that are expressed by most other ILC populations. CD8α- Ly49E+ cells expressed CD49a and CD103, 
suggestive of an intraepithelial ILC1-like cell. Moreover, as CD8αα- Ly49E+ cells have an NKp46- NK1.1-/low 
phenotype and do not express typical NK receptors, such as NKG2D, NKG2A/C/E and other (non-Ly49E) 
Ly49 receptors, they are not NK cells. To further explore the possibility that we had uncovered a novel ILC 
population present in the intestinal epithelium of mice, we performed a number of additional studies. First 
of all, cells were sorted to high purity to analyse their morphology. We found that the intestinal non-T/B 
CD8α- Ly49E+ intraepithelial cells have a lymphoid morphology and contain cytoplasmic granules. 
Secondly, we analysed the presence of CD8α- Ly49E+ cells in the intestinal epithelial fraction from a large 
array of mouse strains carrying specific deletions for transcription factors or cytokine receptors. Group 1 
ILC NK cells and ILC1 cells are dependent on the transcription factor Eomes and T-bet respectively, group 
3 ILCs are dependent on the transcription factor RORγt [111]. Our analysis revealed that CD8α- Ly49E+ 
cells are independent of Eomes, T-bet and RORγt for development. This suggests that CD8α- Ly49E+ cells 
cannot be classified on the basis of these common ILC transcription factors, and that CD8α- Ly49E+ cells 
perhaps constitute a separate ILC lineage. Nonetheless, intranuclear staining showed high expression of T-
bet in CD8α- Ly49E+ cells, suggesting that these cells could have an ILC1-like phenotype. Additionally, the 
analysis showed that CD8α- Ly49E+ cells are dependent on signalling through the γc-chain for 
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development and/or survival. Specifically, we found CD8α- Ly49E+ cells to be dependent on IL-15, but not 
IL-7 signalling. This is in accordance with intermediate expression levels of CD122, but absence of CD127, 
on the cell membrane of these cells. It is also in agreement with previous data showing dependency of 
most ILC populations on signalling through the γc-chain [116,129,246]. To gain a broader and more 
detailed insight into this novel subset of ILC cells, we performed a microarray analysis of sorted CD8α- 
Ly49E+ cells, and compared our microarray data to that of established ILC populations. Indeed, global 
microarray analysis confirmed that CD8α- Ly49E+ are a unique ILC population, with an expression profile 
intermediate to that of lamina propria NK and intestinal ILC1 cells. Finally, we wished to examine a 
putative function for this novel NKp46-negative CD8α- Ly49E+ ILC1-like population. In vitro stimulation of 
CD8α- Ly49E+ intraepithelial cells revealed that these cells can be stimulated by IL-12+IL-15+IL-18 to 
produce IFN-γ, as is the case for group 1 ILCs. Thus, our preliminary data suggests that CD8α- Ly49E+ ILC 
may play an important role in Th1-mediated intestinal immunity.  
Thus, conclusively, our research identified a novel NKp46-negative ILC1-like population, present in the 
intestinal epithelium. CD8αα- Ly49E+ cells display characteristics of core ILC subsets, including NK cells 
and ILC1s. However, the lack of typical NK cell surface expression markers, in combination with their 
independence of Eomes, confirms that these cells are not NK cells. Furthermore, there are crucial 
differences between these CD8αα- Ly49E+ cells and the previously described intestinal intraepithelial and 
lamina propria ILC1 cells. In contrast to intraepithelial ILC1 cells as described by Fuchs et al. [127], 
intraepithelial CD8αα- Ly49E+ cells have an NKp46- NK1.1- phenotype, are positive for CD103 and negative 
for CD160. In addition, intraepithelial ILC1 are dependent on T-bet and largely independent of IL-15Rα 
[127], which is opposite to what we observed for CD8αα- Ly49E+ ILCs. Lamina propria ILC1 have an 
NKp46+ NK1.1+ phenotype and express CD127, CD90 and CD117 [123], whereas these surface markers are 
not expressed by CD8αα- Ly49E+ ILCs. Moreover, and again in contrast to CD8αα- Ly49E+ ILCs, lamina 
propria ILC1 cells are dependent on T-bet. Thus, although CD8αα- Ly49E+ ILCs have group 1 ILC 
characteristics, including their overall transcriptome and IFN-γ production capacity, they are uniquely 
different as compared to NK cells and to the previously described intestinal intraepithelial and lamina 
propria ILC1 cells. CD8αα- Ly49E+ ILCs are therefore a novel and unique intestinal intraepithelial ILC1-like 
population. 
Future research with respect to this novel ILC population should include an investigation of Id2 
dependency. This could be investigated through the use of Id2GFP/GFP mice, where absence of CD8αα-
Ly49E+ cells in these mice would be indicative of Id2-dependency.  However, as Id2GFP/GFP mice are growth 
retarded, findings should be complemented and confirmed through adoptive transfer experiments, 
wherein fetal liver hematopoietic stem cells are transferred from Id2GFP/GFP mice to irradiated WT 
recipients. If fetal liver Id2GFP/GFP cells are able to reconstitute CD8αα- Ly49E+ ILC in the gut of recipient 
mice, this would indicate that Id2 is not required for development of CD8αα- Ly49E+ ILC.  
Our results suggest that CD8αα- Ly49E+ ILCs have an ILC1-like phenotype and also have functional 
characteristics of ILC1 cells. We have demonstrated that CD8αα- Ly49E+ ILC produce IFN-γ when 
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stimulated with specific cytokines in vitro.  However, how these cells behave in vivo, and the full functional 
potential of these cells, is still unexplored. Therefore, the role of CD8αα- Ly49E+ ILCs in specific models of 
intestinal disease should be investigated. A role for CD8αα- Ly49E+ ILCs could be investigated by focusing 
on intestinal disease models that are reliant on Th1-mediated immunity such as anti-CD40-mediated 
colitis [127], T.gondii infection [123,156], Clostridium difficile infection [247] and S. typhimurium infection 
[143].  
General discussion and future perspectives 
Human studies have demonstrated a function for killer-cell immunoglobulin-like receptors (KIRs) in 
mediating susceptibility to IBD and colorectal cancer development. As such, a negative correlation 
between KIR2DL2 and KIR2DL3 [248], and a protective influence of KIRDL1, have been observed in 
development of Crohn’s disease and ulcerative colitis [248,249]. Furthermore, a recent study shows that 
activating KIRs are associated with long-term disease free survival in colorectal cancer [250]. The human 
equivalent of the Ly49E receptor is currently unknown.  Interestingly, a number of studies have suggested 
KIR receptors to be the human homologs of murine Ly49 receptors [126,251]. On the basis of currently 
available data, showing structural homology between Ly49E and human KIR2DL4, and the illustrated 
capacity of KIR2DL4 to function as an inhibitory receptor [126,252-254], we propose that KIR2DL4 could 
be the human equivalent of Ly49E. In order to extrapolate our data to human research, it would therefore 
be highly relevant to investigate whether this is indeed the case. As previously mentioned, we recently 
showed that uPA is capable of triggering the Ly49E receptor. Thus, to assert if KIR2DL4 is the human 
Ly49E homolog, one approach would be to establish whether human uPA is capable of triggering the 
KIR2DL4 receptor. To study the capacity of uPA to trigger the KIR2DL4 receptor, KIR2DL4 reporter cells 
could be developed, expressing the extracellular domain of the KIR2DL4 receptor fused to the 
transmembrane and intracellular domain of the activating KIR3DS1 receptor, as well as expressing the 
human DAP12 signalling chain. If KIR2DL4 is shown to be the human equivalent of murine Ly49E, 
advances can subsequently be made in studies of human disease. Although we have could not 
demonstrate a function for Ly49E expression on IEL in mediating IBD or intestinal cancer development 
and progression, one could continue work on the ILC aspect of this thesis, examining the human intestine 
for the presence of innate KIR2DL4-positive cells that have an ILC1-like phenotype and function.   
Research conducted over the past few years highlights the heterogeneity and the functional diversity of 
lymphoid gut populations. Due to overlapping phenotypical and functional traits, classification of some 
populations remains unsure. However, it is becoming apparent that, as is the case for ILC1 and ILC3 cells, 
some subpopulations may transition from one cell type into another, underscoring the difficulty of 
assigning one particular phenotype or function to a specific population. Nonetheless, this heterogeneity 
and functional flexibility is an asset to the mucosal immune system, allowing it to optimally adapt to any 
immune challenge.
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Where IELs (CD3+) and ILCs (CD3-) are concerned, one could argue that these are parallel and 
complimentary sides of the mucosal immune system, both exhibiting a phenotype that allows for a rapid 
and robust immune response. However, it remains possible that intermediate gut IEL-ILC-like populations 
exist that are as yet unidentified, and that carry out complimentary functions to individual IEL and ILC 
populations. An important and recent paper by Dadi et al. [255] indeed shows the existence of ILTC1 
populations in mammary tissue, where ILTC1 cells exhibit phenotypical and functional characteristics of 
both IEL and ILC1 cells.  ILTC1 cells were shown to be either TCRαβ- or TCRγδ-positive, and to express 
NK1.1, CD103 and high levels of CD49a, whereas these cells are negative for CD127. Principal component 
analysis (PCA) as well as gene expression analysis shows that these cells are more closely related to 
mammary ILC1-like (termed ILC1-like and not ILC1 due to their lack of CD127 expression and Eomeslo 
phenotype) and cNK cells (TCR- NK1.1+ CD49a-) than to classical TCRγδ+ NK1.1- and TCRαβ+ CD8α+ NK1.1-
populations. ILTC1 cells were also shown to express high T-bet levels, to have low or no detectable Eomes 
expression, and to be dependent on IL-15 for their development and/or survival. Thus, ILTC1 cells have a 
phenotype and expression profile that is intermediate to IEL and ILC1-like cells. Most interesting here, is 
the observation that both mammary ILC1-like cells and ILTC1 cells express intermediate cell membrane 
levels of Ly49E, with 10-15% and 20-30% Ly49E-positive cells in ILC1-like and ILTC1 populations, 
respectively. Additionally, ILTC1 cells express granzyme B and display cytotoxic activity towards 
mammary tumour cells [255]. 
We, and others, have previously shown that Ly49E expression is relatively high on innate-like 
unconventional IEL of the gut [94,196,256]. Furthermore, the research presented in this doctoral thesis 
describes the existence of a novel Ly49E-positive ILC population that is NKp46-negative and is 
characterised by ILC1-like properties. As this novel intestinal NKp46-negative Ly49E+ ILC1-like 
population also has a CD127- CD103+ CD49ahi tissue-resident phenotype, expresses high T-bet levels, is 
dependent on IL-15-mediated signalling for development and/or survival, and has an ILC1-like gene 
expression profile (including high granzyme B expression), this population is highly reminiscent of ILC1-
like and ILTC1 cells in mammary tissue [255]. Thus, research conducted by us and Dadi et al. [255] 
demonstrates that Ly49E receptor expression is characteristic to innate-like intestinal IEL and tissue-
resident CD127- ILC1-like cells, and mammary ILTC1 cell populations. Future research must elucidate 
whether ILTC1 cells also exist in the intestine, and whether these may similarly be characterised by Ly49E 
expression. Furthermore, we hypothesize that IEL, ILC and ILTC1 populations may not be restricted to the 
intestine or the mammary tissue, but may represent a common feature of all mucosal tissues. Again, future 
research should be conducted to examine this. And lastly, with the demonstration that mammary ILC1-like 
and ILTC1 cells are important regulators of tumour immune responses, it would be valid to investigate 
whether the novel intestinal intraepithelial NKp46-negative ILC1-like population also functions in 
mediating intestinal tumour immune response.  
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